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Summary of Thesis 
Background 
Within the African regions, there are striking differences in human immunodeficiency virus 
(HIV) prevalence yet social and cultural differences are relatively small suggesting that sexual or 
vertical transmission alone may not explain HIV infections in Sub-Saharan Africa (SSA). 
Several factors may contribute to the variation in the pandemic distribution in the region, for 
example, unsafe medical care, differences in host genetics or HIV-1 genetic diversity. The 
hallmark of HIV-1 is its extensive genetic diversity that emanates mainly from high mutations. 
Phylogenetically, HIV can be classified into geographically confined groups, types, subtypes and 
circulating recombinant forms (CRFs) that are subject to change over time. The plasticity of the 
HIV-1 env gp120 gene may also cause variation in chemokine co-receptors usage, numbers and 
distribution of potential glycosylation sites (PNGS) including amino acid length polymorphism. 
HIV genetic diversity may partially explain the observed heterogeneity in HIV prevalence and 
has also been reported to impact on viral transmissibility and differential rates of disease 
progression. Zimbabwe is one of the countries in the world with the highest HIV-1 prevalence. 
Despite the high HIV-1 prevalence in the general populace which translates to high vertical 
transmission rates, the desire to have future pregnancies among HIV-1 positive mothers has been 
increasing. Concurrently, the decade long volatile economic climate has forced over 80% of 
jobless Zimbabweans into self-employment through cross-border trading all over the world. This 
desperate economic situation may have led some traders to engage in risky sexual behaviour. 
With the world fast becoming a global village, new HIV strains are emerging in areas where they 
were originally non-existent. There is paucity of information on the current HIV-1 diversity; 
xxii 
 
 
types, subtypes and recombinants circulating in Zimbabwe. Tracking the presence of new HIV 
strains is important not only for surveillance purposes but also for monitoring disease 
progression, facilitating personalized targeted therapy as well as using this data for the 
development of the much anticipated effective vaccines against this scourge. 
Aim of the study 
The main goal of this study was to characterise HIV genetic diversity among Harare peri-urban 
pregnant women and ascertain its role in diagnosis, transmission and disease progression. 
Materials and Methods 
Pregnant women at 36 gestational weeks who were enrolled in a national prevention of mother to 
child transmission (PMTCT) programme were studied. The design of the study was a case-
control study in which the cases and controls were sampled from an antiretroviral therapy (ART) 
naive PMTCT cohort of pregnant women attending Antenatal Clinics (ANC) around Harare. 
Single dose nevirapine (SdNVP) was offered to all HIV-1 positive women during labour and 
their infants within 72 hours post-delivery. Follow-ups were from delivery, six weeks, four and 
nine months and thereafter three monthly until two years. At each subsequent follow-up visit 
HIV-1 negative mothers and all exposed infants were re-tested for HIV antibodies and viral 
DNA, respectively. Similar procedures were followed in subsequent pregnancies. Women who 
were included in our study were enrolled from an initially sexually transmitted infections (STI) 
study. Some of these women’s spouses also consented to participate in the HIV diversity study. 
Genotyping of HIV-1 env gp120 C2V5 region was done for subtype and viral co-receptor usage 
determination. Mother-infant viral heterogeneity, potential N-linked glycosylation site(s) (PNGs) 
xxiii 
 
 
variations and amino acid length polymorphisms were also investigated including immunological 
and virological markers of disease progression  
Results 
HIV Types:  
x HIV-1 prevalence was 25.6% and contributed 98.4 % of the HIV infections. 
x HIV-2 prevalence was 0%. 
x HIV/HIV-2 co-infections contributed 1.6% of the HIV infections. 
HIV-1 Subtypes: 
x All mother–infant pairs were infected with HIV-1 subtype C virus. 
x Sequences clustered closely with other regional HIV-1 subtype C sequences. 
x Phylogenetic analysis was suggestive of a localized expansion of the subtype C. 
x Unusually high variation in amino acid sequence was observed within the HIV-1 subtype 
C supposedly constant region 3 (C3) as well as the atypical fairly constant variable region 
3 (V3). 
Antenatal HIV-1 Co-receptor Usage: 
x R5 co-receptor usage was the predominant genotype (82%). 
x X4 genotype was significantly associated with higher viral load. 
x GPGR amino acid motif within the V3 crown was associated with X4 genotype and 
lymphadenopathy; p=0.031 and 0.043, respectively. 
Mother-Infant(s) HIV-1 env gp120 C2V5 Viral Heterogeneity 
x Degree of HIV-1 subtype C viral heterogeneity: mothers> first siblings>second sibling. 
Env C2V5 Glycosylation Patterns and Sequence Length Polymorphisms: 
x HIV-1 env C2V5 amino acid length and PNGs tended to increase with age and HIV 
disease progression. 
x Directionality of the HIV transmission events with respect to C3 region sequence length 
polymorphism was suggestive of a 50-50 transmission events in either direction, whether 
male to female (MTF) or female to male (FTM). 
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x Increases in PNGs or amino acid lengths within the C3, C4 and V3 sub-regions positively 
correlated with CD4 counts or percentage (%) but negatively correlated with viral load. 
HIV-1 Vertical Transmission: 
x The risk of transmission increased by 29% for each unit increase in log10 viral load; 
p=0.023. 
x Transmission rates were 7.5% and 15.3 % for the in utero and intra-partum/postpartum 
periods, respectively. 
x 90% of the transmissions occurred below viral load of 16 000 HIV-1 RNA copies /mL. 
x Generally more than one maternal variants were responsible for infant‘s infection. 
x Maternal co-receptor genotype was generally preserved in vertical transmission and was 
predictive of the infant’s viral genotype. 
x None of the infants had dual R5X4 genotype. 
x Vertically infected children were surviving longer than was expected even without ART. 
Risk Factors for Vertical Transmission 
x High antenatal plasma HIV-1 RNA load, low total lymphocytes count (TLC) and anemia 
were each significantly associated with vertical transmission. 
x Lack of antibody reactivity to HIV gag p39 antigen on western blot band profiles was 
associated with vertical transmission and advanced disease. 
 
HIV Diagnosis 
x HIV-1/HIV-2 rapid kits test results concordance was 100%. 
x Non- reactivity to pol antigens was associated with acute HIV-1 infection; p=0.002. 
HIV-1 Disease Monitoring 
x 28% of the 64 mothers had undetectable HIV-1 RNA load yet 10% proceeded to transmit 
to their infants. 
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Conclusion 
Despite the high mobility, there seems to be no new types, subtypes nor CRFs being introduced 
at least in this population based on the analysis of the HIV-1 env C2V5 region. The sensitivity 
and specificity of the HIV-1/HIV-2 screening and confirmatory diagnostic tests used were 
appropriate as concordance was 100%. However, disease monitoring test, viral load 
determination, may not have been as sensitive as shown by mothers with undetectable viral load 
who nevertheless transmitted to their infants. Alternatively, this observation is pointing to the 
complex factors associated with MTCT of HIV. Data are suggestive that subtype C env sequence 
may be different from that of subtype B and hence extrapolation of subtype B findings to non-B 
subtypes may not be accurate. Since CCR5 was the most predominant genotype it entails that 
ART combinations that include R5 entry inhibitors can be used in this population. HIV-1 
infected infants inherited their respective mothers’ co-receptor genotypes, were more likely to be 
infected with more than one maternal viral variants and were also surviving longer even without 
ART. These long term survivors require tailor-made HIV-care especially during the adolescent 
period. Continuing following up these HIV-1 infected mother-infant pairs inclusive of all 
subsequently born children is worthwhile for documentation of disease progression and trends in 
drug resistant mutations under such settings whereby the host factors can be controlled. Future 
bigger studies comparing HIV-1 transmission rates from a population like ours with exclusive 
subtype C infection to other cohorts with mixed infections inclusive of subtype C could partly 
explain the observed heterogeneous distribution of HIV prevalence. 
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CHAPTER 1 
1.0 Background 
1.1.0  HIV/AIDS Disease Burden and Geographical Distribution 
1.1.1  Historical Background of HIV/AIDS 
 
A syndrome associated with severe immunodeficiency was observed in the United States of 
America (USA) among previously healthy homosexual men and intravenous drug addicts in 
1981 1. The aetiological agent was isolated from the lymph nodes of suspected patients two 
years later 2;3. By then it was called human T-cell lymphotrophic virus type-3 (HTLV-III) or 
lymphadenopathy-associated virus (LAV) but was later re-named human immunodeficiency 
virus (HIV) 4. Transmission can be through vaginal, anal or oral sex, blood transfusion, 
hypodermic needles or from a pregnant mother to her unborn child during pregnancy, 
childbirth or through breastfeeding 5-7. HIV causes progressive immunodeficiency leading to 
Acquired Immunodeficiency Syndrome (AIDS). It is currently one of the most devastating 
infectious diseases in the history of mankind. The earliest anti-HIV-1 sero-positive blood 
sample was from an individual in Kinshasa, Congo in 1959 8 yet, globally by 2010, 20 million 
people had since died from the infection whilst another 33 million are living with HIV/AIDS 
as shown in Figure 1.1. 
 
Sub Saharan Africa (SSA) with just a mere tenth of the world‘s population, harbors about two 
thirds of all HIV infections globally and 90% of all pediatric infections 9. A disturbing 
phenomenon in Africa is the high HIV/AIDS burden observed amongst women unlike in the 
USA and Europe, where it is concentrated among hemophiliacs, intravenous drug users 
(IDUs) and homosexual men 10;11. In view of the fact that many Africans even in stable 
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relationships are also infected, there has been growing interests to understand the dynamics 
and risk factors of HIV-1 transmissions 12. 
 
 
Figure 1.1: Global Heterogeneous HIV Burden 13. 
 
1.1.2. Origin of HIV and Zoonosis 
The origin of HIV can be traced back to a Simian Immunodeficiency Virus (SIV) isolated 
from a Chimpanzee (cpz) sub-species, Pan troglodytes troglodytes (SIVcpz) in Southern 
Cameroon 14. It is hypothesized that cross species transmission of HIV occurred from its 
primary host, the SIVcpz to humans. This zoonotic transmission of the virus from the non-
human primates (NHPs) to humans is thought to have occurred through practices of hunting 
and butchering of NHPs or during the process of caring for captive NHPs alongside with poor 
laboratory handling of their respective virally infected tissues and/or fluids 15;16. Interestingly, 
there is another alternative but unsubstantiated propositions of this complex and controversial 
topic on the origin of HIV 17. 
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1.1.3. HIV prevalence and Trends in Africa 
During the 1980s, researchers in Africa observed a high HIV prevalence among female 
commercial sex workers and patients attending sexually transmitted infections (STIs) clinics 
18-21. Consequently, a consensus was reached among AIDS experts dealing with Africa that 
heterosexual and vertical transmissions were the primary modes of HIV acquisition in adults 
and children, respectively 22-24. Thus, it is now widely accepted that the HIV-1 epidemic in 
SSA is mainly driven by heterosexual transmission 25. Husbands have been shown to acquire 
HIV-1 infection first from extra marital affairs and then proceed to infect their wives 26;27. 
Cultural practices such as inheritance of widows and re-use of sharps by traditional healers 
have also been implicated in driving the pandemic to alarming levels in some regions. As a 
result HIV pandemic within the continent reflects many co-existing sub-epidemics in different 
regions as shown in Figure 1.2.  
 
Figure1 2: HIV Prevalence trends among the 15-49 year olds over the past 10 years in SSA 28  
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1.1.3.1. Striking Differences in HIV Prevalence in SSA 
Within Africa there are striking regional differences in HIV prevalence 29;30. Among women 
attending antenatal care (ANC), HIV prevalence increased from 20–26 % between 1997 and 
2002 for Southern Africa, but actually declined from 14% to 1.4% and 5% to 4% for Eastern 
and Western Africa, respectively during the same period 31. Interestingly, in Kinshasa, the 
purported region for the origin of HIV, sero-prevalence amongst pregnant women steadily 
rose from 0.25% in 1970, to 3.0% in 1980 and 5.7% in 1990s 32. Amongst some neighboring 
SSA countries huge differences in HIV prevalence have been observed being, 38%, 20%, 
14% and 10% for Botswana, Zimbabwe, Mozambique and Tanzania, respectively yet social 
and cultural differences among these African countries are relatively small 33. HIV prevalence 
discrepancies are so distinct suggesting that there could be other possible unique but currently 
unknown precipitating factors in the high prevalence countries contributing to the pandemic. 
 
1.1.3.2. HIV Transmission Modes in Africa, Controversies 
Some researchers in an attempt to explain the observed heterogeneity in HIV prevalence are 
supportive of the hypothesis that HIV infections in SSA may not be explained by sexual or 
vertical transmissions alone 34-38. Studies have demonstrated that STIs facilitate HIV 
transmission 39-41. Assuming this synergism, a high burden of STIs should correlate with high 
HIV prevalence. However, ecological comparative studies from population based surveys 
from high and relatively low HIV prevalence areas in Zimbabwe and Tanzania respectively, 
have reported more or less similar burdens of STIs but distinctive HIV prevalence 42. More 
interestingly, studies have also shown that Hepatitis B virus (HBV) which has similar modes 
of transmission to HIV and in addition much more infectious has generally a much lower 
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prevalence 43. HBV infection is common in SSA with Mozambique having the highest 
incidence rate yet this country’s HIV-1 prevalence is amongst the lowest in the region 44;45.  
 
HIV infection has been confirmed in a number of pediatric cases where its source has not 
been adequately explained 46;47. Studies have observed an unexplained high HIV-1 incidence 
among pregnant women who were sero-negative at the first antenatal visit but sero-converted 
later during antenatal and post-partum periods 48;49. This observation is suggestive that 
whatever happens during pregnancy and post-partum periods whether iatrogenic, sexual or 
otherwise accounts for the high HIV incidence rates observed among these generally low 
risky women. Some researchers argue that the massive increase in use of medical injections 
for parenteral therapies to treat diseases could have been the possible source of the 
background effect of high HIV infection in some communities 50-55. HIV has been shown to 
stay infectious on a needle for more than two weeks 56. This hypothesis of unsafe medical 
injections has been shown to be scientifically implausible as some countries like Egypt where 
despite the vigorous parenteral anti-schistosomal treatment campaigns has very low HIV 
prevalence but interestingly the highest hepatitis C virus (HCV) disease burden in the world.  
 
Paradoxically, recent meta-analysis studies have observed relatively large proportions of HIV-
1 discordant couples in Africa with women as likely as men to be the index HIV-1 positive 
partners 57;58. Even more intriguingly has been the observation that some of these HIV sero-
discordant couples continue to bear children implying unprotected sex 57 suggesting that 
something other than simply heterosexual transmission could be involved. Regional 
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differences in HIV-1 prevalence of discordant couples vary from 8-31%, and 16-31% for 
Eastern and Southern Africa respectively, coincidentally, reflecting the same trend with HIV-
1 prevalence 59. Thus, there are research gaps to elucidate the precipitating factors which 
could have contributed to a relatively much more efficient transmission of HIV-1 in SSA 
resulting in the virus infecting more than a quarter of the population in some communities 60-
63. Thus, several factors may contribute to the differential spread of the HIV pandemic within 
the region including behavioral, biological factors, viral characteristics, unsafe medical 
practices and ethnic variation in host HIV restriction genes. Each of these factors alone or in 
combination could determine susceptibility to infection and consequently affecting the 
observed differential rates in progression towards AIDS. 
 
1.2.0. Zimbabwe: Geographical Location, Demographics and Socio-Economics 
Southern Africa      Zimbabwe 
 
Figure 1.3: Geographical Location of Zimbabwe and Study Sites 
 
Study Sites 
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1.2.1. Geographic Profile  
Zimbabwe lies north of the Tropic of Capricorn between the Limpopo and Zambezi rivers. 
Situated in Southern Africa, it is a landlocked country covering an estimated area of 390,784 
km². Zimbabwe borders Zambia, Mozambique, Botswana and South African to the north, 
east, west and south, respectively. A narrow Caprivi Strip is also shared in the north-western 
border with Namibia. For administrative purposes the country is divided into ten provinces 
which are further divided into 58 districts. Zimbabwe attained its independence from the 
British in April 1980 after a protracted armed guerilla struggle. Since then until the late 1990s 
all sectors of the economy performed well. 
 
Zimbabwe boasts of abundant natural resources that include 9 million hectares of potentially 
arable land and more than 5 million hectares of forests, national parks, and wildlife estates. 
The country is adored for its extensive and varied mineral resources such as platinum, gold, 
asbestos, coal, nickel, iron, copper, lithium, including precious gems like emeralds and 
diamonds. There are adequate supplies of surface and ground water which are not only 
enough for domestic and industrial uses but can also be harnessed for generation of hydro-
electric power and irrigation of crops. Thus, the economy is diversified but biased towards 
agriculture, mining and tourism. However, despite the abundance of these natural resources 
the country has been riddled with profound socio-economic and political challenges in the last 
decade that nearly drove the economy into oblivion had it not been for the government of 
national unity (GNU) signed in February 2009 by the three major feuding political parties.  
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1.2.2. Population Size and Trends  
A national census is carried out every ten years since 1931. Currently the 2012 census is 
ongoing. The population has been doubling almost every 20 years. According to the previous 
2002 census, Zimbabwe had 11.6 million people, 1.2 million more than in 1992 and 4.2 
million more than in 1982 64. There are dissensions to the effect that the 2002 census excluded 
about three million Zimbabweans who are economic refugees in the Diaspora. About 70% of 
the population lives in the rural areas. Africans constitutes about 98% of the population. 
Major ethnic groups are the Shona (82%) and Ndebele (14%) tribes with the rest being other 
ethnic minorities as shown in Table 1.1. Zimbabwe is generally a Christian nation and in 
some instances mixed with traditional beliefs. About 1% of the population is Muslim. 
National literacy rate is very high (94%) with almost all the urbanites being literate. The 2002 
population pyramid had a wide but tapering base depicting a population experiencing a 
decline in fertility probably due to previous socio-economic hardships and/or the current 
HIV/AIDS pandemic. On a lighter note, the current total fertility rate for Zimbabweans is 4.1 
children per woman slightly higher than the previous the rate 65. 
Table 1.1: Trends of Selected Demographic Indicators in Zimbabwe 64 
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National surveys which involve HIV testing called Demographic and Health Surveys (DHS) 
are conducted every five years. The primary objective is to provide current information and 
statistics on key health indicators such as fertility levels, sexual activity and mortality rates 
including HIV infection for policymakers, planners and researchers. Though quite expensive, 
these surveys offer nationally representative statistics as more than 11000 randomly chosen 
households are enumerated and over 43000 individuals interviewed. According to the latest 
2010-11 DHS, females represented 53% of the population whilst the proportion of children 
under 15 and senior citizens above 65 years of age were 43% and 5%, respectively, 65. Median 
ages at first marriage among women and men were 19.7 and 24.8 years, respectively. Eleven 
percent of married women were married to men already in polygamous unions 65.  
 
1.2.3. Socio-economic conditions  
Zimbabwe has been the only country in the Southern Africa Development Community 
(SADC) region experiencing a negative economic growth rate following political and 
economic crisis since year 2000. The economy deteriorated from one of Africa's strongest to 
the world's worst with the official inflation rate estimated at more than 1 000% in 2006 66. 
Excessive demand for foreign currency pushed inflation from 231 million percent in July 
2008 to more than 79.6 billion percent per month, thus translating to an annual inflation rate 
of over 90 sextillion (1021) percent 67. Zimbabwean currency of billions denomination, as 
shown in Figure1.4 below, was literally not worth the paper on which it was printed.  
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Figure 1.4: Zimbabwean Currency during Hyperinflation Period 
 
The country experienced acute shortages of foreign currency, food stuffs, liquid fuels, 
electricity, medical equipment and drugs. With over 80% formal unemployment levels, the 
informal sector has been growing stronger over the years. Compounded by sanctions, 
hyperinflation has been the major problem for the past decade in Zimbabwe until April 2009 
when the new coalition government suspended the use of local currency in favor of multi 
foreign currencies. Economic challenges encountered in the period 2000-2008 led to acute 
poverty. Coping strategies to mitigate food and foreign currency shortages were devised. 
Most jobless Zimbabweans especially women resorted to cross border trading with regional 
and Asian countries exposing themselves to sexual and other forms of abuse during the 
execution of their work 68. As the economy deteriorated further, farmers failed to cope with 
the economic volatility triggered by land reforms. Consequently, food shortages were 
inevitable. Low remuneration not commensurate with the then prevailing economic conditions 
made working in the health sector non-conducive leading to low morale. Consequently, there 
was massive brain-drain of experienced professionals in all sectors of the economy among the 
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general population to unprecedented levels. Challenges associated with staff attrition in the 
health sector negatively impacted on the quality and coverage of HIV/AIDS health programs.  
 
1.2.4. Health Care 
Soon after independence, the Zimbabwean government adopted national policies that 
benefited the black majority such as access to free education and health care. One of the 
salient policy tenets in post independent Zimbabwe was “Health for all by year 2000”. To this 
end, the government built over 240 new health centres and refurbished and upgraded over 500 
pre-existing centres. The Zimbabwean’s healthcare system was so good that 85% of the 
population lived within 10 kilometers of a health care facility. Quality of life of most 
Zimbabweans improved dramatically as depicted by key health indicators such as life 
expectancy, maternal and infant mortalities. Sadly, these early socio-economic gains were 
short lived as maternal mortality rate increased from 283 per 100000 in 1994 to 555 deaths 
per 100000 live births in 2005 69. Infant mortality rate rose from 50 per 1000 live births in 
1990 to 60 per 1000 in 2006 70. Adult mortality rate sky-rocketed from 286 per 1,000 in 1990 
to 751 per 1000 in 2006, aggravated by the fact that over 91% of the population did not have 
health insurance 70. This drastic fall in vital health statistics was a consequence in part due to 
the diminished access to healthcare, closures of public hospitals, scarcity of essential drugs 
and inadequate or prohibitive medical care services complicated by foreign currency 
shortages. Most distressing was the fact that average life expectancy at birth fell dramatically 
from 60 years for both sexes in 1990 to about 40 years in 2006 as shown in Figure 1.5. 
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Figure.1.5: Trends in Life Expectancy in Zimbabwe Relative to other African Countries 71 
 
Malnutrition and high HIV prevalence were major factors that precipitated the decline in life 
expectancy 72-77. On a lighter note, the current economic stability and recovery resulting in 
better health delivery and increased access to HIVAIDS therapy as well as better nutrition 
have seen marked improvement in welfare of most Zimbabweans 78. 
 
1.3.0. The Zimbabwean HIV/AIDS Situation  
1.3.1. HIV/AIDS; the Beginning  
The first AIDS case was reported in Zimbabwe in 1985 79. Since then more patients began to 
present with illnesses suggestive of HIV infection. Young adults presented with severe 
respiratory infections, herpes zosters, persistent generalised lymphadenopathy and diarrhea 
associated with weight loss 80. Children were seen who appeared to be suffering from 
malnutrition but whose socio-economic backgrounds were inconsistent with poverty and such 
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patients failed to respond to standard nutritional and conventional medical treatments, 
suggesting an immunodeficiency condition.  
 
1.3.2. HIV in Blood Donors 
The foregoing observation was the basis for the introduction of routine HIV-1 testing of 
donated blood and blood products in August 1985 by the National Blood Service Zimbabwe 
(NBSZ). Since then, HIV testing has been available to clinicians 81. HIV-1 sero-prevalence 
amongst blood donors by then was 2%. Ten years later, the HIV sero-prevalence amongst 
blood donors had arisen to 8.8% with a sero-incidence of 2.1 per 100 person-years being 
highest among married first-time blood donors of 21-45 years of age 82;83. From 1995 
onwards, HIV testing included screening for both the two types, HIV-1 and HIV-2 84. As of 
2010, NBSZ reported an HIV-1 prevalence of 0.74%, a slight decline from 0.77% in 2009 85. 
Within this healthy blood donor population the hepatitis B virus (HBV) and syphilis sero-
prevalence were 0.97% and 0.68%, respectively 85. Over the years there has been a 
remarkable decline in HIV-1 prevalence among blood donors as shown in Figure 1.6.  
 
Figure 1.6: HIV Sero-Prevalence Trends among Blood Donors (1995-2009) 85 
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1.3.3. HIV-1 in the Military Population 
Militaries are generally reluctant to divulge figures on HIV prevalence for security reasons. 
However, Zimbabwe Defense Forces’ (ZDF) figures are believed to be high 95;96. The risky 
behaviour of military personnel compounded by the high HIV-1 sero-prevalence within this 
population has been a cause for concern 97;98. ZDF personnel have been actively involved in 
peace keeping mission in Somalia, Rwanda, and Angola. Controversially, they have been 
deployed in the Democratic Republic of Congo (DRC) and Mozambique to fight civil war in 
support of the ruling regimes alongside other troops from Angola and Namibia. These 
external missions, whether offensive in nature or peace keeping have had a bearing on the 
transmission of HIV/AIDS within the armed forces to and from the civilian population both at 
home and abroad. There has been a deep concern regarding the possibility of ZDF personnel 
introducing new infections into the country inclusive of HIV infections. There are suggestions 
to the effect that the epidemic originated from multiple introduction into the country in the 
late 1970s during the demobilization phase of war corresponding to rapid influx of native 
military personnel from neighbouring countries 99 . 
 
1.3.4. HIV-1 Trends and Distribution in the General Population  
Following the diagnosis of the first case of HIV-infection in 1986 in the Northern district of 
Hurungwe, a local hospital based surveillance system was introduced to monitor the spread of 
the epidemic. This was before the official notification system included the HIV syndrome. 
AIDS cases increased exponentially from 19 in 1986 to 290 in 1987, 433 in 1988, and 145 
during the first quarter of 1989 86. As early as 1987 the prevalence had shot up to 3.2% and 
interestingly all infections were found in the 17-30 years old group 87. A cross sectional 
hospital-based study screening for STIs amongst adult volunteers at Murehwa rural district 
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hospital, 100km north east of Harare demonstrated a 50% HIV-1 sero-positivity in adults with 
STIs 88. This fast growing HIV epidemic became a major threat to the health and development 
of the district, nation, region and the world at large, raising many questions. Where did this 
infection come from and why so many cases in a very short space of time? Sadly in 
Zimbabwe, there was so much denial by the government until 1990 when HIV/AIDS issues 
were debated in the public domain.  
 
The coming together of traditional culture with the colonial legacy of men migrating to cities 
for employment leaving behind their spouses has influenced family structures and sexual 
relations. 89. In Zimbabwe just like the rest of Africa young women continued to bear the 
brunt of the pandemic. Thirty four percent of women and 21% of men tested for HIV and 
received their results in the past year in the 2010-11 DHS relative to just 7% for both sexes in 
the 2005-6 DHS. One percent of the women and 11% of men of the 15-49 age group reported 
having sex with at least two partners during the past year of which 48% and 33% of the 
women and men, respectively reported using of a condom during their last sexual intercourse. 
All in all 15% of adults were HIV-1 positive down from 18% in the previous 2005-6 DHS. 
When stratified by gender HIV-1 prevalence was 18% and 12% for women and men, 
respectively and generally HIV was more prevalent in urban settings as depicted in Figure 
1.7. Interestingly, there was also no clear relationship between wealth and HIV prevalence 
among both women and men 65. Similarly no clear relationship between level of education 
and HIV prevalence has been observed among women. Conversely, HIV prevalence 
decreased as education level increased amongst men. Circumcised men in the age group 15-
49 were slightly more likely to be HIV positive than those who were uncircumcised 65. Thus, 
sadly circumcision may be giving a false sense of HIV protection among these men. 
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Figure 1.7: HIV-1 Prevalence among the 15-24 years old by Gender and Place of Residence 65. 
 
Recent statistics on 2700 co-habiting couples has shown that in 79% of the cases both partners 
were HIV negative whilst 10% were both HIV positive 65. Interestingly, 11% were discordant, 
that is, one partner was infected with HIV whilst the other was not 65. Thus, sexual contact 
with an HIV infected person represents only a necessary, but not sufficient, condition for HIV 
transmission through sex suggestive that other cofactors may be central in fueling the HIV 
epidemic in SSA. Studies have observed a synergistic relationship between HIV and co-
infections including malnutrition and these have been implicated as possible cofactors for 
HIV-1 acquisition and transmission 90-93.  
 
The scale of the epidemic at country level reflects its widely disseminated nature with HIV 
prevalence in small towns, farming estates and mines located in rural areas (22%) exceeding 
that in the major cities (14.5%). Significant variations in the pandemic prevalence are also 
observed across the country provinces with Matabeleland South, bordering Botswana showing 
the highest prevalence. Ironically Harare, the capital city recorded the lowest as shown in 
Figure 1.8. 
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Figure 1.8: HIV Prevalence by Province in Zimbabwe 65. 
 
Using the Epidemic Projection Package (EPP) and Spectrum software, declines have also 
been observed in both sentinel surveillance of pregnant women and in the National HIV 
Estimates process that models all available data. Single digit prevalence is being projected 
from the year 2016 as shown in Figure 1.9. 
 
 
Figure 1.9: Zimbabwean Trends in Adult HIV Prevalence and Projections, 1970-2015 94. 
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1.3.5. Impact of HIV/AIDS in Zimbabwe 
In 2009 alone 83,000 HIV/AIDS related deaths were recorded. The number of children 
orphaned that is, a child with one or both parents dead due to HIV/AIDS in Zimbabwe 
remains unacceptably high (20%). The approximate number of such orphans is estimated to 
be one million 100. The Food Agriculture Organisation (FAO) estimated that Zimbabwe lost 
about 23% of its agricultural workforce due to the HIV/AIDS pandemic 101. 
 
Exacerbated by 
the apparent shortages of inputs, poor irrigation and low capitalisation levels the agricultural 
sector experienced a negative average growth rate of minus 8% over the past decade 101 and 
this had obvious negative repercussions on food security and the general health of the nation 
at large. One million two hundred thousand people are living with HIV/AIDS of which 
200000 are children under 15 years. Access to antiretroviral therapy (ART) is quite limited in 
Zimbabwe. With over 300,000 people in need of ART, Zimbabwe is among the 20 countries 
identified by the World Health Organization (WHO) as having the highest unmet needs for 
ART. AIDS stigma has been an impediment to the uptake of voluntary counseling and testing 
(VCT) of HIV 102. On a positive note, access to treatment has mitigated the stigma and 
fatalism associated with HIV infection and AIDS thereby enhancing uptake of VCT. 
Maintaining millions of people on treatment throughout their lifetimes is not sustainable and 
hence the importance of prevention strategies needs not to be over-emphasised. 
 
1.3.6. HIV/AIDS & Legislation  
In Zimbabwe discrimination of HIV positive people is prohibited under National HIV and 
AIDS Policy of 2000 and the Statutory Instrument (SI 202) of 1998 which prohibits HIV 
screening for purposes of employment. The country has not been able to fund its response to 
HIV/AIDS through domestic and international sources of finance. It was against the 
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background that the government of Zimbabwe used the Presidential Powers (Temporary) 
Regulations to declare HIV/AIDS a national disaster. This consequently legally empowered 
Zimbabwe to manufacture antiretroviral generic drugs locally. Criminal Law (Codification 
and Reform) Act 23 of 2004 is an extraordinary piece of legislation which makes it a crime 
for a person who knows that he or she has HIV to infect another, even between husband and 
wife. Some authors’ summaries it all by saying “that such a law creates a crime not of effect 
and consequence, but of fear and possibility” 103. They go on to argue that enacting of HIV-
specific laws to criminally punish transmission of, exposure to, or non-disclosure of HIV, is 
counter-active to good public health conceptions and unacceptable to elementary human 
rights principles. 
 
1.3.7 Mitigation Strategies  
As part of the nation’s attempts to raise funds for the control and management of HIV/AIDS 
the Government of Zimbabwe introduced the National AIDS Trust Fund (also called AIDS 
Levy) which entails collection of 3% of all taxable individuals and corporates incomes to fund 
HIV/AIDS programmes. There has been introduction and integration of family planning with 
HIV/STI and maternal health services voluntary counseling and testing (VCT), prevention of 
mother-to-child transmission (PMTCT) including primary care to identify the infected 
individuals with the intention of preventing both horizontal and vertical transmissions. 
Widowhood has been shown to play an important role in the transmission since it has been 
associated with 8–17% of all HIV cases 104. As such family structures of traditional intra-and 
intergenerational coping mechanisms such as the levirate, whereby a widow is re-married to a 
close family member of the deceased husband are now discouraged 105. Since 2009, 
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Zimbabwe has made available circumcision procedure to adult and adolescent men through a 
there has been collaborative effort between the government and technical agencies with the 
aim to reach 1.2 million 15–29 year-olds by 2015 for male circumcision 106;107. The steady 
HIV-1 prevalence decline is also attributed to several factors such as behaviour change, 
condom use or high mortality rate of the infected 108-110. Hopefully it continues to fall. The 
severe economic decline in the last decade has played a considerable role in sexual behavior 
change, particularly partner reduction especially amongst urban men 34. With less disposable 
income during the economic meltdown many men were not able to purchase sex or sustain 
multiple sexual relationships 110;111. Decline could also be due to the early adoption of a 
home-based care policy by the Zimbabwean government's which could inadvertently have 
fast-tracked the process of behavior change. It has been hypothesized that, when AIDS 
patients die at home, a situation where family members and friends have direct confrontation 
with AIDS mortality is more likely to instill fear of contracting the infection unlike a situation 
where such patients are cared for in health institutions 112. The epidemic in Zimbabwe is also 
believed to be declining as result of the impact of the prevention programmes such as 
Prevention of Mother to Child Transmission (PMTCT). Mother to child transmission (MTCT) 
of HIV is a huge problem in Zimbabwe which has become the major cause of infant and child 
mortality 118. 
 
1.4.0. Pregnancy, HIV and PMTCT in Zimbabwe 
1.4.1. HIV and Pregnancy Disease Burden and Trends 
Besides the DHS much of the information on national HIV prevalence in Zimbabwe is 
derived from surveillance of pregnant women attending ANC. In such generalized epidemics, 
pregnant constitute an easily accessible population which is generally representative of the 
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general sexually active population 119. Routine sentinel surveillance of pregnant women 
attending ANC commenced in 1990. It has provided the estimated HIV prevalence rates for 
the adult population. In some border towns sentinel sites the HIV-1 prevalence among 
pregnant women has been alarming, compared to the national average Figure 1.10. 
 
Figure 1.10: HIV prevalence among pregnant women in some border town sentinel sites 120. 
 
In Harare, the capital city, the picture was different with incidence and prevalence peaking 
around year 2000, Figure 1.11. A large study apparently spanning the peak of the HIV-1 
epidemic among reproductive women in Harare that recruited over 14 000 pregnant women 
reported HIV-1 prevalence from 0% among the 14-year-olds to over 45% among women aged 
29–31 years, falling to 20% among the >40 years age group, with an alarming overall 
prevalence of 32% 122;123. On a positive note, HIV prevalence among women attending ANC 
declined from around 32% in 2000 to about 13% in 2011 118;122;124-130. 
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Figure 1.11: Estimated and fitted curves, HIV incidence(----), prevalence            (         ) and deaths 
(….) among women attending antenatal and maternal clinic in Harare 121 
 
1.4.2. Mother-to-Child Transmission (MTCT) of HIV 
Despite the high HIV-1 prevalence in the general populace which translates to high vertical 
transmission rates, the desire to have future pregnancies among HIV-1 positive mothers has 
increased from 3% to more than 55% over the years, more so with the advent of HIV-1 
PMTCT initiatives 114;131;132. Annual births stand at about 379000 with more recent neonatal 
and infant mortality rates of 36/1000 and 56/1000, respectively 133-135. Out of these 47,494 
pregnant women are HIV infected resulting in about 17,370 new pediatric HIV infections 
annually 135. MTCT of HIV is the most significant source of HIV infection in children below 
the age of 15 years 118. In the absence of ART, MTCT of HIV-1 can occur during pregnancy, 
intra-partum or postpartum through breastfeeding with risks of 10%, 25% or 40%, 
respectively 136. Comprehensive PMTCT services based on single dose Nevirapine (SdNVP) 
to reduce mother-to-child transmission (MTCT) was initiated in 1999. It was only after 
December 2008 that the country started rolling out multiple dose PMTCT regimens 137. 
Between 1980 and 2005, among 10 million children born in Zimbabwe, a cumulative 504,000 
were vertically infected with HIV 138. As of 2010 it is estimated that about 120000 children 
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between the ages of 0-15 are living with HIV/AIDS of which 3.4% of children aged 10 years 
are long-term survivors of MTCT 139. ART has proved effective in reducing rates of MTCT of 
HIV-1 to very low levels not only in resource-rich countries but also in some resource-limited 
settings 140;141 as shown in Figure 1.12.  
 
 
Figure 1.12: Transmission rates and proportions of infections. Panel A without interventions and 
Panel B with short course antiretroviral interventions provided 142 
 
1.4.3. PMTCT Practices in Zimbabwe 
The goal of PMTCT in Zimbabwe is to reduce PMTCT of HIV infection, thereby leading to 
reduction of infant morbidity and mortality. PMTCT practices are carried out during the 
antenatal period, labour and delivery and post-natal period including after hospital/clinic 
discharge as summarised in Figure 1.13 below. 
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Figure 1.13: Summary of PMTCT practices during labour and delivery including postnatal during the 
time of the study. 
 
Sadly, most women go for pregnant registration when their pregnancies are at advanced 
stages, a situation which put their unborn babies at risk. Consequently, the MTCT 
transmission rate remains high 143;144. Studies have shown that if effective antiretroviral drugs 
are not provided, abstinence from breastfeeding or early weaning may result in no benefit for 
HIV-free survival in resource poor settings 145;146. Exclusive breast feeding and provision of 
extended prophylactic HAART to the infant have been the practical option effective in 
prevention of transmission in such settings 147, Figure 1.14. This option is still to be 
implemented in Zimbabwe. 
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Figure 1.14: Balancing adverse outcomes in breastfed and non-breastfed infants. In red colour  are the 
infected infants 145. 
 
Promotion of exclusive breastfeeding within the first 6 months of life has become the 
cornerstone of child survival programs in Zimbabwe regardless of the infant’s or mother’s 
HIV status. Despite encouraging exclusive breast feeding for infants under 6 months of age 
only about 6% of the mothers strictly follow this instruction 78. Early HIV infant diagnosis 
using the HIV DNA PCR testing was introduced at National Medical Reference Laboratory in 
2008 148. 
 
1.4.4. PMTCT Coverage in Zimbabwe 
Coverage (50%) and acceptance (42%) have been relatively low resulting in a relatively slow 
decline in MTCT rates 149;150. Lately most HIV/AIDS services have been decentralised to 
clinics thus improving coverage and access to services in both urban and rural settings. As a 
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result comprehensive PMTCT sites increased from 710 in December 2007 to 920 in 
December 2008 and up to 960 in 2009. Provider Initiated Testing and Counseling (PITC) 
initiative has resulted in a further dramatic increase in HIV testing. This has been achieved 
through training large numbers of healthcare workers accompanied by more health care 
facilities providing testing and counseling services. The country has seen a general increase in 
uptake of PMTCT by pregnant women, although, worrisomely has been the vast gap of 
uptake of such services between mothers and infants as depicted in Figure 1.15. With 
continued efforts to reach women with PMTCT services and renewed commitment to address 
gaps in ANC access national targets for PMTCT can be met. By year 2015, at least 85% of all 
HIV positive pregnant women are to receive antiretrovirals for PMTCT whilst all HIV-
exposed infants are to have virologic testing within 6 weeks of life. 
 
Figure 1.15: PMTCT program performance over 5 years; 2004-2008 148. 
 
1.4.5. PMTCT Impact and Challenges 
There are claims that between 2002 and 2005, SdNVP PMTCT program have averted 4600 
infections 138. However, more infections would have been averted if more efficacious 
regimens could have been used. More efficacious regimens for PMTCT will start at 14 weeks 
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gestation including extended use of nevirapine for infants. It is sad to note that most of the 
sites are still offering SdNVP with very few sites offering more efficacious regiments. Brain 
drain causing high staff attrition rates has been counter-productive as there is constant need to 
train and re-train. Moreover, there is limited access to lab services especially disease 
monitoring tests such as CD4 testing and PCR for viral load testing as they are beyond the 
reach of many. Most HIV/AIDS patients on ART in Zimbabwe also generally use traditional 
herbal remedies to supplement treatment 115-117. There is a gap in knowledge on the safety of 
concurrent use of the traditional herbal remedies and antiretroviral drugs.  
 
1.4.6 Risk Factors for Vertical Transmission 
Cognizance that about 70% of the HIV-1 exposed infants remain unaffected even in the 
absence of antiretroviral prophylaxis means that other factors also come into play in PMTCT. 
Genetic variations in HIV-1 co-receptors and determinants of immunity have been shown to 
influence the outcome of MTCT of HIV-1 151;152. HIV-1 variants that result in either increased 
CCR5 expression or a non-functional receptor (32 base-pair deletion variant) have been 
shown to influence the risk of vertical transmission 153;154. Genetic determinants of innate 
immunity such as the toll-like receptor-9 and mannose-binding protein have also been shown 
to affect the risk of MTCT 155;156. Discordance at the human leukocyte antigen (HLA) class I 
loci between mother and child have been shown to protect against MTCT 157. Dendritic cell–
specific ICAM-3 grabbing-non-integrin (DC-SIGN, encoded by CD209) is a C-type lectin 
that binds to many pathogens including HIV-1 158 resulting in viral capture. Studies have 
reported significant associations between DC-SIGN genetic variants that modulate DC-SIGN 
expression in placental macrophages and increased risk of MTCT 159. High maternal viral 
loads in serum or breast milk and low CD4 cell counts as well as other obstetric factors such 
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as prolonged membrane rupture, preterm and vaginal deliveries have been correlated with 
increased risk of MTCT of HIV-1 152;160;161. Previous reports have shown that treating women 
with low plasma CD4 count reduces postnatal HIV transmission, Figure 1.16 
 
Figure 1.16: Postnatal transmission rates and maternal immunity with and without intervention. Panel 
A: Without intervention postnatal HIV transmission rates in the population are an average of low rates 
among women with high CD4 counts and high rates among women with low CD4 counts. Panel B: 
With ARTs given to women with low CD4 counts, the postnatal HIV transmission rate in this group, 
and in the overall population, declines to low levels 162. 
 
HIV diversity has been shown to play a pivotal role in transmission as some variants have 
been shown to be more transmissible than others. Consequently, the efficacy of regimens of 
PMTCT administered only at labour may not be as protective in different geographical 
regions with different subtypes. The control of MTCT requires not only a deep understanding 
of MTCT of HIV but also the interplay between host-viral factors. 
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CHAPTER 2 
2.0 Introduction 
2.1  HIV Structure and Gene Organisation 
HIV-1 is a member of the genus Lentivirus within the family of Retroviridae 163. The term 
Lentivirus is derived from the Latin word lentus, meaning slow thus relating to the slow 
nature of the course of disease caused by these viruses. The HIV virion has a diameter of 
about 100 nm 164. Host derived lipid bi-layer acquired during budding envelopes the virus. 165. 
The genome is approximately 9 kb consisting of 9 genes encoding 15 different proteins 166. 
Two copies of single stranded RNA genome are packaged in the virus particle alongside with 
enzymes as shown in Figure 2.1.  
 
Figure 2.1: HIV Structure Adopted from Reference 167 
 
HIV genes can be either structural or regulatory. Structural genes are pol gag and env as 
shown in Figure 2.2 below. Pol gene products include enzymes reverse transcriptase (RT) 
(p66), integrase (p32) and protease (p10) 168. RT has strand–switching activity but lacks proof 
reading mechanisms causing mutations 169. Integrase facilitates incorporation of viral DNA 
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into host chromosomal DNA, whilst the protease cleaves the group specific antigen (gag) and 
pol protein precursors into their respective individual components 170;171 . 
 
Figure 2.2: HIV-1 Gene Organisation, Adopted from 167 
 
Gag poly-protein is cleaved into four structural components namely; the matrix (p17), capsid 
(p24), nucleocapsid (p7) and p6 that are each involved in nuclear importation of HIV pre-
integration, binding cyclophilin A, binding RNA and interaction with viral protein R (Vpr), 
respectively 172;173. Accessory or regulatory genes modulate virus replication. These include 
(Vpr; p15), viral infectivity factor (Vif; p23), viral protein U (Vpu; p18), negative regulation 
factor (Nef; p24), transcriptional activator; (Tat; p14) and regulator of viral gene expression 
(Rev; p19) 174. Roles of the accessory genes are summarised in Figure 2.2. Long terminal 
repeats (LTR) constitute the control regions that bind to host transcription factors whilst 
nuclear factor kappa beta (NFκβ) and nuclear factor of activated T lymphocytes (NFAT) are 
critical in the initiation of transcription 175;176.  
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2.1 1 HIV Envelope (env) Glycoprotein (gp) 
HIV env gene encodes the viral gp 120 and gp41 which both recognize and bind to host cell 
surface receptors 177. The gp120 is composed of relatively conserved constant (C) C1 to C5 
and variable (V) V1 to V5 sub-regions 178. HIV env is ranked one of the most heavily 
glycosylated proteins known in nature with potential N-linked glycans (PNGs) constituting 
over 55% of its molecular weight 179. This extensive glycosylation is known to play a critical 
role in viral evasion of the host immune response by masking key neutralization epitopes such 
that the glycosylated env (glycan shield) is presented to the immune system as “self” 180. The 
env gene displays considerable plasticity which enables it to change its three-dimensional 
configuration consequently allowing escape from antibody-mediated neutralization 181. 
Changes in the number of env gp 120 PNGs and variable regions amino acid length 
polymorphisms have been associated with striking a balance between transmission 
competence and resistance to immune challenges 182. Under natural host immune response or 
anti-retroviral therapy (ART) selection pressures, it is postulated that HIV-1 evolves towards 
a denser glycan shield 181;183. Thus, shorter variants with fewer glycans are expected during 
earlier phases of infection whilst longer V1-V5 variants with more glycans evolve at later 
stages of HIV-1 infection 184-187.  
 
2.1.2  Envelope (Env) Protein and HIV Cellular Entry 
HIV-1 gp120 on the surface of the virion binds to the CD4 receptor on helper T cells, 
macrophages and dendritic cells, and either the α-chemokine receptor CXCR4 (T cell-tropic) 
or the β-chemokine receptor CCR5 co-receptor (macrophage-tropic) 188. Based on chemokine 
co-receptor usage, HIV-1 can be classified as CCR5 (R5), CXCR4 (X4), or dual tropic 
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(R5X4) 189. Most new infections are due to CCR5 HIV-1 variants 190. CXCR4-tropic viruses 
generally appear during the late stages of infection and are associated with increased 
pathogenicity 191. Gp120 V3 loop amino acid sequence is the critical genetic determinant of 
cellular co-receptors usage 192. Mutations within this region have been linked to changes in 
viral co-receptor usage 193. Interaction of env gp120 and CD4 surface molecules expressed on 
target cells results in conformational changes that exposes the co-receptor binding sites 194, as 
summarised in Figure 2.3.  
 
Figure 2.3: HIV Infection and Spreading 195. 
 
HIV virions are bound by DCs through the C-type lectin receptor, dendritic cell-specific 
ICAM-grabbing non-integrin-related (DC-SIGNR) also known as CD209L thereby 
augmenting viral spread by carrying virus to activated T-lymphocytes 196;197. Particles also 
bind B-lymphocytes through the complement receptor CD21 198. Virus or virus-infected cells 
ultimately reach the draining lymph nodes where by encounter activated CD4+CCR5+ T-
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lymphocytes that propagate further infection 199. The HIV promoter embedded in the 5′ long 
terminal repeats is able to engage the host’s transcription machinery for viral gene expression 
200;201. Figure 2.4 summarises the life cycle of HIV. 
 
Figure 2.4: HIV life cycle Adopted from 202. DNA is shown in blue while RNA is shown in pink. (A) 
Adsorption. (B) Fusion. (C) Uncoating. (D) Reverse transcription of the viral RNA genome into 
cDNA. (E) Pre-integration complex formation. (F) Nuclear import of pre-integration complex. (G) 
Integration of viral cDNA into the host. (H) Transcription of the proviral DNA. (I) Translation of Tat 
and Rev. (J) Import of Tat and Rev into the nucleus. (K) Rev facilitates the export of HIV-1 RNA 
genome for packaging. (L) Rev exports HIV-1 transcripts to the cytoplasm. (M) Assembly. (N) 
Budding. (O) Maturation.  
 
Eventually HIV disseminate to secondary lymphoid tissue throughout the body with a 
particular predilection for gut associated lymphoid tissue (GALT) where activated 
CD4+CCR5+ effector memory T-lymphocytes are present in high numbers 203. 
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2.2.3 Susceptibility to HIV Infection 
Why some individuals remain uninfected despite repeated sexual exposure to HIV-1 remains 
a mystery 204. However, this observation offers a unique opportunity for studying host genetic 
factors conferring susceptibility to HIV infection and differential progression to AIDS. 
Among host genetic factors identified for their roles in HIV-1 acquisition and/or transmission 
include polymorphisms in the genes encoding chemokine receptors CCR5, CCR2, stromal 
derived factor 1 (SDF-1) and human leukocytes antigens (HLA) ligands 205;206. Some alleles 
are protective 207;208 whilst others increase susceptibility to HIV acquisition 209-213  
2.2 Acute HIV Infection 
Acute or primary HIV infection is defined as the first period of infection from the detection of 
plasma HIV RNA up until the formation of HIV-specific antibodies 3-4 weeks post infection 
214. Consequently plasma viral load increases exponentially reaching a peak 21-28 days post 
infection. See Figure 2.5. Acute HIV infection leads to depletion of CD4+ T-lymphocytes in 
GALT subsequently causing irreversible damage to the host immune system 215. 
 
Figure 2.5: Natural History of HIV disease 216. 
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Viral reservoirs established during the primary infection facilitate HIV latency and 
persistence. More so, they have slower rate of decay relative to T-lymphocytes such that 
overall the virus cannot be eliminated even by highly active antiretroviral treatment (HAART) 
within the life time of the patient 217. 
 
2.2.1  Signs, symptoms and Diagnosis 
Acute infection is characterised by plasma HIV RNA levels of greater than 10,000 copies per 
milliliter (mL) 218;219. Patient(s) may develop symptoms of the acute retroviral syndrome 
which include influenza-like illness with fever, sore throat, lymphadenopathy and exanthema 
220. Frequently observed hematological abnormalities include thrombocytopenia, anemia, 
leucopenia, lymphopenia and monocytosis 221. CD4 counts are usually decreased and there is 
a reversal of the CD4:CD8 cell ratio 222. Tools used to detect primary HIV infection in the 
absence of sero-conversion include p24 antigen assays and nucleic acid testing 223;224. Assays 
for p24 antigen are widely available and relatively cheap. However, the test of choice is the 
polymerase chain reaction (PCR) for HIV-1 RNA which is rather expensive.  
 
2.2.2  Viral Load and Set point 
Eventually the viral load decreases over 12-20 weeks to reach a viral set point 225. HIV set 
point is the viral load that stabilises after acute HIV infection which is maintained at a plateau 
during the asymptomatic phase 226. Measurement of plasma HIV-1 RNA load is an important 
predictor of disease progression 227;228. The higher the viral load of the set point the faster the 
patient will progress to AIDS whilst the lower the value the longer the patient will remain in 
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clinical latency. See Figure 2.6 for the host and viral dynamics for typical, rapid and slow 
progressors including long term non-progressors.  
 
 
Figure 2.6: Viral and host dynamics and progression to AIDS adopted from 229  
 
Without antiretroviral therapy, the median time from initial infection to immune failure or 
AIDS amongst typical progressors is 7-10 years (75-80% of all patients) whilst the remaining 
patients experience either a more rapid progression to AIDS within 2-3 years (rapid 
progressors, (10-15%) or more extended periods without clinical disease progression >10 
years, long term non-progressors, (5-10%) 230. Interestingly, there is also a small unique 
subset of HIV sero-positive antiretroviral naive patients who remain aviremic with viral load 
below the detection limit of less than 50 HIV RNA copies/ml) for extended periods (elite 
suppressors (<1%) 230. 
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2.3 Control of Viremia 
Primary HIV infection presents with a high HIV titre that is initially controlled by a CD8+ 
cytotoxic T-lymphocyte (CTL) response alongside with anti-HIV antibodies 231;232. An 
effective cell mediated immune response is also characterised by increased numbers of natural 
killer cells and high cytokine levels such as INF-γ, TNFα and IL-1β 233. Humoral response is 
initially effective but declines as the disease progresses with neutralizing antibodies tending to 
be weak and lacking broad cross-reactivity 234. Despite the impediment of masking of env 
epitopes by the glycan shield, high HIV-1 genetic diversity is also a major challenge to 
antibody–mediated neutralization. Mutant viruses notoriously resistant to antibody 
neutralization are generated and archived in memory cells of viral reservoirs. HIV-1 diversity 
is one among several challenges that needs to be combated in attempts to design effective 
anti-HIV vaccines as generating broadly neutralizing antibodies that can efficiently inactivate 
or neutralize HIV variants remains elusive.  
 
CTLs are a heterogeneous population of cells that vary in their antiviral efficacy 235. They 
bear the CD8 molecule and are the major immunological mechanism in the control of viremia 
236. Non progression of HIV may associated with certain populations of HIV-specific CD8+ 
T-lymphocytes that display poly-functional characteristics and/or proliferative capacity that 
ensure maintenance of low plasma viral load. Up to 20% of circulating CD8+ T-lymphocytes 
can be HIV-specific in untreated chronically infected patients 237. Activation of CTLs also 
results in the release of soluble antiviral factors which inhibit progeny viruses from entering 
target cells 238. Such factors include the beta chemokines RANTES (regulated on activation 
normal T cell expressed and secreted), macrophage inflammatory protein 1 alpha and beta 
(MIP-1α and MIP-1β) which are all active against CCR5 viruses 239. 
38 
 
 
Mammalian cells harbor intrinsic cell-autonomous activities which can suppress viral 
replication, collectively called host restriction factors. Major classes of host restriction factors 
comprise, HLA alleles, killer-cell immunoglobin-like receptors (KIR), 240 apolipoprotein B 
mRNA-editing, enzyme-catalytic, polypeptide-like 3G (APOBEC3G) 241 proteins, tripartite 
motif-containing protein 5 alpha (TRIM5α) and tetherins 242-245 as shown in Figure 2.7. 
 
 
Figure 2.7: Host Restriction factors to HIVinfection. ART drugs block is shown in grey colour as it is 
not natural as drugs exert viral suppression only in patients undergoing therapy 246. 
 
ART drugs are also used to control viremia and details will be discussed in Section 2.4.5. In 
the absence of therapy HIV-specific CD8+ T-lymphocytes cannot completely clear the 
infection and consequently a chronic infection develops.  
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2.4. Chronic HIV Infection 
Chronic HIV-1 infection has been shown to be associated with persistent high level viral 
replication with half-life of plasma HIV RNA ranging from 0.5-6 hours such that half the 
plasma virus pool is replaced in thirty minutes 247. Major part of the chronic phase of HIV-1 
infection is a clinically asymptomatic period characterised by remarkably stable but subdued 
HIV-1 RNA load 248. While acute HIV infection is characterized by widespread explosive 
infection and massive depletion of memory CD4+ T-lymphocytes, chronic HIV infection is 
associated with gradual loss of the remaining CD4+ T-lymphocytes alongside with 
insufficient replenishment of the lost cells and persistent immune activation 249;250.  
 
2.4.1. Immune Activation 
Chronic activation of the immune system is a hallmark of progressive HIV infection that 
better predicts disease outcome than plasma viral load 251;252;253. Intriguingly, viral 
constituents such as gp 120, nef, including viral nucleic acids produced during viral 
replication including pro-inflammatory type 1 cytokines have been shown to be central 
players in the immune activation process 254;255. A vicious cycle is established during which 
HIV-1 replication promotes immune activation and immune activation promotes HIV-1 
replication 256. Nonetheless, the extent of activation during the course of HIV-1 infection is 
such that the stimulation with viral antigens may not solely account for the complete 
phenomenon of immune activation observed 257. The massive depletion of CD4+ T cells in the 
mucosal lymphoid tissues can result in the disruption of the different immune components 
that constitute the mucosal barrier in the gut thereby compromising its integrity resulting in 
40 
 
 
microbial translocation from the gut to the systemic immune system 258;259;260. Translocation 
of bacterial products causes profound activation of the innate immune response involving 
lipopolysaccharide (LPS), flagellin and CpG DNA, which are all toll-like receptor (TLR) 
ligands known to directly stimulate peripheral macrophages and DCs to produce a wide range 
of pro-inflammatory cytokines such as TNFα, IL-6 and IL-1β 257. Antigenic stimulation 
during HIV-1 infection may also be induced by some viruses, such as CMV and EBV as 
shown in Figure 2.8. 
 
Figure 2.8: Causes and consequences of immune activation are in yellow or red, respectively. 
Consequences of immune activation that make a parallel with human ageing are in italic 257  
 
Activation leads to robust proliferation and acquisition of effector functions, accompanied by 
cell surface phenotype expression changes that reflect the activation such as CD38, HLA-DR 
and Ki67 on both the CD8+ and CD4+ T-lymphocytes 261. Tenacious antigenic stimulation 
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and viral replication during chronic HIV infection may lead to immune exhaustion a 
phenomenon that has also been correlated with HIV disease progression. 
 
2.4.2  Immune Exhaustion 
Due to persistent viral replication and stimulation, HIV-specific CD8+ T-lymphocytes may be 
gradually driven towards an irreversible exhaustion of their replicative capacities and become 
worn-out cells 262. The term “immune exhaustion” is defined by loss of proliferative capacity 
and diminished effector functions of memory T-lymphocytes as the disease progresses. 
Markers of immune exhaustion include programmed-death 1 (PD-1), T-cell immunoglobulin 
and mucin domain-containing molecule-3 (Tim-3) and lymphocyte activation gene-3 (LAG-3) 
258. Despite the high expression of PD-1 in exhausted T-lymphocytes during HIV infection, 
not all exhausted cells display PD-1, suggesting the role of other inhibitory molecules 263.  
 
2.4.3   Acquired Immunodeficiency Syndrome (AIDS)  
Overall, the immune system of HIV-1-infected individuals faces major challenges of coping 
with massive T cellular destruction at the same time trying to contain viral replication such 
that with time deterioration of the immune system is inevitable. The dropping of CD4 T-
lymphocyte count to 200 cells/mL signals the onset of AIDS. AIDS is defined by the 
occurrence of infections associated with immune system deficiency called opportunistic 
infections. AIDS-Defining Conditions such as HIV-1 co-infections with cytomegalovirus 
(CMV), Herpesviruses, Pneumocystis carinii, Mycobacterium avium, Toxoplasma gondii and 
Candida among others have been shown to be associated with increased risk of death 264-267, 
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see Figure 2.9. At this stage the host's immune system is immuno-compromised to such an 
extent that without the initiation of HAART the infection progress to AIDS at rapid pace.  
 
Figure 2.9: CD4 T-lymphocyte depletion and progression to AIDS, adopted from 268 
2.4.4.  Highly active anti-retroviral therapy (HAART)  
HAART refers to a combination of anti-HIV drugs directed at different stages of HIV life 
cycle and or host surface cell co-receptors. Antiretroviral drugs include entry, (non)-
nucleoside/nucleotide reverse transcriptase, protease, integration and assembly inhibitors as 
shown in Figure 2.10. Therapy aims to suppress HIV replication, restore or preserve immune 
function and subsequently reducing HIV related morbidity or mortality with minimal toxicity. 
Thus, HAART essentially improves the quality of life of the infected individuals. Currently it 
is recommended to initiate therapy when the CD4 count is ≤350 cells/μL and also during 
pregnancy to prevent vertical transmission 269. HIV RNA infected T-lymphocytes persist in 
the lymphoid tissues despite years of effective HAART even with undetectable viral load 
270;271. 
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Figure 2.10: Potential and current targets for antiretroviral drugs in HIV-1 life cycle. FDA-approved 
(bold italic text), preclinical/abandoned (normal text) inhibitors 272. 
 
Unfortunately HAART cannot eradicate the virus and unfortunately viremia can be re-
activated following cessation of therapy 273. Despite restoring immune function, prolonged 
use of HAART represents additional risk factors for the development of metabolic 
complications 274. 
 
2.4.5.  Immune Recovery Following HAART  
Following successful HAART, there is a prompt and dramatic rise in circulating memory 
CD4+ T-lymphocytes attributed to reduction in apoptosis, redistribution of immune cells from 
lymphoid tissues, peripheral expansion of memory T-lymphocytes with limited T cell receptor 
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(TCR) diversity followed by thymic synthesis of naïve T-lymphocytes with broader TCR 
diversity alongside with restored thymic function 275;276. Within 6 months following the 
initiation of HAART, T-lymphocyte reactivity to recall antigens is restored in most patients 
277. Function of CD4+ cells also improves post-HAART evidenced by restored proliferation 
and cytokine response to mitogens 278. Whilst the amount of circulating T-lymphocytes 
subsequently returns close to normal, CD4+ T-lymphocyte numbers in the GALT remain 
severely reduced even after HAART 279. Restoration of cells may not occur if the patient is 
depleted of circulating naïve T-lymphocytes prior to therapy. It remains debatable whether 
starting HAART in acute HIV infection preserves or restores GALT CD4+ T-lymphocyte 
number and function. There has been significant decline in the incidence of Kaposi sarcoma, 
non-Hodgkin lymphomas and cervical cancers since the advent of HAART suggesting that it 
may be necessary to treat earlier in order to prevent some of these AIDS related tumors 280-282.  
 
2.4.6. Immune Reconstitution Inflammatory Syndrome (IRIS) of HIV  
IRIS refers to the adverse clinical manifestation that occurs in HIV-infected individuals 
successfully treated with HAART. It is characterised by a paradoxical deterioration of clinical 
status despite the remarkable improvement in CD4+ T-lymphocyte counts 283;284. IRIS occurs 
in the first few months of HAART and is also characterized by a markedly pro-inflammatory 
response to a number of pathogens that commonly cause AIDS-associated opportunistic 
infections 285. This inflammatory response is known as either “unmasking” or “paradoxical,” 
depending on whether the provoking opportunistic infection is previously undiagnosed or 
whether an already known infection worsens following treatment, respectively 286. Factors 
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affecting response to HAART include host’s ethnicity, nutritional status, presence of other co-
infections, pre-HAART CD4 count, genetics as well as HIV genetic diversity 246;275;287;288. 
 
2.4.7. HAART Induced HIV Mutations 
With increasing numbers of people on ART, there is also an increased probability of 
development of HIV drug resistance mutations due to drugs selection pressures 289;290. Such 
mutations may also be present in drug-na¨ıve patients but at lower frequencies 291. Shortages 
of drugs in some resource limited settings may exacerbate development of such mutations 292. 
The importance of setting up an efficient and effective HIV drug resistance surveillance 
infrastructure to track and combat the emergence of HIV variants resistant to multiple 
antiretrovirals may not be over-emphasised. Despite these drug-induced mutations other 
intrinsic viral factors also contribute to HIV diversity.  
 
2.5. HIV-1 genetic diversity 
The hallmark of HIV-1 is its extensive genetic diversity 293-296. Diversification is due to errors 
encountered during viral replication including host immune response selection pressures. 
Diversity is manifested as sequence variability particularly within the env V regions 297 
Variability not only makes it difficult for the immune system to identify the virus but it also 
facilitates the rapid viral immune escape. High level of genetic diversity has important 
implications in screening, diagnostic testing, disease monitoring and treatment outcome 224;298-
305. Questions have been raised on whether diversity may also affect viral transmissibility and 
pathogenicity 186;306-310. Sadly, genetic diversity has been the major impediment in the 
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effective vaccine design and development since the human immune response is HIV strain-
specific 311. Four factors vis-a-viz, the infidelity of RT, recombination, superinfection and 
high replication rate of the virus contribute to the development of the extensive HIV genetic 
variation 312;313.  
 
2.5.1. Properties of Reverse Transcriptase (RT) Enzyme and Recombination 
The infidelity of HIV RT enzyme confers mutations at an approximate rate of one error per 
genome per replication cycle 314. RT also accounts for genomic heterogeneity in progeny 
viruses through its role in recombination. Genetic recombination is an evolutionary strategy 
for survival in a changing environment for viral variants with superior fitness at an average of 
1.38 × 10−4 recombination events/adjacent sites/generation in vivo 315. It occurs when an 
individual is co-infected with at least two different HIV strains that are multiplying in the 
same cell 316;317. It is caused by high selection pressure from either the natural host immune 
response or ART drugs 318. Recombinants between highly similar HIV-1 strains are formed at 
highest frequencies while recombination between distant HIV-1 strains occur at very low 
frequencies 319. Infections with dual or even triple HIV-1 variants have been reported 320;321. 
HIV superinfections allow a mechanism for genetic recombinants between distant variants 322-
327. Superinfection and co-infection which both involve re-infection by at least two genetically 
distinct viral variants differ based on whether the second infection is contracted prior to or 
after the primary host immune response has been mounted 328. These are associated with high 
viral loads and accelerated rates of disease progression 329;330. HIV-1 superinfection presents 
an additional concern to the already challenging problem of HIV-1 vaccine design in the face 
of the virus’s rapid evolution 331. 
47 
 
 
2.5.2. High Turnover Rates of HIV-1 in vivo 
HIV-1 virions are produced and cleared at an extremely rapid pace. Since the HIV-1 genome 
is about 103 base pairs in length, then the baseline rate of viral production is approximately 
1010 virions per day 247. This rapid turnover has been considered the major factor underlying 
the pathogenesis of HIV/AIDS alongside with the destruction of CD4+ T-helper lymphocytes 
247. Besides the viral RT, host RNA polymerase II makes minimal contributions to retroviral 
frame shift mutations 332. Diversity may also be enhanced by different genetic factors, 
including HLA in patients from different regions of the world. Viral genetic factors include 
proteins such as Tat, Vif and Rev that interact with human genetic factors such as APOBEC, 
langerin, tetherin and CCR5 and HLA B27, B57, DRB1*1303, KIR and PARD3B 333. The 
inability of Vif to counteract host APOBEC3 proteins lead to the deamination of cytidine to 
uridine consequently, causing viral guanosine to adenosine hypermutations 334. Some error 
causing mechanisms contributing to HIV-1 variations are shown in Figure 2.11.  
 
 
Figure 2.11: A schematic sketch of error-causing machinery causing HIV-1 genetic diversity 246. 
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Genetic variation helps the virus evade the immune system and consequently this viral 
heterogeneity allows for a quick adaptation to the human immune system, antiretroviral drugs, 
or both leading to viral fitness/positive selection in the face of pharmacologic or immunologic 
selection pressures 335. Everyday millions of genetic variants accumulate in latently infected 
cells only to be re-activated at some time in the future 336. Thus, the extensive diversity of 
HIV resulting in a myriad of HIV variants has necessitated the need for its classification. This 
taxonomy facilitates better utilization of the ever growing viral sequence database through 
comparison with previously published works. 
 
2.6. Classification of HIV 
HIV-1 strains are not randomly distributed across the globe but they display a distinctive 
geographical distribution 337. Prior to 1992, HIV-1 strains were classified into two main 
classes on the basis of their respective geographical origin being then, the North American 
and African variants 338. Thus, HIV variation is highest among viruses from different 
geographical locations, higher among isolates from different individuals within the same 
location. However, variants present as relatively similar quasi-species within the same 
individual 339;340. A quasi-species is a cloud or swarm of genetically diverse variants that are 
linked through mutations that interact cooperatively on a functional level and collectively 
contributing to the characteristics of the viral population 341.  
 
With the advent of phylogenetic analysis the env gene has revealed the existence of multiple 
phylogenetic clusters that were used in the compilation of the 1992 HIV classification 
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compendium based on viral sequence similarities 342;343. As the env sequence database 
increased over the years the gag and pol gene sequences were also incorporated in the 
classification process consequently identifying HIV types, groups, subtypes, sub-subtypes and 
circulating recombinant forms (CRFs) 296;344-356, as summarised in Figure 2.12. 
 
Figure 2.12: Summary of HIV Classification 357 
 
2.6.1. HIV types 
Phylogenetically HIV can be classified into two types; type 1 (HIV-1) and type 2 (HIV-2) 353. 
Both viral types cause AIDS. HIV-1 is the first in the class of human retroviruses and 
accounts for most of the world’s HIV infections. Its origin can be traced back to a Simian 
Immunodeficiency Virus (SIV) isolated from a Chimpanzee (cpz) sub-species, Pan 
troglodytes troglodytes (SIVcpz) cross species transmission to humans 15;358;359. HIV-2 is the 
second in the same class of human retroviruses but is largely confined to West Africa. The 
primate reservoir of HIV-2 is sooty mangabey, Cercocebus atys (green monkey) 360;361. Thus, 
(SIVCPZ) is closely related to HIV-1, while SIV from sooty mangabey (SIVSM) is closest to 
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HIV-2 362. HIV-1 and HIV-2 are closely related viruses with nucleotide sequence homology 
of 58%, 59% and 39% in the gag, pol and env genes, respectively 363. Despite similar modes 
of transmission, HIV-2 is not as efficient in transmission horizontally and vertically 353;364;365. 
Relative to HIV-1, HIV-2 has a reduced rate of disease development and has shown natural 
resistance to readily available NNRTIs 366. Genetic recombination between HIV types-1 and-2 
has been reported 367. Distinction of HIV types is not only essential for accurate surveillance 
or diagnosis purposes but is also critical for correct administration of appropriate 
antiretroviral therapies. 
 
2.6.2. HIV Groups 
Phylogenetic analysis of HIV-1 suggested that zoonosis occurred on at least three independent 
cross species transmission events from chimpanzee, Pan troglodytes (pts), Pan troglodytes 
troglodytes (ptts) or gorilla (gor) resulting in three main distinct HIV groups called the major 
(M), outlier (O) or non–M/non–O (N) as shown in Figure 2.13. Studies have estimated the 
timing for the zoonosis of each lineage of groups M, O, and N at around 1931, 1920 and 
1963, respectively 368. Group M is responsible for more than 90% of the world HIV infections 
369. Interestingly, the genetic analysis of sequences from clinical materials obtained from 
members of a Norwegian family infected much earlier than 1971 showed that they carried 
viruses of the group O, mainly restricted to West Africa 8. HIV groups have genetic sequence 
differences of >40% in some coding regions 370;371. More recently, a new putative group, 
designated P, was reported in France from a Cameroonian female immigrant 372. Group P 
viral sequences have been shown to form a distinct HIV-1 lineage with SIV sequences from 
western gorillas (SIVgor; Gorilla gorilla gorilla), suggesting that group P originated from 
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gorillas 373. Reports have indicated that HIV-1 group P infections are rare, accounting for only 
0.06% of HIV infections in Cameroon 374. Unlike groups O, N and P, group M has been 
classified into subtypes.  
 
Figure 2.13: Evolutionary relationships of HIV groups. SIVcpzPts (blue), SIVcpzPtt (red), SIVgor 
(yellow), and HIV-1 group M, N, O, and P (gray) strains based on partial env (gp41) sequences. 
Arrows indicate the ape reservoirs of the different HIV groups. Dotted arrows indicate that the direct 
reservoirs for HIV-1 groups O and P remain elusive 375.  
 
2.6.3.  HIV-1 subtypes 
Subtypes are phylogenetically linked strains of HIV-1 that are approximately the same genetic 
distance from one another. Group M has been classified into nine distinct subtypes, also 
called clades or genotypes, denoted with letters, A, B, C, D, F, G, H, J and K, thus making the 
development of effective blanket diagnostic and monitoring tests or vaccine a challenge 
370;376. Inter-subtype variation is about 30% with respect to the env gene sequence and 15% for 
both the gag and pol genes sequences 377. Different risk groups for HIV infection are 
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associated with certain subtypes with IDUs including the gay communities and heterosexual 
population generally acquiring subtype B and non-B subtypes, respectively 378-380.  
 
2.6.4. HIV-1 Sub-Subtypes 
Within each subtype numerous HIV-1 variants exist that exhibit minor intra subtype genetic 
diversity of within 10% called sub-subtypes 381. These are distinctive HIV-1 lineages that are 
closely related to a particular subtype lineage, but are not genetically distant enough to justify 
calling them new subtypes. Sub-subtypes are denoted by numerals for instance in the case for 
subtype A these have been named A1, A2 or A3 382. Recent studies have demonstrated the 
need for HIV classification using full-length genomic sequences if new distinctive subtypes 
are to be accurately identified rather than relying on sequencing of different viral gene 
fragments as has been the standard. 
 
2.6.5.  HIV recombinants 
Full genome sequencing of HIV has resulted in the discovery of circulating and unique 
recombinant forms (CRFs) and URFs, respectively. Recombinants are unique in the sense that 
they may be described in isolated individuals without any evidence of epidemic spread. To be 
classified as a CRF, a virus strain must be detected in at least three epidemiologically 
unlinked individuals and must be capable of establishing an epidemic on its own. Thus, these 
mosaic HIV-1 strains reflecting a mixture of subtypes circulating in different populations may 
have altered pathogenic and/or transmissibility properties 383. CRFs are referred to by their 
number that is assigned according to the order of their discovery, underscore and the 
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respective subtypes involved for example CRF02_AG or by their number(s) followed by the 
letters `cpx' (for complex), when more than two subtypes are involved for example 
CRF04_cpx or CRF06_cpx 384. One of the most prevalent group M CRF common in 
Southeast Asia was earlier on incorrectly designated subtype E but was later correctly re-
named CRF01_AE following full HIV genome sequencing 385. To date more than 21 CRFs 
and several URFs have been described 386. All CRFs together account for 18% of the world’s 
HIV-1 infections 387. HIV-1 subtypes and recombinants may differ with respect to plasma 
viral load levels 388 transcriptional activation levels, disease progression and response to 
chemotherapy including drug induced/natural resistance patterns 389-392.  
 
2.7. Distribution of HIV-1 Subtypes and Recombinants 
Over 50 different subtypes and CRFs have been described 291;393. Subtype B is geographically 
confined to North America, Western Europe and Australia. See Figure 2.14. Paradoxically 
subtype B is quite rare in Africa, the purported origin of HIV. Global proportions of HIV-1 
subtypes and recombinants have shown that subtype C accounts for more than 50% of world’s 
infections followed by 12%, 10%, 6% and 3% for subtypes A, B,G and D respectively, whilst 
subtypes F, H, J and K together accounted for about 0.94% of all the infections 377. 
CRF01_AE and CRF02_AG are each responsible for 5% of the global infections while 
CRF03_AB is responsible for 0.1% with the other recombinants responsible for the remaining 
8% of the infections 377. 
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Figure 2.14: Global distribution of HIV-1 subtypes and recombinants 394  
 
In most Southern African nations subtype C predominate, contributing 93-100% of the HIV-1 
infections amongst individual countries 377;395. Interestingly, the greatest diversity of subtypes 
and recombinants is present in Central Africa, Central African Republic, Gabon, Angola and 
Chad harboring only about 5% of the world’s infected individuals 395. Thus, a general 
observation is that higher diversity of subtypes is associated with relatively slower epidemics 
whilst explosive epidemics generally have only one predominant subtype.  
 
2.7.1. Subtypes Trends and Distribution in Zimbabwe  
Previous Zimbabwean studies in the 1990s and early 2000 have observed a predominant HIV-
1 subtype C infection 396-398. The origins and evolutionary history of HIV-1 subtype C in 
Zimbabwe with respect to the pol sequence data sets generated from four sequential cohorts 
of antenatal women in Harare, from 1991–2006 has demonstrated increasing sequence 
divergence over the 15-year period. This data also dated the most recent common HIV 
ancestor to be around 1973 with three epidemic growth phases: an initial slow phase (1970s) 
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followed by exponential growth (1980s), and a linearly expanding epidemic to the present day 
99. However, current HIV subtype(s) distribution in Zimbabwe remain elusive in view of the 
influence of the population movements in the past decade as result of the economic meltdown 
which could have facilitated subtype inter mixing. Generally, subtype specific variations may 
exist that influence differential transmissibility in different regions 399-401. 
 
2.7.2. HIV Diversity, Transmission and Disease Progression 
Following sexual transmission of HIV the virus initially replicates locally in the vaginal or 
rectal mucosa 402. Genetic diversity of HIV is lost during horizontal transmission as the virus 
gradually evolves towards a common ancestral sequence once in the new host 306;403. Newly 
infected individuals acquire a subset of the viruses that would be circulating in the 
transmitting partner 404. Studies have correlated high HIV replication capacity with increased 
transmission rates 405. Understanding the quantitative relationship between plasma HIV-1 
RNA and HIV-1 transmission risk has been the cornerstone for ART preventive interventions 
that strive to reduce plasma HIV-1 levels that in turn reduce the risk of HIV-1 transmission 
406. Interestingly, Langerhans cells have shown minimal susceptibility to infection with 
subtype B virus but has demonstrated substantially greater sensitivity to infections by subtype 
C viruses 407 . In the Rakai, Ugandan study, subtype A viruses have been shown to have a 
significantly higher rate of heterosexual transmission relative to subtype D viruses. 408. 
Differential subtype transmission efficiency may be important for HIV vaccine evaluation 
especially for the subtype-specific HIV epidemic in SSA. HIV-1-discordant couples are 
increasingly viewed as a valuable source of participants for HIV vaccine and prevention trials 
57. Interestingly, HIV-1 subtype C has been found to be the predominant subtype in sero-
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discordant couples followed by subtypes B and A, respectively 409. Increasing HIV-1 
replication efficiency has also been related to a concomitant increase in HIV-1 diversity, 
which in turn has been the determining factor in disease progression 410;411. Non-A subtype 
infections have been shown to progress to AIDS faster than those infected with subtype A 412. 
More so subtype D has been associated with the most rapid disease progression relative to 
subtypes A, C and CRFs 413;414;415. 
 
Pregnancy has been shown to increase the risk of female-to-male HIV-1 transmission by two 
folds 416. Pregnant women infected with subtype C shed significantly more HIV-1-infected 
vaginal cells than those infected with subtypes A or D 417. Increased HIV-1 shedding has been 
correlated with a more complex population of HIV-1 quasi-species in the genital tracts of 
parturient women, which may increase the probability of transmission of fetotropic viral 
strains 418. 
 
2.7.3. HIV Diversity and vertical transmission 
Maternal neutralizing antibody response with broad specificity and low viral load may protect 
the child from HIV-1 infection 419;420. Factors associated with an increased risk of perinatal 
HIV transmission include advanced maternal disease, prolonged duration of ruptured 
membranes and increased quantity of HIV in maternal blood at delivery 421. Maternal DC-
SIGNR expressed at the maternal-fetal interface play a crucial role in MTCT of HIV-1 as 
impaired placental DC-SIGNR expression has been shown to increase the risk of transmission 
422. Presence or absence of some PNGs at specific sites on the gp120 env has also been 
associated with increased HIV-1 MTCT 423. Transmission can be in uterine, intra-partum or 
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postpartum mainly through breast milk 424;425. Different factors may influence HIV 
transmission during each of these time periods, and hence interventions strategies to reduce 
transmission need to be period specific. The probability of HIV-1 infection per liter of breast 
milk ingested by an infant has been shown to be similar in magnitude to the probability of 
heterosexual transmission of HIV-1 per unprotected sex act in adults 426. Infants may be 
infected with the most prevalent maternal strain, a minor maternal variant or multiple 
maternal quasi-species 427;428. In utero transmitters have been shown to be more likely to 
transmit single or multiple maternal viral variants whilst intrapartum transmitters are more 
likely to transmit minor HIV-1 variants 429. After transmission HIV-1 infected infants harbour 
either homogenous or heterogeneous virus populations 430;431. HIV-1 inter-subtype 
recombinants may also be effectively transmitted vertically to infants 432.  
 
SdNVP given to mothers before delivery and to newborns after delivery can reduce the risk of 
transmission by 10-15% 433 although this can select for nevirapine resistant variants which 
decrease with time, but remain above pre-dose levels 434. The rate of nevirapine resistance 
mutations after SdNVP has been shown to be significantly higher in women with HIV-1 
subtype C than in women with subtype A or D 435. This observation has a bearing on the 
efficacy of subsequent antiretroviral therapy containing nevirapine or other NNRTIs 436. 
Efficiency of MTCT of HIV may be among those properties that vary with HIV diversity. A 
few and controversial results have been described so far with respect to subtype and vertical 
transmission. Subtype C has been shown to be more transmissible than other subtypes 417;437. 
However, other studies have shown no apparent differences in the rate of MTCT of HIV-1 
among women with different subtypes 438-440. As a result the efficacy of regimens of PMTCT 
administered only at labour may not be as protective in different geographical regions with 
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different subtypes. In vertical transmission, a closely related maternal and infant HIV-1 
diversity is suggestive of late pregnancy or perinatal transmission. On the other hand, wide 
genetic differences are suggestive of an earlier transmission during pregnancy 441. Subtype 
specific identification of such patterns of MTCT points may be useful in the PMTCT 
programmes. V3 region of the env gene is a key determinant of MTCT 442;443. There is need 
for further research in HIV-1 diversity and transmission patterns to achieve remarkable 
reduction of MTCT rates especially for developing countries. Subtype and CRFs 
determination is generally done using the gag/env heteroduplex mobility assay (HMA) 
originally developed by Delwart 444 which was later modified by Heyndrick 445et al, in the 
year 2000. Sequencing remains the gold standard although partial sequencing also gives good 
results at reasonable cost.  
 
2.8. Rationale of the study 
The geographic distribution of subtypes is subject to constant change. Recombinant forms of 
the virus will continue to appear as long as the different subtypes of HIV-1 continue to 
circulate between continents and recombination continues to occur. With the world fast 
becoming a global village new HIV strains are emerging in areas where they were originally 
non-existent. Thus importation and exportation of new types, subtypes and even CRFs of HIV 
is possible. Due to political and socio-economic challenges most Zimbabweans have resorted 
to cross border trading within the region and abroad. Furthermore the ZDF personnel have 
been actively involved in peace keeping mission all over the world. The risky behaviour of 
military personnel plus high HIV-1 sero-prevalence within this group may have facilitated the 
introduction of new HIV types, subtypes or recombinants within the armed forces themselves 
and to the general population both at home and abroad. There is a paucity of data on the 
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current HIV diversity in Zimbabwe. Tracking the presence of new HIV strains is important 
for surveillance purposes, effective chemotherapy, diagnosis and disease monitoring including 
vaccine design and development. Identifying the specific genetics characteristics of 
successfully transmitted variants is also paramount in the development of an effective 
vaccine. 
 
2.9. Hypothesis 
There are no new types, subtypes and CRFs in the population and no biological and genetic 
differences exist between HIV-1 subtypes 
 
2.10. Aim of the study 
The main goal of this study to determine and characterise genetic diversity of HIV among 
pregnant women and their infants in Harare peri-urban and ascertain its role in diagnosis, 
disease monitoring and transmission 
2.11. Objectives 
To investigate:  
1. Antenatal plasma viral load and its role in vertical transmission 
2.  HIV types and or co-infections among Zimbabwean pregnant women  
3. The distribution of HIV-1 subtypes and CRFs among women and their infants 
4. HIV viral co-receptor usage genotype of the mothers and their infants 
5.  HIV subtype C env gp 120 glycosylation patterns and diversity following 
horizontal and vertical transmission  
6. The role of HIV-1 gp120 env PNGs variations and sequence length 
polymorphism following transmission events  
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CHAPTER 3 
3.0. Materials and Methods 
3.1. Study Population and Design 
This was a nested case-control study within a PMTCT cohort of ART naive pregnant women 
and their infants. A case was a sero-positive mother who transmitted HIV-1 to her infant 
(transmitter). All transmitting mothers were included. The transmitter was matched to one 
HIV-1 positive but non-transmitting mother (control). Noteworthy is that antiretroviral drugs 
were not readily available in Zimbabwe at the time of recruitment of study participants. HIV 
positive women who consented for themselves and their infants were eligible to participate. 
Mothers who were too ill were excluded. 
 
3.2. Study Sites 
Harare peri-urban antenatal clinics approximately 20 kilometres from the city centre namely 
Epworth, Seke North and Saint Mary’s Chitungwiza were the study sites. See site map, 
Figure 1.3. Residents living in these communities are generally of low socio-economic status, 
without piped water supplies or if the piped water infrastructure is available, supplies are 
erratic. Most of the adult population is formally unemployed making them informally 
employed.  
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3.3. Sampling and Procedures 
Women were sampled from a bigger cohort of 691 pregnant women. Matching of cases and 
controls was done with respect to maternal age, educational level, marital and socio-economic 
status, parity, current STIs, the date of last menstruation, and uptake of SdNVP prophylaxis. 
SdNVP prophylaxis was offered to all HIV-1 positive mothers during labour and their infants 
within 72 hours post-delivery. All mothers answered a structured questionnaire at enrolment 
from which information regarding their socio-demographics, sexual behavior, obstetric and 
reproductive health issues was obtained. A gynecologist performed physical and 
gynecological examinations.  
 
Study participants were classified into of two groups as shown in Figure 3.1. The main group 
comprised of pregnant women who were HIV-1 positive at enrolment, referred to as having 
chronic HIV-1 infections and a minor group of women who were HIV-1 negative during 
pregnancy but sero-converted after delivery during the follow-up period, regarded as having 
acute HIV-1 infections. Follow-up of women was from delivery, six weeks, four and nine 
months and thereafter three monthly until two years generally coinciding with infant 
immunization visits. At each subsequent follow-up visit, previously HIV-1 negative mothers 
and infants were re-tested for HIV-1 antibodies and HIV-1 DNA, respectively. A pediatrician 
examined infants. Date of birth, birth weight, gender, SdNVP therapy and breastfeeding 
patterns for each infant were recorded. Infant deaths were also documented during the follow-
up period. Mothers were encouraged to exclusively breastfeed during the first six months 
following delivery. HIV-1 positive mothers were followed up again in cases of subsequent 
pregnancies and similar procedures were followed. Since this was initially an STI cohort, four 
of mothers’ spouses also consented to participate in the HIV diversity study. Plain and EDTA 
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blood samples were collected from the mothers at each follow up visit. Samples were 
processed, aliquoted and appropriately stored until testing. Concurrently, infants’ venous 
EDTA whole blood samples were collected and stored at -86°C until testing. 
 
Figure 3.1: Summary of enrolment procedures of the 32 cases and 32 controls 
 
3.4.0. HIV Testing 
3.4.1. Mothers’ HIV-1/HIV-2 Screening 
Better sensitivity and specificity of almost 100% are achieved using an algorithm combining 
two tests for HIV antibodies, a practice currently considered the best option for low-resource 
settings446. Serial HIV-1/2 algorithm antibody tests were done using Determine (Abbott 
Diagnostics, Illinois USA) and OraQuick (Abbott Diagnostics, Illinois, USA) rapid kits on 
serum samples. 
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3.4.1. Determine T.M. Test 
Abbott Determine TM HIV-1/2 kit is a qualitative immuno-assay that is used to visually detect 
antibodies to HIV-1 and or HIV-2 in human plasma, serum or whole blood. The test is based 
on the immuno-chromatography principle. Briefly, the sample is added on to the sample pad, 
flows up to mix with the selenium colloid antigen conjugate in the conjugate pad and finally 
forms a red line on the patient window site on the solid phase of immobilized HIV-1/2 
recombinant antigens and synthetic peptides as shown on Figure 3.2. 
 
 
Figure 3.2: The Determine HIV-1/2 Test Strip. The white arrows point to the direction of the sample 
flow from sample pad. First strip from the left shows non-reactive sample without a red line on the 
patient’s window. The second and third strips are both reactive regardless of differences in red lines 
intensities. 
 
Thus, the second HIV test used in our study was Oraquick.  
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3.4.2. OraQuick HIV-1/2 Antibody Test 
OraQuick® ADVANCE Rapid HIV-1/2 Antibody Test is also a qualitative immunoassay that 
detect viral antibodies in oral fluid, fingerprick whole blood, venipuncture whole blood and 
plasma specimens. Comprised of a single-use test device and a vial containing buffered 
developer solution, the test is based on a lateral flow immuno-assay technique. The test strip 
contains synthetic peptides from the HIV env region and a goat anti-human IgG procedural 
control immobilized onto a nitrocellulose membrane in theTest (T) zone and the Control (C) 
zone, respectively. 
 
Figure 3.3: OraQuick Test Kit. The first and second strips showing a reactive and non-reactive 
samples, respectively. 
 
The developer solution facilitates the flow of the specimen into the device, rehydrates the 
protein-A gold colorimetric reagent contained in the device, continues migrating up until it 
reaches the T zone where the presence of HIV-1/-2 antibodies to the immobilized antigens on 
the nitrocellulose membrane causes the appearance of a reddish-purple line. With this new 
technology of rapid testing, the turn around time has been reduced to about twenty to thirty 
minutes, rather than waiting for weeks for the results as has been the case with traditional 
testing methods. However, for both the rapid tests the intensity of the test line does not 
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necessarily correlate with HIV antibody titre in the sample. Due to the antibody testing 
limitations regarding the window period all HIV-negative patients were scheduled for re-
testing after three months. 
 
3.4.2. Mothers’ HIV-1/HIV-2 Western Blot Testing 
Western blot (WB) is another HIV testing technique that provides additional information not 
readily gathered from rapid test such as the immuno-dominant proteins 447-449. WB test 
continues to be of value in confirming results from antibody tests. HIV proteins used in 
western blotting can be produced by recombinant DNA through a technique called 
recombinant immunoblot assay where viral proteins are separated and transferred on a 
nitrocellulose strip. Diluted serum is applied to the membrane and if antibodies are present in 
the serum they bind to some of the HIV antigens. Antibodies that do not bind to viral 
antigen(s) are washed away. Enzyme-linked antibodies with the capability to attach to the 
patient's antibodies determine to which HIV antigens the person has antibodies to. 
  
Figure 3.4 Serodia WB Testing kits used. 
 
Confirmation of HIV-1/2 rapid test results was done at the Norwegian Institute of Public 
Health using the WB test (HIV blot 2.2, MP Diagnostics, Singapore) according to the 
66 
 
 
manufacturer’s instructions, kit shown in Figure 3.4. Interpretation of the WB test results was 
done in line with the World Health Organization (WHO) guidelines 450. Though very specific 
WB test is rather expensive and there is no universal criterion for interpreting the test results. 
 
3.5 Determination of Total Lymphocyte Counts (TLC) 
EDTA-anti-coagulated venous blood samples were processed within six hours for full blood 
counts using Abbott Diagnostic Cell Dyne 3500R SL Hematology Analyser. TLC was 
enumerated as the total white blood cell count multiplied by the lymphocyte percentage. In 
this resource poor setting, TLC was used as a surrogate marker for CD4 cell count since by 
then, the capacity to determine the latter was not readily available at the University of 
Zimbabwe due to prohibitive costs 451. TLC of 1200 cells/mm3 was the threshold value used 
equivalent to a CD4 count of 200 cells/mm3 452;453. 
 
3.6. CD4 cell counts enumeration 
A CD4 count has been a useful marker used to monitor immune system function and disease 
progression in HIV-positive individuals. CD4+ T lymphocytes were enumerated using a 
Partec Cyflow counter (Cyflow, Partec, Munster, Germany) within 6 hours of blood collection 
as previously described 454. This test was done only on a few family samples. 
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3.7. HIV-1 RNA Load Determination 
Serum and plasma samples were shipped on dry ice to the Institute of Microbiology at the 
University of Oslo in Norway for further laboratory analysis. Maternal baseline serum 
samples were quantified for HIV-1 RNA load using an automated TaqMan Roche Amplicor 
1.5 Monitor Test (Cobas AmpliPrep/Cobas TaqMan, Roche Diagnostics, Branchburg NJ), 
according to the manufacturer’s instructions. HIV-1 viral load testing is considered essential 
when initiating antiretroviral therapy ART, monitoring ART response, and when considering 
switching ART regimens. 
 
3.8. Infants’ Qualitative HIV-1 DNA PCR Test 
Qualitative HIV-1 proviral DNA PCR tests have three main diagnostic applications. These 
include direct detection of viral sequences in the pre-seroconversion window period which 
may be positive up to 8 days prior to the development of HIV specific antibodies; resolution 
of indeterminate HIV serological tests and in the diagnosis of neonates born to seropositive 
mothers where maternal antibodies may be detectable for up to 15 months postpartum. Early 
detection of HIV-1 infection in infants is complicated by the persistence of maternal 
antibodies and by diverse HIV-1 subtypes 455. Detection of infants’ HIV-1 infection was 
determined using a qualitative 1.5 Roche Amplicor HIV-1 DNA PCR kit (Roche Diagnostics 
Incorporation, Branchburg, New Jersey). The test amplifies and detects several target 
sequences located in specific HIV genes, such as gag or pol 456 .Testing was done in the 
Obstetrics and Gynecology Department, Medical School, University of Zimbabwe. Infants 
that tested HIV-1 DNA PCR positive on whole blood collected within 10 days of birth were 
considered to be infected in utero. Infants having negative HIV-1 DNA PCR results within the 
first 10 days of life and positive HIV-1 results at six weeks postpartum and/or thereafter were 
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considered to be infected intra-partum/postpartum 144;457. HIV antigen testing using such a 
nucleic-acid-based technology has shortened the window period between infection and 
detectability of disease. However, the issue of testing infant samples with respect to the 
volume of blood required remains a challenge as the volumes of sample required are often 
difficult to obtain from little infants 458 . 
 
3.9. Nucleic acid extraction  
Total RNA was extracted from plasma using the NucliSENS isolation kit, based on the Boom 
et al., method 459. Briefly samples were ruptured in a lysis buffer containing a chaotropic 
agent, guanidine thiocyanate. Cells, bacteria and viruses in the samples were lysed whilst 
proteins such as nucleases were denatured and inactivated. DNA and RNA bound to silica 
particles whilst everything else was washed following several washing steps with the wash 
buffer. Finally the nucleic acids were eluted from the silica particles using the elution buffer.  
 
Figure 3.5: Boom Technology Principle, Adopted from 460 
 
The eluate was highly purified and concentrated enough for PCR amplification. It is a smart 
method where no columns are needed and different specimens can be used. 
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3.10. DNA amplification  
3.10.1. Taq Polymerase 
Taq polymerase is a thermostable DNA polymerase named after the hot spring Thermus 
aquaticus bacterium461. It is often abbreviated to "Taq Pol" or simply "Taq". Frequently used 
in PCR reaction for amplifying short segments of DNA, Taq is a heat stable enzyme able to 
withstand the protein-denaturing temperatures required during PCR 462. It can replicate a 1000 
base pair strand of DNA in less than 10 seconds at 72°C 463. However, one of Taq's 
drawbacks is its relatively low replication fidelity as it lacks the 3’ to 5’ exonuclease 
proofreading activity and consequently translating to an error rate of at about 1 in 9,000 
nucleotides 464  
 
3.10.2. First Round: RT PCT 
The viral RNA is extracted from the patient's plasma and was first converted to cDNA using 
RT. The PCR process is then applied, using two primers unique to the virus's env region and 
Taq. The primary PCR amplified an approximately 800-base pair (bp) fragment spanning the 
V3 and V4 region of the envelope (positions 6948–7537) on the HIV-HXB2 genome using 
HIV primers ENV 2 and NY3. 
 
Table 3.1: RT PCR Reagent Preparations 
Reagent      Volume/Sample (μL) 
Buffer (5x)        10 
dNTPs           2 
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NY3 Primer 1 (10 pmol/μL)        3 
ENV primer 2 (10 pmol/μL)        3 
Enzyme mix (RT and Taq)        2 
RNAase (40U/μL)         0.5 
Template (from boom extraction)     10 
RNA free water       19.5 
Total Volume       50 
 
Table 3.2: Reverse transcription (RT) Thermal cycler cycles 
Temperature (ºC)      Time (minutes) 
50         30 
95         15 
 
Table 3.3: Amplification with Taq polymerase  
Temperature (ºC)      Time (seconds) 
94         15 
55         30 
72         60 
         29 cycles in total 
72         120 
04         ∞ 
 
3.10.3. DNA amplification Nested PCR 
Secondary or nested PCR amplified a 535-bp env gene fragment. 
Table 3.4: Nested PCR Reagent Preparations 
Reagent      Volume/Sample (μL) 
Ammonium Buffer (10x)        5 
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20mM dNTPs          2 
JA168 primer 1 (10 pmol/μL)       2 
ES 8 primer 2 (10 pmol/μL)        2 
50mM MgCl2          2 
Taq Pol          0.5 
Template (from RT PCR)        1 
RNA free water       35.5 
Total Volume       50 
 
Table 3.5: Nested PCR cycles Programmed on the Thermal Cycler 
Temperature (ºC)      Time (seconds) 
95         60 
94         20 
55         30 
72         60 
         24 cycles in total 
72         120 
04         ∞ 
 
3.11. Detections of Nested PCT Amplicons 
Detection and quantification of secondary PCR amplicons were done using a 1% agarose gel 
electrophoresed together with a standard mass ladder and then stained with SYBR safe stain, 
Figure 3.6a and b.  
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LOADING SECONDARY PCR PRODUCTS ON A 1% 
AGAROSE GEL
 
Figure 3.6: Loading PCR Amplicons on a gel & Gene Doc Gel Reader (Bio-Rad) 
 
3.12. Purification of Nested PCR amplicons  
In preparation for sequencing excess primers and salt were removed using Microspin columns 
(Amersham Bioscience), Figure 3.7. 
 
 
Figure 3.7: Microspin columns for purification of the extracted DNA.  
 
3.13. Dye-Terminator Cycle-Sequencing 
PCR products that produced the expected band sizes were sequenced together with negative 
controls for procedural quality assessment. Amplicons were diluted to a final concentration of 
5–20ng of template DNA prior to sequencing. For each sample two reaction mixtures were 
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prepared with either the upstream or downstream primers in separate reaction tubes to 
facilitate both forward and reverse sequencing. Big dye-terminator cycle-sequencing 
technology was used where the purified template DNA was first subjected to PCR with Big 
dye which contains Taq DNA polymerase, dNTPs (deoxynucleotides) in excess 
concentration, ddNTPs (dideoxy nucleotides) with fluorescent dyes in low concentration. 
Dideoxy nucleotides are nucleotides that lack a 3’-OH group and these causes the termination 
of the extension process each time they are encountered during the PCR reaction.  
Table 3.6: Big Dye PCR Reaction Mixture 
Reagent       Volume (μL)/Microplate well 
Template           1 
Primer (ES8/ JA168)         1 
RNAase free water       13 
*Master Mix          5 
Total Volume       20 
 
*Components of Master Mix 
Reagent        Volume (μL) 
Buffer         3.5 
RNAase water       0.5 
Big Dye        1.0 
Total         5.0 
 
Thus, the Big Dye contained dNTPs and ddNTPs in a mixture of approximately 100:1 such 
that each time the polymerase added a nucleotide, there was a small chance that it would have 
added a ddNTP. Consequently, repeating the PCR-cycle many times resulted in a population 
of fragments ranging from the length of the primer plus one nucleotide to the length of the 
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primer plus all nucleotides of the entire PCR product. Since these extension products were 
labeled with different fluorescent dyes depending on the base composition, the composition of 
the 3’ nucleotide bases were identified by separating the fragments on a gel and scanning the 
fluorescence pattern with a UV laser that energized the dyes attached to each ddNTP. Each 
dideoxy nucleotide, ddCTP, ddATP, ddTTP, or ddGTP, had a different fluorescent dye 
attached to it with one unique color for each ddNTP. When exposed to a UV laser, the four 
different ddNTPs fluoresced at four different wavelengths which were detected and recorded 
by a sensor on the DNA sequencer, Figure 3.8. The outputs were chromatograms depicting 
the nucleotide sequence for both the forward and reverse primers. Contigs were constructed 
which were later aligned and analysed. 
 
 
Figure 3.8: ABI 3730 DNA analyzer (Applied Biosystems/HITACHI, Tokyo, Japan). 
 
3.14. TOPO Cloning 
In the event that direct sequencing failed to yield clean chromatographs then cloning was 
done using an Invitrogen TOPO TA cloning kit version J, 2006. Taq pol has a non-template-
dependent terminal transferase activity that such it makes adenine (A) overhangs at the 3' ends 
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of its products. The linearized vector supplied in the kit had overhanging 3´deoxythymidine 
(T) residues which allowed PCR inserts to ligate efficiently in the vector without ligase, post-
PCR procedures nor requirement of PCR primers. Topoisomerase I from Vaccinia virus binds 
to duplex DNA at specific sites and cleaves the phosphodiester backbone after 5′-CCCTT in 
one strand 465 and thus facilitating the ligation of purified nested PCR product into the 
pCR™2.1-TOPO vector as shown in Figure 3.9. 
 
Figure 3.9: Ligaton of the PCR product into the TOPO vector using Topoisomerase Adopted from 466. 
 
The transformed the recombinant vector was taken up and expressed in chemically competent 
E. coli (C4040-03) as per the manufacturer’s instructions 466. Recovery and plating was done 
on Luria-Bertani (LB) plates with kanamycin and 5 bromo-4-chloro-3 indolyl-beta-D-
galactopyranoside (x-gal) as the selective agents for the chemical transformation. 
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Figure 3.10: X-gal Structure 
 
X-gal is an analog of lactose that was hydrolyzed by the β-galactosidase enzyme, yielding 
galactose and 5-bromo-4-chloro-3-hydroxyindole which was further oxidised to 5,5'-dibromo-
4,4'-dichloro-indigo, an intensely blue product which is insoluble. See Figure 3.11. Thus, in 
the presence of X-gal and the artificial inducer of the Lac operon, isopropyl thiogalactoside 
(IPTG) in the agar medium, bacterial colonies with the functional Lac Z gene were blue. 
However, E coli transformed by the PCR inserts in the Lac Z open reading frame were not 
able to make β galactosidase enzyme and hence appeared as white colonies.  
 
Figure 3.11: Formation of the insoluble blue product from X-gal, adopted from 467. 
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Thus, in gene cloning X-gal is used to indicate whether or not there is expression of the β 
galactosidase enzyme which is encoded by the LacZ gene, a technique called “blue/white 
screening”. For each sample four white colonies streaked separately on LB plates containing 
kanamycin and incubated over night at 37º C. Finally plasmid DNA isolation was done using 
the mini-preparation method and checked on a 1% agarose gel before sequencing. 
 
3.15. Data analysis 
The data were collected and analyzed using SPSS (version17.0, Chicago, IL). Viral load 
values were log10 transformed. The Student’s t-test was used to compare means. Regression 
analysis was used to investigate the associations. Tests of statistical significance included the 
95% confidence interval of unadjusted relative risks, two-sided p values based on Chi-square 
and Fisher’s exact tests. Sequences contigs were assembled using the Vector NTI Advance 10 
program. Alignment was attained using Gene Doc, BioEdit, and Clustal X2 sequence 
alignment programs including manual editing to ensure that deletions or insertions did not 
alter the reading frame. Prediction of co-receptor usage genotype was automatically generated 
on a sub-C Position-Specific Scoring Matrices (PSSM on website: 
http://mullinslab.microbiol.washington.edu/computing/pssm/6). HIV-1 subtype was 
determined using BioAfrica-Bioinformatics tool (version 2.0), website 
http://www.bioafrica.net/. MEGA version 5.0 was used in sequence phylogenetic analysis and 
tree drawings. 
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3.16. Ethical Issues 
The study was approved by the Medical Research Council of Zimbabwe (MRCZ), reference 
number MRCZ/A/1407 and the Ethical Review Committee of Norway. Written consent to 
participate in the research study was obtained from the mothers and they were free to 
discontinue at any given time without any prejudice. Mothers also consented to have their 
blood samples and that of their infants used for future HIV related research. Participants were 
assured of confidentiality See participants consent form sample in both English and 
vernacular languages (Shona) in the Appendix section. All mother-infant pairs were offered 
free treatment for other ailments other than HIV and were re-imbursed their bus fare to and 
from the clinic. 
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CHAPTER 4 
4.0.  Some Experimental Results 
4.1.  First and Second Round PCR Amplicons ran on a 1% Agarose gel 
 
Figure 4.1: Gel Picture, Samples were in wells 1-10; ML denote molecular ladder in well number 11. 
On the right are the molecular weights for each ladder and the corresponding approximate DNA 
concentration of in nonagrams (ng). Gel was stained with sybr green. 
 
4.2. A Typical Clean Chromatogram 
\  
Figure 4.2: A Portion of a clean chromatogram from the Vector NTI program of the reverse primer 
viral sequence of Mother ID 122. Peaks in blue, red, black and green colours represent nucleotide 
cytosine (C), thymidine (T), guanosine and adenine, respectively. Size of the peak is directly 
proportional to concentration of the nucleotide(s). 
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4.3. Typical Raw Data from the DNA Analyser 
 
Figure 4.3: Typical Sequence Raw data for Father ID 375 showing sequences for both the forward 
(F) and reverse ® primer sequences 
 
4.4. Mother-infant Nucleotide Sequence Alignment 
 
Figure 4.4: GeneDoc nucleotide alignments for mother-infant pair ID 210 and mother ID 257. The 
darker the shed the more the similar the nucleotide sequences. Region 306-333 looks like a hot spot 
for mutations. Red arrow shows all mother sequences had an adenine on position 44 whilst the baby 
sequences had a guanine on that same position. 
81 
 
 
4.5. Family 205 part Amino Acid Sequence Alignment 
 
Figure 4:5: Amino acid Clustal X program alignment for the viral variants infecting family 205. FA, 
MO, 1ST and 2ND represent father, mother first sibling and second sibling viral sequences, 
respectively followed by a letter representing a clone. Coloured letters represent the amino acid. 
Amino acids with similar or related chemical properties are shown in the same shade of colour. 
Generally the viral variant are closely related. However, there are some mutations for example 
deletions in positions 111 for all mothers’ and second siblings’ viral DNA. All father’s sequences have 
4 amino acids deletions on positions from 146-150. 
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4.6. Phylogenetic Analysis 4 Family Sequences 
 
Figure 4.6: Rooted Neighbour joining tree for HIV-1 env (C2V5) sequences for the 4 families. 
Bootstrap values were expressed as percentages per 1000 replicates and only proportions of > 70% are 
shown as shaded triangles and circles represent fathers’ and mothers’ sequences, respectively. Open 
triangles and circles represent sequences of first and second siblings, respectively whilst filled in 
squares represent Outlier, HIV group O sequence. 
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4.7. Phylogenetic Analysis of Family sequences in relation to other subtype C 
sequences from different regions 
 
Figure 4.7: Phylogenetic relationships between families’ sequences and other subtype C from 
different geographical regions; AR: Argentina, BW: Botswana, ZA: South Africa, TZ: Tanzania, IN: 
India, ZW: Zimbabwe & CN: China. Bootstrap values expressed as percentages per 1000 replicates 
and only proportions of > 70% are shown. Generally the family subtype C viruses are closely related 
to other regionally subtype C as shown by the high boot strap values.  
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4.8. Unique HIV subtype C env V3 and C3 sequences 
 
 
Figure 4:8: Unique HIV subtype C env V3 and C3 sequences. According to subtype B sequence V3 
region and C3 regions are hypervariable region and constant regions, respectively. However, our 
subtype C V3 region is relatively constant (top part) whilst the supposedly constant C3 region is rather 
hypervariable (lower part) especially the first part. Dots represent similarity and each letter denotes an 
amino acid. 
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CHAPTER 5 
5.0.  Published Papers 
5.1. Paper I 
Antenatal HIV-1 RNA load and timing of mother to child transmission; a nested case-control 
study in a resource poor setting;  
Duri K, Gumbo FZ, Kristiansen KI, Kurewa NE, Mapingure MP, Rusakaniko S, Chirenje 
MZ, Muller F and Stray-Pedersen B 
Virology Journal 2010, 7: 176  
 
Objective 
To determine HIV-1 RNA load during the third trimester of pregnancy and evaluate its effect 
on in utero and intra-partum/postpartum transmissions in a breastfeeding population 
 
Design 
A nested case-control study within a PMTCT cohort of antiretroviral therapy naive pregnant 
women and their infants 
 
Methods 
A case was a mother who transmitted HIV-1 to her infant (transmitter) who was matched to 
one HIV-1 positive but non-transmitting mother (control). 
Results 
From a cohort of 691 pregnant women, 177 (25.6%) were HIV-1 positive at enrolment and 
from these 29 (23%) transmitted HIV-1 to their infants, 10 and 19 during in utero and intra-
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partum/postpartum respectively. Twenty-four mothers sero-converted after delivery and three 
transmitted HIV-1 to their infants. Each unit increase in log10 viral load was associated with a 
178 cells/mm3 and 0.2 g/dL decrease in TLC and hemoglobin levels, p=0.048 and 0.021 
respectively, and a 29% increase in the risk of transmission, p=0.023. Intra-
partum/postpartum transmitters had significantly higher mean viral load relative to their 
matched controls, p=0.034. 
 
Conclusion 
Antenatal serum HIV-1 RNA load, TLC and hemoglobin levels were significantly associated 
with vertical transmission but this association was independent of transmission time. This 
finding supports the rationale for preventive strategies designed to reduce vertical 
transmission by lowering maternal viral load. 
 
5.2. Paper II 
Genotypic Analysis of Human Immunodeficiency Virus Type 1 (HIV-1) env V3 Loop 
Sequences: Bioinformatics Prediction of Co-receptor Usage among 28 Infected Mother–
Infant Pairs in a Drug-Naive Population. 
Duri K, Soko W, Gumbo F, Kristiansen K, Mapingure M, Stray-Pedersen B,  Muller, F  and 
the BHAMC Group. 
AIDS Research and Human Retroviruses 2010, 26; 11  
 
We sought to predict virus co-receptor utilization using a simple bioinformatics method based 
on genotypic analysis of human immunodeficiency virus types 1 (HIV-1) env V3 loop 
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sequences of 28 infected but drug-naïve women during pregnancy and their infected infants 
and to better understand co-receptor usage in vertical transmission dynamics. The HIV-1 env 
V3 loop was sequenced from plasma samples and analyzed for viral co-receptor usage and 
subtype in a cohort of HIV-1-infected pregnant women.  
 
Results 
Predicted maternal frequencies of the X4, R5X4, and R5 genotypes were 7%, 11%, and 82%, 
respectively. Antenatal plasma viral load was higher, with a mean log10 (SD) of 4.8 (1.6) and 
3.6 (1.2) for women with the X4 and R5 genotypes, respectively, p=0.078. Amino acid 
substitution from the conserved V3 loop crown motif GPGQ to GPGR and lymphadenopathy 
were associated with the X4 genotype, p = 0.031 and 0.043, respectively. The maternal viral 
co-receptor genotype was generally preserved in vertical transmission and was predictive of 
the newborn’s viral genotype. Infants born to mothers with X4 genotypes were more likely to 
have lower birth weights relative to those born to mothers with the R5 genotype, with a mean 
weight (SD) of 2870 (332) and 3069 (300) grams, respectively.  
 
Conclusion 
These data show that at least in HIV-1 subtype C, R5 co-receptor usage is the most 
predominant genotype, which is generally preserved following vertical transmission and is 
associated with the V3 GPGQ crown motif. Therefore, antiretroviral-naive pregnant women 
and their infants can benefit from ARV combination therapies that include R5 entry inhibitors 
following prediction of their co-receptor genotype using simple bioinformatics methods. 
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5.3 Paper III 
Human Immunodeficiency Virus (HIV) types Western blot (WB) band profiles as potential 
surrogate markers of HIV disease progression and predictors of vertical transmission in a 
cohort of infected but antiretroviral therapy naïve pregnant women in Harare, Zimbabwe 
Duri K, Muller F, Gumbo FZ, Kurewa NE, Rusakaniko S, Chirenje MZ, Muller F and Stray-
Pedersen B. 
BMC Infectious Diseases 2011, 11:7 
 
Background 
Expensive CD4 count and viral load tests have failed the intended objective of enabling 
access to HIV therapy in poor resource settings. It is imperative to develop simple, affordable 
and non-subjective disease monitoring tools to complement clinical staging efforts of 
inexperienced health personnel currently manning most healthcare centres because of brain 
drain. Besides accurately predicting HIV infection, sequential appearance of specific bands of 
WB test offers a window of opportunity to develop a less subjective tool for monitoring 
disease progression. 
 
Methods 
HIV type characterization was done in a cohort of infected pregnant women at 36 gestational 
weeks using WB test. Student-t test was used to determine maternal differences in mean full 
blood counts and viral load of mothers with and those without HIV gag antigen bands. 
Pearson Chi-square test was used to assess differences in lack of bands appearance with 
vertical transmission and lymphadenopathy. 
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Results 
Among the 64 HIV infected pregnant women, 98.4 % had pure HIV-1 infection and one 
woman (1.7%) had dual HIV-1/HIV-2 infections. Absence of HIV pol antigen bands was 
associated with acute infection, p=0.002. All women with chronic HIV-1 infection had 
antibody reactivity to both the HIV-1 envelope and polymerase antigens. However, antibody 
reactivity to gag antigens varied among the women, being 100%, 90%, 70% and 63% for p24, 
p17, p39 and p55, respectively. Lack of antibody reactivity to gag p39 antigen was associated 
with disease progression as confirmed by the presence of lymphadenopathy, anemia, higher 
viral load, p=0.010, 0.025 and 0.016, respectively. Although not statistically significant, 
women with p39 band missing were 1.4 times more likely to transmit HIV-1 to their infants. 
 
Conclusion 
Absence of antibody reactivity to pol and gag p39 antigens was associated with acute 
infection and disease progression, respectively. Apart from its use in HIV disease diagnosis, 
WB test could also be used in conjunction with simpler tests like full blood counts and patient 
clinical assessment as a relatively cheaper disease monitoring tool required prior to accessing 
antiretroviral therapy for poor resource settings. However, there is also need to factor in the 
role of host-parasite genetics and interactions in disease progression. 
 
5.4 Paper IV  
Phylogenetic Analysis of Human Immunodeficiency Virus type 1 (HIV-1) Subtype C Env gp 
120 sequences among four drug naïve families following subsequent heterosexual and vertical 
transmissions 
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Duri K, Gumbo FZ,Kristiansen KI, Mapingure MP, Munjoma M, Rusakaniko S, Chirenje 
MZ, Stray-Pedersen B and Muller F 
 
AIDS Res and Hum Retroviruses Journal 2012, 28(8): 885-893 
 
We sought to characterise phylogenetic relatedness of plasma HIV-1 RNA subtype C env 
gp120 viral variants capable of establishing an infection following heterosexual and 
subsequent vertical transmission events by sequencing a 520 base pair fragment of the C2V5 
sub-region from four HIV-1 infected families. Analysis was done using MEGA software. 
 
Phylogenetic analysis performed on families’ sequences suggested a localized expansion of 
the subtype C pandemic and that several mechanisms may be involved in both vertical and 
heterosexual transmission. Second siblings’ sequences were homogeneous and clustered in a 
single branch whilst first siblings’ sequences were more heterogeneous, clustering in separate 
branches, suggestive of more than one donor variants responsible for the infection or 
evolution from founder variant(s) could have occurred. Though the directionality for 
heterosexual transmission could not be determined, homogeneous viral variants was a unique 
characteristic of maternal variants vis-a–viz the more heterogeneous paternal variants. 
Sequences clustered quite closely with other regional HIV-1 subtype C sequences supported 
by a bootstrap value of 86%. Bigger studies are warranted to address the caveats of this study 
and build on the strengths. Our study could be the beginning of family-based HIV-1 
intervention research in Zimbabwe. 
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5.5 Paper V 
HIV-1 Env gp120 C2V5 Potential N-Linked Glycosylation site(s) (PNGs) and amino acid 
length polymorphisms following among infected family members 
 
Duri K, Gumbo FZ, Kristiansen KI, Mapingure MP, Chirenje MZ, Rusakaniko S, Muller F 
and Stray-Pedersen B 
Advances in Infectious Diseases Journal; 2011, 1, 1-13 doi:10.4236/aid.2011.11001 
 
Objective 
To ascertain the role of HIV-1 gp120 env PNGs variations and sequence length 
polymorphism following transmission events as possible supporting forensic evidence to 
determine directionality of HIV transmission 
 
Method 
An observational study of HIV-1 infected family members, where median and range values of 
the amino acid lengths and PNGs for the genotyped C2V5 region were calculated. Wilcoxon 
rank-sum test was used to determine differences in these parameters between different family 
members. 
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Results 
For heterosexual transmission, two mothers had longer C3 sequences relative to that of their 
spouses; p=0.006 and=0.025 whilst the opposite was observed for one mother, p=0.028. No 
clear trends were observed for PNGs. In three families, index children had longer C2V5 
amino acid sequences compared to their mothers; p=0.013, 0.040 and 0.043. Second siblings’ 
V4 and V5 sequences were generally shorter relative to the maternal ones; p=0.039 and 0.028, 
respectively. Generally adults had longer V3 amino acid sequences compared to the children; 
p=0.018. Similar trends were also observed regarding PNGs within the entire C2V5 region, 
C3 and V4 sub-regions; p=0.0025, 0.005 and 0.008, respectively. First siblings’ C2V5 and C3 
sequence lengths were significantly longer relative to those of the second siblings; p=0.005 
and 0.007, respectively. 
 
Conclusion 
Our results are suggestive that HIV-1 env C2V5 amino acid length and PNGs tend to increase 
with age and HIV disease progression. Though sensitive and should be cautiously handled, it 
is tempting to propose the directionality of the HIV transmission events with respect to C3 
region length polymorphism. Correlating HIV-1 env C2V5 sequence lengths and age of 
infection may be the first step towards a possible valuable piece of forensic evidence which 
may be useful in criminalisation of willful HIV infections. However, bigger studies are 
warranted to substantiate the authenticity of this potentially useful application. 
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CHAPTER 6 
6.0 Discussion  
6.1 Study Design 
In such poor resource settings of our study the nested case control design reduced costs and 
efforts of data collection considerably with relatively minor loss in statistical power 468-471. 
Despite the relatively small sample size, this retrospective case-control study is novel in HIV 
diversity and transmission mainly among mothers and their infants and to a lesser extent the 
respective fathers in that it enunciates new observations pertinent to the scientific fraternity 
especially for resource limited communities. Additionally, numerous new avenues for further 
studies have been opened.  
 
6.2 HIV Spread and Diagnosis 
Worryingly, mothers did not know when and how they got infected by HIV-1. On a positive 
note our study observed a decline of HIV-1 prevalence as compared to previous studies 123. 
Certain viral types, groups or subtypes are found in particular regions of the world or in 
certain populations. Travellers contribute to the spread of HIV-1 genetic diversity worldwide, 
a situation exacerbated by migration of rural populations and civil wars in developing 
countries 472. Different categories of travelers ranging cross border traders, immigrants, 
military personnel, seamen, tourists, expatriates, diplomats to high profile business persons 
are at risk “exporting” and “importing” HIV infections from different locations across the 
globe. In our study sero-conversion of HIV-1 was more likely observed amongst mothers who 
reported having a travelling spouse or sexual partner, Paper I 473, supporting the hypothesis of 
the association of travel and acquisition of HIV infection. Host genetic effects, transmission 
bottlenecks, social/behavioral and environmental limitations, founder effect and other viral 
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factors could have contributed to variable spread through the human population 309. This 
differential spreading of HIV-1 variants has implications for diagnostic, disease monitoring, 
treatment, and vaccine development. Continued developments in HIV testing technology and 
practices are the cornerstone for all HIV prevention strategies if the curbing of this pandemic 
is to be realised 474;475.  
 
6.2.1. Serological HIV Diagnosis 
6.2.1.1 Rapid HIV Tests 
Serial testing method was used although the relatively more expensive parallel algorithm 
could have been more appropriate to reduce false results. Ideally HIV antibody tests should be 
sensitive enough to detect all known HIV variants. At least in our study concordance of HIV 
rapid testing was 100% for the two kits used as illustrated in Paper III 476. However, the 
bigger mother cohort showed a rapid test results discordance of 5% 477. The development of 
blood screening reagents is nearly always based on conserved viral antigens or viral 
sequences derived from 'prototype' strains or antibodies raised against these prototype strains. 
Therefore in situations where an individual is infected by a viral strain that is genetically and 
antigenically distantly related to the prototype strain used in the development of the test, 
screening failure may occur 478. Cases of antibody-negative HIV infections have been 
reported 479 480. Depending on tests or algorithms used, up to 6% of HIV-1 group M and 80% 
of HIV-1 O infected patients may be misdiagnosed 481. Co-infections especially with 
tuberculosis which is high among HIV positive people in SSA has been associated with 
increase in the diversity of HIV quasi-species 482 may be also be the reasons behind some 
inaccurate HIV diagnosis. Apart from obvious human errors and HIV genetic diversity, 
discrepancy in the results could be due to antibody cross reaction of patient specimen with 
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some kit components or non-specific immune reactivity 446. Generally the interpretation of 
indeterminate or discrepant results between different rapid tests on one sample poses a 
challenge and under such circumstances WB test is generally used as the tie breaker. 
 
6.2.1.2. WB Test 
No challenges of indeterminate results were among the mothers. Regardless of that 
observation all our mothers’ rapid test results were confirmed on WB. Although WB test 
remains relatively more expensive compared to rapid tests it could be worthwhile using it as it 
provides more information on patients’ serology Paper III 476. Studies have shown African 
sera to exhibit a significantly higher number of indeterminate WB patterns 483. None of our 
women showed indeterminate WB test results. Unfortunately most kits are developed and 
validated in developed countries using their predominant subtype B antigen preparations 
which contribute less than 10% of all global HIV infection. However, the same kits when 
used in regions with non-B subtypes may not be as effective and accurate.  
 
6.2.2. Qualitative DNA PCR 
Like the Rapid tests most molecular diagnostic assays for the detection of HIV infection have 
been approved and licensed specifically for subtype B. Despite the high viral variability 
observed, some essential portions of the HIV genome are highly conserved and such regions 
are used in universal primer design which theoretically should pick up all the viral variants. 
Accordingly, some studies have successfully detected non-B subtype infections using USA 
Food and Drug Administration licensed subtype B specific diagnostic assays 484. In our study 
infant HIV-1 status was determined using qualitative Roche DNA PCR which previous 
studies have demonstrated 100% sensitivity and 100% specificity at least amongst 
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Zimbabwean infants and adults with predominant HIV-1 subtype C 485. For our study there 
was no other test employed to validate the Roche DNA PCR qualitative test results and as 
such some few misdiagnoses could not be ruled out completely. Constant HIV-1 genomic 
variability within and across strains plays a major role in relation to the sensitivity of such 
tests, sometimes leading to misdiagnosis 300;486-489. Thus some studies have shown that 
Amplicor DNA PCR HIV-1 test does not detect all subtypes with equivalent sensitivity 490. 
Clinicians should be aware of this particular limitation of this commonly used assay. 
Therefore constant monitoring of the performance of such molecular screening tests is very 
critical. It is imperative that alternative cheaper in-house test(s) be urgently developed taking 
cognizance that the Roche DNA qualitative PCR test is rather expensive and beyond the reach 
of many in resource limited settings where ironically HIV prevalence is unacceptably high.  
 
6.3 HIV Monitoring 
Monitoring antiretroviral therapy requires that HIV-1 viremia assays be applicable to all 
distinct HIV variants. Unfortunately, Like the diagnostic test excellent viral load quantitation 
results have been observed for subtype B compared to other subtypes or CRFs 491-499;499. 
Accurate HIV-1 RNA quantitation have been shown to be compromised by primer and probe 
sequence polymorphisms as a result of the extensive tremendous genetic diversity as a result 
of ongoing HIV-1 evolution. Inaccurate quantification could be the underlying reason for the 
observation of pregnant mothers in our study who despite having undetectable plasma viral 
loads, went on to transmit to their infants, Paper I 473. Thus, non-detection of HIV RNA 
among these women could be explained by subtype B specific primers mismatches in subtype 
C amplifications. This has been confirmed by previous studies that have shown that 
approximately 30% of non-B subtypes specimens have been shown to be under-quantified by 
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at least -0.51 log10 by the Amplicor version 1.5 PCR 500;501. Such observations emphasise the 
importance of efficient designing of primers and probes for optimal quantitation of plasma or 
serum HIV-RNA in non-B subtypes. Studies have shown similar sensitivity and performance 
with serum or plasma 502. Mothers’ host factors such HLA and CYP polymorphisms and 
psychosocial factors also remain important predictors of disease progression they may impact 
on viral load 229. 
 
Other more affordable and easily measurable markers of disease progression such as TLC, 
hemoglobin, body mass index and delayed type hypersensitivity may be used in resource poor 
settings in desperation particularly at this time of scaling-up of antiretroviral therapies 229. 
Taking cognizance of the high cost per test, there is an urgent need for low-cost, simple, and 
accurate HIV-1 RNA load monitoring technologies tailor made for resource-limited settings 
In our study indeed TLC and hemoglobin levels correlated with viral load Paper I 473. Since 
unintentional viral load underestimation may lead to further infections or inappropriate 
treatment decisions other sequence-independent tests remain valuable requirements for 
confirming a low viral load. 
 
6.4 HIV Diversity and Transmission 
6.4.1 Types 
HIV-2 was not found in our mothers yet its prevalence of this viral type is relatively high in 
neighbouring Mozambique and Angola. These countries are amongst those frequented by 
most Zimbabwean cross border traders and ZDF personnel in the past three decades. 
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However, transmission of HIV-2 in Zimbabwe has remained very low if any. This observation 
could be attributed to the low transmissibility properties of HIV-2 relative to HIV-1 365.  
 
6.4.2. Subtypes /CRFs  
Despite the high mobility there seems to be no new HIV types being introduced into this 
population, supporting the null hypothesis. Based on the sequencing of the C2-V5 HIV-1 env 
gene exclusive subtype C was observed among the mothers and their infants. Our study 
results are consistent with previous Zimbabwean studies that have demonstrated subtype C as 
the predominant subtype 396-398 except for one study with unconvincing methodology that 
reported several double and triple recombinants 503. HIV-1 env subtype C clusters were clearly 
distinguished with high bootstrap values suggestive of infections of monophyletic origin or a 
localized expansion of the subtype C epidemic. Previous studies also done in Harare in the 
same population have also observed the same picture but with the pol gene 99. Env C2-V5 
sequences clustered with other HIV -1 subtype C from South Africa, Malawi, Botswana, 
Tanzania, India, China and Argentina as well as from other previous studies Zimbabwean 
subtype C sequences as evidenced by a high bootstrap values, Paper IV 504, thus confirming 
the challenges associated with classifying subtype C sequences on a geographical location 
basis.  
 
Generally the regional distributions of individual subtypes are mostly stable, although CRFs 
may play an increasing role in the HIV pandemic 505. The geographic distribution of subtypes 
and CRFs is subject to constant change. Historically the North American and Western 
European are dominated by HIV-1 subtype B virus. However, this paradigm is changing 
rapidly as migrants and refugees from developing countries with non-B subtype infections 
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often now present for care in the developed world, and travelers to developing countries 
acquire non-B subtype infection abroad and present for care at home 506. Thus continued 
diversification and global redistribution of HIV groups, subtypes and CRFs makes it 
imperative that these monitoring molecular assays be constantly or periodically designed and 
evaluated to ensure reliable performance to detect all HIV variants. Interestingly some studies 
have indicated that the dominance of HIV-1 subtype C in the current epidemic might be 
related to the lower virulence of this subtype compared with other subtypes hypothesizing 
HIV-1 as has either reached peak virulence or has already started the slow path to attenuation 
507. The most severe HIV-1 pandemic is occurring in Southern Africa. It is caused by HIV-1 
subtype C 377 508. Consequently, understanding the molecular phylogeny and genetic diversity 
of HIV-1 subtype C viruses may not be over-emphasised especially for the design and 
evaluation of an effective HIV vaccine. 
 
6.4.3 Subtype C Uniqueness 
Most of what is known about HIV is based on information from subtype B studies. However, 
questions are being raised around the possibility of genetic and phenotypic differences in 
HIV-1 regarding transmissibility efficiency, infectivity and pathogenicity, in addition to 
responses to therapy and vaccines. Findings in this study are suggestive of fact that subtype C 
may different from subtype B probably due to its unique genetic and biological properties, 
Papers II, IV, V 504;509;510. Compared to other subtypes, subtype C has been shown to 
replicate and to be transmitted more efficiently 388;511-513. It is possible the transmissibility of 
HIV-1 subtype C is so high such that even with very low or undetectable viral load in some 
mothers vertical transmission was inevitable, Paper I 473. Subtype C may also be biologically 
different as demonstrated by the predominant R5 co-receptor usage, Paper II 509, a phenotype 
100 
 
 
that has been shown to persist throughout the course of infection whereas in the case of 
subtype B switching from R5 to X4 is observed as the disease progresses in 50% of the 
patients 514. Traditionally, V3 region has been considered a variable domain based on analysis 
of subtype B sequences. Surprising, our study population’s V3 region sequences were 
relatively constant, Paper IV 504. Interestingly, similar results of a relatively constant subtype 
C V3 region have been obtained elsewhere 293;515-518. Another consistent unique feature of our 
sequence analysis showed the highest levels of variation within the env gp120 C3 regions, 
challenging whether the so-called ‘constant region’ with respect to subtype B is really a 
constant one when it comes to subtype C. Other distinctive findings included the extensive 
deletion of the V4 region, amino acid length polymorphism of the V3 sequence and a 
characteristic GPGR motif on the crown of the V3 loop Papers II, IV and V 504;509;510. Thus 
HIV-1 subtype C envelope seems to show significant differences and unique characteristics 
compared to its subtype B counterpart, thus refuting the null hypothesis. In view of these 
observations extrapolation of findings from one subtype to the other should be discouraged. 
 
6.5. Vertical Transmission 
However, figures for both vertical and heterosexual transmission of HIV-1 were still 
unacceptably high in this population, Papers I; III 473;476 . Of note was the highly significant 
relationship between antenatal HIV-1 RNA load, at 36 weeks gestational period with vertical 
transmission, Paper I 473. Similar to other studies 420, no threshold for transmission was 
observed in this cohort that could predict transmission or non-transmission. Risk factors for 
vertical transmission in our study included high antenatal viral load, low TLC and anemia 
with the risk of transmission increasing by about 30% for each unit increase in log10 viral load 
supporting preventive interventions that lower maternal viral load Paper I 473. It was also 
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interesting to note that maternal co-receptor genotype was preserved upon vertical 
transmission Paper II 509. Findings are suggestive of the fact that the child acquired more or 
less the same number of PNGs from the mother which tends to decrease with disease 
progression Paper IV 504. Phylogenetic analysis performed for each family sequences set 
suggested that several mechanisms may be involved in both vertical and heterosexual 
transmission as also previously demonstrated 519;520. There is need for further research on the 
possible reasons behind the observed highly efficient vertical transmission phenomenon 
observed in some mothers who had undetectable viral load. There is also need to address 
subtype C specific research questions rather than extrapolating and applying subtype B 
findings if curbing of the pandemic is to be realized.  
 
6.6. Horizontal Transmission  
Homogeneous viral variants were a unique characteristic of maternal variants vis-a–viz the 
more heterogeneous paternal variants. Similar results have also been previously reported 521. 
This study also showed that C2V5 amino acid length and PNGs tended to increase with age 
and disease progression. This relationship can applied and used as potential supporting 
forensic evidence to determine the directionality of HIV transmission in court cases of willful 
HIV transmission where it is currently difficult to prove who infected who, Paper V 510 
Anecdotal of verbal autopsy suggests that generally Zimbabweans think most men infect their 
spouses whether willingly or unwillingly. However, this pilot study suggests otherwise 
pointing to a possible 50-50 transmission in either direction whether male to female (MTF) or 
female to male (FTM) transmission Paper V 510. Bigger studies are warranted to address the 
caveats of this study and build on its strengths.  
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6.7. Methodological Issues 
The gold standard in subtype determination entails that the whole HIV genome be sequenced 
but this approach has its own technical challenges and prohibitive costs. The second best 
approach of determining subtype is based on sequencing all the three main HIV genes, env, 
pol and gag or any two. HIV-1 subtypes determination using at least were determined using 
two or three genes, gag, pol, and env using several methods 522. Thus at least one more gene, 
for example the pol gene could also have been sequenced for subtype determination which 
would in addition give an idea of HIV-1 pol gene mutation profiles in the absence of selection 
of antiretroviral therapy. When at least one gene is genotyped, subtype determination for each 
gene can be concordant or discordant which could be indicative of recombination 523. 
However, there is also a chance of missing out on CRFs in other regions of the HIV genome. 
More so due to the same bottlenecks, the number of clones cloned per sample of about 4 on 
average fell short of the expected. Normally an average of 12 clones per sample could have 
been the ideal practice for more conclusive observations. 
Originally it was planned that direct sequencing be done for all the samples. However, it was 
very challenging to directly sequence 50% of the samples probably due to mutations hence 
the need to first TOPO clone such samples. Consequently, we ended up having some samples 
assayed by either method. Comparing such data has been a challenge. We had also anticipated 
comparing viral heterogeneity between transmitting and non-transmitting mothers which can 
only be done after controlling for such methodological challenges. Complete genomes are 
often not available and there is need for a method which accurately determines the subtype of 
strains for which only a segment of the genome has been sequenced. Relatively new methods 
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524;525 have been developed to improve the accuracy of HIV-1 subtype classification 
73526;526;527.  
6.8. Strength of the study 
This is a unique, advanced and technologically high-powered study which applied state-of the 
art techniques and equipment in biomedical research and analysis. As such, it opens countless 
windows of opportunities for North to South technology transfer, institutional and national 
capacity building and mutual co-operation in biomedical research. This study could be the 
beginning of research including family-based HIV-1 intervention research in Zimbabwe 
where males can be persuaded to participate in the PMTCT studies. The study’s unique cohort 
could be a sound and solid basis for lengthy follow-up periods which must be continued as 
most of the study participants are still available and willing to participate in research.  
 
6.9 Limitation of the study 
6.9.1 Sample Size and Follow up 
The sample size used is generally small. All the transmitters were included in this study as 
planned but to increase the statistical power of this study it was originally envisaged that each 
transmitter would be matched to four non-transmitting mothers but failed due to other 
technical and financial constraints. Due to the foregoing constraints, a one to one matching 
was settled for in anticipation that this would be more of a pilot study which could be scaled 
up depending on the results obtained. However, all transmitting and non-transmitting mothers 
selected in the study may not be a full representation of all the cases and controls in the 
original cohort due to failure to follow up all the mothers and infants. Nonetheless, the follow-
up rate was generally good. The socio-economic situation deteriorated fast during the follow 
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up period and some of our study participants relocated to the rural areas where cost of living 
was relatively cheaper there-by up-setting follow up rates. Some infants were seen at delivery 
and only reappeared after 15 months of age, Paper I 473. Since they did not turn up for their 
six week visits, it was impossible to know whether they were infected intra-partum or 
postpartum. Consequently, this resulted in the unusual categorization of time of infection of 
infants as intra-partum/postpartum, Paper I 473. 
 
6.9.2 Methodological Challenges 
In poor resource settings, subtype and CRFs determination is generally done using the 
gag/env HMA originally developed in 1993 and later modified by others seven years later 
444;445. However, full genome sequencing remains the gold standard method though expensive. 
Partial sequencing gives good results at reasonable cost. In our study subtype determination 
was done by genotyping a relatively long fragment of the most variable region of HIV which 
was very appropriate. Generally, it appears that no new subtypes or recombinants were being 
introduced in our study population.  
105 
 
 
CHAPTER 7 
7.0 Conclusion and Recommendations 
1. Based on the HIV-1 env gp 120 C2V5 there seems to be no new types or 
subtypes despite high mobility of the Zimbabweans.  
2. The strongest predictor for sero-conversion was having a travelling partner.  
3. High viral load was a risk factor for vertical transmission. The diagnostic 
(qualitative DNA-PCR) and disease monitoring (viral load test) kits used may not 
have been sensitive enough for this population.  
4. R5 co-receptor genotype was the most predominant in both the mothers and 
their infants and co-receptor usage genotype and PNGs were preserved upon 
vertical transmission. 
5. Mother viral heterogeneity was more or less the same with that of the second 
sibling whilst that of the first siblings showed diverse heterogeneity.  
6. Our subtype C clustered closely with other subtype C from other geographical 
regions and had unique V3 and C3 sequences.  
 
The following recommendations are being made: 
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Besides accurately predicting HIV infection, sequential appearance of specific bands on WB, 
test results offer a window of opportunity to develop a less subjective tool to monitor disease 
progression in poor resource settings. 
In resource poor settings with predominant R5 HIV-1 genotype, patients may benefit from 
ARV combination therapies that include anti-R5 entry inhibitors such as Maraviroc which can 
be taken with or without food and does not require refrigeration. If the poor communities are 
to benefit, the cost of the tropism test as well as the drug itself must be curtailed.  
Extrapolation of one subtype findings to another should be discouraged. Genetic differences 
observed may translate to variations in biological properties which in turn may translate to 
differences in transmission efficiency, disease progression, diagnostic and monitoring test 
sensitivity as well as treatment outcome.  
It is imperative to set up health care facilities to cater for long term survivors of vertical 
infection as HIV-1 infected children reaching their fifth birthday without ART and possibly 
maturing into adolescents. Currently existing institutions and facilities do not seem to cater 
for this generation of children. Their health conditions may demand more frequent and 
specialised medical attention.  
Lastly but more importantly technology transfer from North to South initiated by this 
collaboration should be taken to a higher level where a state of art molecular biology 
laboratory should be established in the Zimbabwe for advancement of research for the benefit 
of the nation and SSA region at large. This will be a step in the right direction towards 
addressing problems unique to this region that include co-infections and malnutrition and how 
these modify HIV acquisition and disease progression. 
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CHAPTER 8 
8.0 Further Studies 
There is need to assay the same population but this time sequencing at least two HIV gene 
fragments or even sequencing the whole HIV subtype C genome to conclusively rule out 
presence or absence of CRFs.  
 
Necessary are bigger multi-centred studies in regions with different HIV-1 disease burdens 
but having overlapping subtypes to address transmissibility efficiencies of HIV. These bigger 
studies will also have to substantiate this pilot study’s findings:  
a) The underlying reason(s) behind undetectable viral load from both the viral and 
host aspects including validating the assays in our own settings 
b) To substantiate the antenatal reactivity of p39 antigen on WB test as a possible 
predictor of vertical transmission 
c) To further determine the role of amino acid length polymorphism and PNGs 
variation in transmission and or disease progression 
d) To further assess and evaluate the potential of env length polymorphism and 
PNGs to predict the directionality of heterosexual transmission. 
e) Further follow up the infected children into adolescence studying the 
immunological and virological markers and their association with disease 
progression. 
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Further research to identify the selective factors governing which variants are transmitted, 
how the compartmentalization of HIV in different cells and tissues contributes to 
transmission, and the influence of host immunity, viral diversity, and recombination on 
MTCT may provide insight into new prevention strategies and the development of an 
effective HIV vaccine. 
 
Additional prospective research study is warranted to determine the concordance of HIV-1 
genetic diversity in different compartments in addition to the blood such as the genital tract 
(GT) and breast milk and their roles in transmission. 
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Antenatal HIV-1 RNA load and timing of mother 
to child transmission; a nested case-control study 
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Abstract 
Objective: To determine HIV-1 RNA load during the third trimester of pregnancy and evaluate its effect on in utero 
and intra-partum/postpartum transmissions in a breastfeeding population. 
Design: A nested case-control study within a PMTCT cohort of antiretroviral therapy naive pregnant women and 
their infants. 
Methods: A case was a mother who transmitted HIV-1 to her infant (transmitter) who was matched to one HIV-1 
positive but non-transmitting mother (control). 
Results: From a cohort of 691 pregnant women, 177 (25.6%) were HIV-1 positive at enrolment and from these 29 
(23%) transmitted HIV-1 to their infants, 10 and 19 during in utero and intra-partum/postpartum respectively. 
Twenty-four mothers sero-converted after delivery and three transmitted HIV-1 to their infants. Each unit increase 
in log10 viral load was associated with a 178 cells/mm3 and 0.2 g/dL decrease in TLC and hemoglobin levels, p = 
0.048 and 0.021 respectively, and a 29% increase in the risk of transmission, p = 0.023. Intra-partum/postpartum 
transmitters had significantly higher mean viral load relative to their matched controls, p = 0.034. 
Conclusion: Antenatal serum HIV-1 RNA load, TLC and hemoglobin levels were significantly associated with 
vertical transmission but this association was independent of transmission time. This finding supports the rationale 
for preventive strategies designed to reduce vertical transmission by lowering maternal viral load. 
Introduction 
Sub-Saharan Africa continues to be the epicentre of the 
HIV-1 epidemic contributing more than 90% of the 370 
000 infants who acquire the infection from their 
mothers annually worldwide [1]. More than half of the 
HIV-1 infected children die before their second birthday 
[2]. The HIV-1 epidemic among pregnant women poses 
a challenge to child health and survival of future 
generations. 
  Zimbabwe is among the Sub-Saharan countries with 
the highest HIV-1 prevalence in the world. Among 600 
000 women who get pregnant annually, HIV-1 preva- 
lence peaked to 30% in 1997 [3] but has steadily 
declined over the years to 15.6% in 2006 [1,4]. Without 
any intervention, 30-49% of the children born to HIV-1 
* Correspondence: tkduri@yahoo.co.uk 
1Department of Immunology, University of Zimbabwe, Harare, Zimbabwe 
positive mothers are infected by the virus [5]. In Zim- 
babwe the estimate of mother to child transmission rate 
of HIV-1 has been shown to be 30% [6]. The reason 
why some mothers transmit to their infants whilst the 
majority does not is not well documented. 
  Maternal HIV-1 RNA load has been shown to be the 
strongest predictor of vertical transmission [7,8]. In 
Zimbabwe, among exclusively breastfed infants, in utero 
and intra-partum transmission has been shown to be 
9.4% and 16%, respectively [6] with a postpartum trans- 
mission rate of 12% [9]. However, both studies have 
made no reference to maternal viral load. More so, 
other previous studies have pooled the three transmis- 
sion periods; in utero, intra-partum and postpartum 
cases and this may underestimate time specific risk fac- 
tors of vertical transmission [8]. 
© 2010 Duri et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in 
any medium, provided the original work is properly cited. 
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  Despite the high HIV-1 prevalence in the general 
populace which translates to high vertical transmission 
rates, the desire to have future pregnancies among HIV- 
1 positive mothers has increased from 3% to more than 
55% more so with the advent of HIV-1 Prevention of 
Mother To Child Transmission (PMTCT) initiatives 
[10,11]. Therefore there is a need for the development 
of a simple, effective and time specific vertical transmis- 
sion preventive strategy to curb this epidemic. This 
study aims to determine HIV-1 RNA load during the 
third trimester of pregnancy and evaluate its association 
with in utero and intra-partum/postpartum vertical 
transmissions. 
infants were aliquoted and appropriately stored for 
further tests in the event that they sero-converted. 
Mothers and Infants Demographic characteristics and 
Examination 
All mothers answered a structured questionnaire at 
enrolment and information regarding their socio- 
demographics, sexual behavior, obstetric and reproduc- 
tive health issues was obtained. A gynecologist 
performed physical and gynecological examinations. 
  A pediatrician examined infants. Date of birth, birth 
weight, gender, single dose nevirapine therapy and 
breastfeeding patterns were recorded. Infant deaths were 
also recorded during the follow up period. 
Mothers’ Tests 
Methodology 
Study Design and Setting 
This was a nested case-control study in which the cases 
and controls were sampled from an antiretroviral ther- 
apy naive PMTCT cohort of pregnant women attending 
Antenatal Clinics at Epworth, Seke North and Saint 
Mary’s Chitungwiza, all around Harare. Antiretroviral 
drugs were not readily available in Zimbabwe at the 
time of recruitment of study participants. 
Study Population and Procedures 
The study population consisted of two groups of HIV-1 
positive pregnant women. The main group comprised of 
pregnant women who were HIV-1 positive at enrolment, 
referred to as having chronic HIV-1 infections and a 
minor group of women who were HIV-1 negative dur- 
ing pregnancy but later on sero-converted after delivery 
during the follow-up period, regarded as having acute 
HIV-1 infections. Each HIV-1 positive mother who 
transmitted the virus to her infant (case) was matched 
to one HIV-1 positive but non-transmitting mother 
(control). Matching of cases and controls was done with 
respect to maternal age, educational level, marital and 
socio-economic status, parity, alcohol intake, sexually 
transmitted infections, the date of last menstruation, 
and uptake of single dose nevirapine therapy. 
  Pregnant women were enrolled at 36 gestational weeks 
in a national PMTCT program between April and Sep- 
tember 2002. Pre-and post-HIV test counseling was pro- 
vided. Single dose nevirapine therapy was offered to 
HIV-1 positive mothers during labour and to their 
infants within 72 hours post delivery. Mothers were 
encouraged to exclusively breastfeed during the first six 
months. Follow-up was from delivery, six weeks, four 
and nine months and thereafter three monthly until two 
years. Follow up visits generally coincided with infant 
immunization visits. At each subsequent follow-up visit, 
HIV-1 negative mother and infants were re-tested for 
HIV-1 antibodies and HIV-1 DNA, respectively. Serum 
samples from the HIV-1 negative mothers and their 
Serial HIV-1/2 algorithm antibody tests were done using 
Determine (Abbott Diagnostics, Illinois USA) and Ora- 
Quick (Abbott Diagnostics, Illinois, USA) rapid kits on 
mothers’ serum samples. EDTA-anti-coagulated venous 
blood samples were processed within six hours for full 
blood counts using Abbott Diagnostic Cell Dyne 3500R 
SL Hematology Analyser. Total Lymphocyte Count 
(TLC) was enumerated as the total white blood cell 
count multiplied by the lymphocyte percentage. In this 
resource poor setting, TLC was used as a surrogate mar- 
ker for CD4 cell count since by then, the capacity to 
determine the latter was not readily available to the gen- 
eral public due to prohibitive costs. TLC of 1200 cells/ 
mm3 was the threshold value used equivalent to a CD4 
count of 200 cells/mm3 [12,13]. 
  Blood samples were shipped on dry ice to the Institute 
of Microbiology at the University of Oslo in Norway for 
further laboratory analysis. Maternal baseline serum 
samples were quantified for HIV-1 RNA load using an 
automated TaqMan Roche Amplicor 1.5 Monitor Test 
(Cobas AmpliPrep/Cobas TaqMan, Roche Diagnostics, 
Branchburg NJ) according to the manufacturer’s instruc- 
tions. As for sero-converters, the first HIV-1 positive 
sample was quantified. The linear range of the test was 
between 40 (1.6log10) and 107 (7log10) copies/mL and 
the detection limit of the assay is 40 copies/mL based 
on a sample volume of 1 mL thus the detection limit for 
this study was 400 copies/mL based on a serum sample 
volume of 100 L that was topped up to 1 mL with 
HIV-1 negative serum. 
Infants’ Tests 
Infants’ venous EDTA whole blood samples were col- 
lected at each follow up visit. Samples were stored at 
-86°C until testing. Detection of infants’ HIV-1 infection 
was determined using a qualitative 1.5 Roche Amplicor 
HIV-1 DNA PCR kit (Roche Diagnostics Incorporation, 
Branchburg, New Jersey). Testing was done in the 
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Obstetrics and Gynecology Department, Medical School, 
University of Zimbabwe. Infants that tested HIV-1 DNA 
PCR positive on whole blood collected within 10 days of 
birth were considered to be infected in utero. Infants 
who had negative HIV-1 DNA PCR results within the 
first 10 days of life and positive results at six weeks 
postpartum and/or thereafter were considered to be 
infected intra-partum/postpartum [14]. 
Statistical Analysis 
Data were collected and analyzed using STATA version 
10 from Texas and SPSS version 16.0 from Illinois, 
USA. Viral load values were log 10 transformed. Viral 
load values of below the detection limit were assigned 
half the value of the detection limit. The Student t-test 
was used to compare mean log 10 viral load between 
transmitting and non transmitting mothers, chronic and 
acute HIV-1 infections, in utero and intra-partum/post- 
partum transmitters. Mean log 10 viral load of each of 
these groups was also compared with their respective 
matched controls. Regression analysis was used to inves- 
tigate the association between log10 viral load, TLC or 
hemoglobin levels, and vertical transmission. Tests of 
statistical significance included the 95% confidence 
interval of relative risks, two sided p values based on 
Chi-squared and Fisher’s exact tests. 
Ethical Consideration 
The study was approved by the Medical Research Coun- 
cil of Zimbabwe and the Ethical Review Committee in 
Norway. Written consent to participate in the research 
study was obtained from the mothers and they were free 
to discontinue at any given time without any prejudice. 
Mothers also consented to have their blood samples and 
that of their index infants’ used for future HIV related 
research. 
no statistically significant differences between transmit- 
ting and non-transmitting mothers with respect to age, 
level of education, parity, type of marriage, socio- 
economic status and number of life sexual partners. The 
transmitters and non-transmitters also had comparable 
burdens of reproductive tract infections and obstetric 
history, see table 1. 
  When the transmitters were stratified by time of 
infecting their infants, there were no statistically signifi- 
cant differences with respect to demographics, sexual 
behaviour, reproductive health characteristics and medi- 
cal history between those who transmitted during in 
utero and those who transmitted intra-partum/ 
postpartum. 
  Mothers with acute HIV-1 infection, the sero- 
converters, were generally younger relative to HIV-1 
negative mothers in the cohort, with mean age of 21.8 
(4.6) and 23.7(5) years respectively although not sta- 
tistically significant, p = 0.06. There were also no sta- 
tistical significant differences with respect to parity, 
level of education, age of sexual debut and reproduc- 
tive tract infections between these two groups. Sero- 
converters were more likely to be single, have more 
than one sexual partner(s), syphilis, clinical warts, and 
a history of blood transfusion with p values of 0.000, 
0.019, 0.041, 0.002 and 0.033 respectively. Transmit- 
ting sero-converters were more likely to report having 
a travelling partner, p = 0.022 and were significantly 
younger than transmitters with chronic HIV-1 infec- 
tions, with mean age of 20(1.7) and 27(5.5) years 
respectively, p = 0.04. 
HIV-1 Prevalence and Transmission 
Results 
Demographic and reproductive health characteristics of 
32 transmitters and matched 32 non-transmitters 
There was no statistical significant difference with 
respect to socio-demographic characteristics, sexual 
behavior, reproductive genital tract infections and medi- 
cal history between the 64 HIV-1 positive mothers con- 
stituting this study population and the rest (113) of the 
HIV-1 positive mothers in the cohort. However, the 32 
transmitters and matched 32 non-transmitters were 
more likely to have more children relative to the other 
113 HIV-1 positive but non transmitting mothers who 
were not part of the study population, p = 0.016. 
  Mothers’ mean age (SD) was 26.0 (5.6) years with that 
of transmitters and non-transmitters being 26.3 (5.6) 
and 25.6 (5.6) years respectively p = 0.610. All the 
mothers had spontaneous vaginal deliveries. There were 
At enrolment, 691 pregnant women attending national 
PMTCT program were sampled between April and Sep- 
tember 2002. Of these, 177 (25.6%) and 514 (74.4%) 
were HIV-1 positive and negative respectively. There 
were two stillbirths each among the HIV-1 positive and 
negative mothers and these were excluded from analysis. 
From the 176 mothers with chronic HIV-1 infections 
that delivered live births 134 (76%) mother-baby pairs 
were successfully followed up and tested, see figure 1. 
There were no statistically significant differences with 
respect to socio-demography and reproductive health 
characteristics between the 42 women lost to follow up 
and the 134 with complete data sets. Twenty-nine (22%) 
mothers transmitted the virus to their infants, 10 (34%) 
and 19 (66%) during in utero and intra-partum/postpar- 
tum transmissions with rates of 7.5% and 15.3% 
respectively. 
  Out of the 514 HIV-1 negative mothers at baseline, 24 
sero-converted during the 2 year follow-up period, giv- 
ing an HIV-1 cumulative incidence rate of 2.3 per hun- 
dred women years. Among the 24 sero-converters with 
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Table 1 Socio-demographics, sexual behavior, medical history and baby characteristics of the 32 transmitters and 32 
non-transmitters 
Variable 
Age in years 
Mean (sd) 
Years in school 
     <8 
Parity 
At least 1 child 
Polygamous marriage 
Yes 
Subsidised income 
Yes 
Age at sexual debut 
     ≤ 16 years 
Life time partners 
>1 
Vaginal discharge 
Abnormal 
Genital ulcer 
Present 
Dysuria 
   Yes 
Lymphadenopathy 
Yes 
Abortion history 
Yes 
Infant death history 
Yes 
Schistosomiasis infection history 
    Yes 
Mothers’ARV Prophylaxis 
No 
Infant gender 
Male 
Birth weight 
<2500 
Deceased infant 
    Yes 
Breastfed 
Yes 
Baby ARV prophylaxis 
Yes 16/27 (59) 13/25 (52) 0.87 (0.51-1.49) 
9/31 (29) 
28/31 (90) 
2/30 (7) 
19/25 (76) 
4.35 (1.02-18.52)* 
1.79 (0.69-4.64) 
2/31 (6) 1/30 (3) 1.36 (0.58-3.15) 
14/30 (47) 12/29 (41) 1.11 (0.67-1.83) 
7/32 (22) 
17/32 (53) 
4/31 (13) 
16/32 (50) 
1.32 (0.78-2.24) 
1.00 (0.60-1.66) 
4/32 (13) 7/32 (22) 0.69 (0.30-1.57) 
7/32 (22) 3/32 (9) 1.51 (0.92-2.49) 
7/32 (22) 
3/28 (11) 
4/31 (13) 
1/31 (3) 
1.32 (0.78-2.25) 
1.65 (0.87-3.12) 
5/32 (16) 3/30 (10) 1.25 (0.69-2.28) 
15/32 (47) 13/31 (42) 1.10 (0.68-1.79) 
6/32 (19) 
17/32 (53) 
3/32 (9) 
16/32 (50) 
1.41 (0.82-2.42) 
1.06 (0.65-1.74) 
4/32 (13) 8/32 (25) 0.62 (0.27-1.43) 
4/31 (13) 4/30 (13) 0.98 (0.47-2.06) 
4/32 (13) 
28/32 (88) 
3/32 (9) 
25/32 (78) 
1.16 (0.58-2.33) 
1.40 (0.60-3.30) 
26.3 (5.6) 25.6 (5.6) 1.01 (0.95-1.08) 
Transmitter 
N = 32 (%) 
Non Transmitters 
N = 32 (%) 
RR (95% CI) 
acute HIV-1 infections, three (13%) transmitted the 
virus to their infants through breastfeeding around 9 
months postpartum. All the three infants were exposed, 
through breast milk for about three months before 
acquiring HIV-1 infection at about 12 months 
postpartum. 
  Thus there were a total of 32 transmitting mothers in 
this cohort, giving an overall transmission rate of 21.3%. 
Maternal Viral Load and Transmission 
Of the 32 transmitters and 32 matched non-transmitters, 
26 (81%) and 20 (63%), respectively had detectable serum 
HIV-1 RNA load ranging from 400 to 3 000 000 copies/ 
mL. Vertical transmission occurred throughout the entire 
range with 90% of the transmissions occurring below 16 
000 HIV-1 RNA copies/mL. The mean (95% Confidence 
Interval) log 10 viral load was 3.55(3.15-3.96) and 2.92 
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Figure 1 Summary of the sampling of the 32 transmitters and 32 non-transmitters. 
(2.59-3.26) for transmitters and non-transmitters respec- 
tively, p = 0.018, see table 2. For each unit increase in 
log 10 viral load, the risk of transmission increased by 
29%, p = 0.023. Mean log 10 (SD) viral load of mothers 
with acute and chronic HIV-1 infection was 4.22 (1.01) 
and 3.55 (1.09) respectively, p = 0.317. Mean log10 (SD) 
viral load of transmitting sero-converters and non-trans- 
mitting sero-converters were 3.99 (1.34) and 2.77 (0.81) 
respectively, p = 0.248. There was no statistical signifi- 
cant difference in mean log10 viral load between in utero 
Table 2 Baseline HIV-1 RNA load, TLC and hemoglobin levels of 32 transmitters and non-transmitters 
Variable 
Hemoglobin g/dl 
<10 
TLC 
Mean cells/mm3(sd) 
Viral load 
Mean log10 copies/ml 3.55 (1.12) 2.92 (0.92) 1.29 (1.07-1.55)* 
2147 (111) 2505 (132) 0.99 (0.99-0.99)* 
7/32 (22) 2/32 (6) 1.71 (1.08-2.69)* 
Transmitters 
N = 32 
Non-transmitters 
N = 32 
RR (95% CI) 
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and intra-partum/postpartum transmitters. In-utero 
transmitters generally had higher mean log10 viral load 
compared to their matched controls though not statisti- 
cally significant and similarly intra-partum/postpartum 
transmitters had significantly higher mean viral load rela- 
tive to their respective matched controls, p = 0.034. 
   Among the 32 transmitting and 32 non-transmitting 
mothers 6 (19%) and 12 (37.5%), respectively had unde- 
tectable viral load respectively and none of them were 
from the acute infection subgroup. Mothers with unde- 
tectable viral load were less likely to transmit when 
compared to mothers with detectable viral load. There 
were no statistically significant differences regarding 
socio-demographic and reproductive health characteris- 
tics between mothers with detectable and undetectable 
viral loads. 
HIV-1 RNA load, TLC, Hemoglobin levels and Transmission 
transmitters relative to their matched controls p = 
0.038, see table 3. Anaemic mothers with hemoglobin 
levels of less than 10 g/dL were 1.7 times more likely to 
transmit compared to those with hemoglobin levels of 
more than 10 g/dL in univariate analysis. After control- 
ling for the effect of viral load and TLC this relationship 
ceased to be significant. 
Infant Factors, Mortality and Transmission 
Infant sex, birth weight, single dose nevirapine therapy 
and breastfeeding patterns were not significantly differ- 
ent neither between transmitters and non-transmitters 
nor among in utero and intra-partum/postpartum trans- 
mitters. HIV-1 infected infants were 4 times more likely 
to die compared to those uninfected (p = 0.003), see 
table 1. The odds of dying were 14 (p = 0.04) for infants 
infected in utero compared to their respective unin- 
fected controls. 
Mean TLC for transmitting mothers and non-transmit- 
ting mothers were 2147 cells/mm3 and 2505 cells/mm3 
respectively, p = 0.04. HIV-1 RNA load negatively corre- 
lated with TLC, correlation coefficient of -0.254. Each 
unit increase in log10 viral load was associated with a 
178 cells/mm3 decrease in TLC, (p = 0.048). There were 
no statistical significant differences in mean TLC of 
mothers with acute and chronic HIV-1 infections and 
also between in utero transmitters and their respective 
controls. However, there was a statistically significant 
difference in mean TLC between intra-partum/postpar- 
tum transmitters and their matched controls, p = 0.030, 
see table 3. 
  Each unit increase in log10 viral load was associated 
with a 0.2 g/dL decrease in hemoglobin levels, p = 
0.021. There were no statistically significant differences 
in hemoglobin levels between mothers with acute and 
chronic HIV-1 infection and also among in utero and 
intra-partum/postpartum transmitters, p = 0.870 and 
0.980 respectively. Mean hemoglobin levels were signifi- 
cantly different between intra-partum/postpartum 
Discussion 
This is a first study in Zimbabwe where viral load was 
determined in pregnant women and was related to time 
point vertical transmission. This nested case-control 
study of Harare peri-urban pregnant women provided 
data on risk factors of vertical transmission by assessing 
maternal HIV-1 RNA load, TLC and hemoglobin levels 
of transmitting and non-transmitting mothers, who were 
otherwise similar with respect to demographic and 
reproductive health characteristics. 
  Of note was the highly significant relationship 
between antenatal HIV-1 RNA load, at 36 weeks gesta- 
tional period, with vertical transmission. Similar to other 
studies [7,8,15,16], transmitting mothers had a signifi- 
cantly higher viral load compared to non-transmitting 
mothers. 
  No threshold for transmission was observed in this 
cohort that could predict transmission or non- 
transmission, as transmission occurred throughout the 
whole range of viral load values, contrary to previous 
Table 3 Comparison of in utero and intra-partum/postpartum transmitters and their respective matched non- 
transmitting controls with respect to viral load, TLC and hemoglobin levels 
Variable In utero 
transmitters 
N = 10 
10.7 (0.9) 
2133 (724) 
In utero matched 
controls 
N = 10 
10.5 (1.3) 
2207 (443) 
RR (95%CI) Intra/Postpartum 
Transmitters 
N = 22 
Intra-/postpartum 
Matched Controls 
N = 22 
11.4 (1.0) 
2632 (790) 
RR (95% CI) 
Hemoglobin 
Mean g/dl (sd) 
TLC 
Mean cells/ml 
(SD) 
Viral load 
Mean log10 
copies/ml 
0.99 (0.98-1.00) 2153 (576) 0.98 (0.97 = 0.99)* 
1.10 (0.74-1.65) 10.5 (1.5) 0.82 (0.71-0.94)* 
3.5 (1.2) 3.0 (0.9) 1.60 (0.70-3.79) 3.6 (1.1) 2.9 (1.0) 2.0 (1.02-3.81)* 
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studies [17]. More so, no threshold of HIV-1 RNA load 
was associated with in utero and intra-partum/postpar- 
tum transmissions contrary to some studies [18-20]. 
Our findings are analogous to those by Garcia et al., 
where serum HIV-1 RNA levels predicted the risk but 
not the timing of vertical transmission [21]. While viral 
load was an important determinant of vertical transmis- 
sion, it was not the only one, as six percent of non- 
transmitting mothers had high viral loads of >100 000 
copies/mL yet they did not transmit. Besides high levels 
of viremia, other risk factors of vertical transmission 
such as maternal host genetic factors, neutralizing anti- 
bodies, HIV-1 phenotype and/or genetic diversity could 
have also played a role in transmission. 
  Eighteen (28%) of the 64 mothers had undetectable 
viral load yet some (n = 6) still transmitted the virus to 
their infants. A Spanish study has also observed some 
pregnant women with undetectable plasma viral load 
who were at risk of vertically transmitting the HIV-1 
RNA during vaginal delivery [22]. Quantification of 
HIV-1 RNA in cervico-vaginal secretions has been 
shown to be more useful when investigating vertical 
transmission risk associated with vaginal delivery [23]. 
African mothers who are immigrants in Europe have 
been shown to have lower HIV-1 RNA loads but were 
more likely to vertically transmit relative to their non- 
African counterparts [23-26] probably due to differences 
in HIV-1 subtypes and host genetic factors. This group 
of mothers with undetectable viral load could be elite 
controllers [27-29]. Elite controllers have been shown to 
maintain high levels of CD4+ CD25+ regulatory T cells 
in their peripheral blood [30]. These are of high 
research interest as they may provide novel insights 
regarding host mechanism of virus control. The percen- 
tage of the mothers with undetectable viral load in this 
study was relatively higher compared to previous Zim- 
babwean studies done in the late 1990 s which was 
around 10% [8,31]. This could be attributed to differ- 
ences in quantitation methods used. The fully auto- 
mated COBAS AmpliPrep/COBAS TaqMan Viral RNA 
load test used has been shown to excellently satisfy the 
requirements for reliable quantification of HIV-1 RNA 
in clinical specimens of all HIV-1 subtypes [32,33] and 
the automation itself reduced inter and intra assay 
variation. 
  Infant HIV-1 status was successfully determined using 
qualitative Roche DNA PCR. This test has shown 100% 
sensitivity and 100% specificity at least in Zimbabwean 
infants and adults with predominant HIV-1 subtype C 
[6,34]. The observed in utero and intra-partum/postpar- 
tum transmission rates of 7.5%, and 15.3% were quite 
comparable but lower relative to a previous Zimbab- 
wean study that has shown in utero, intra-partum/early 
postpartum and late postpartum transmission rates of 
9.4%, 16% and 5.3%, respectively [6]. The rates were also 
quite comparable to those obtained in a Tanzanian 
cohort with an in utero and intra-partum transmission 
rates of 8.4% and 16.1% respectively [19]. The overall 
vertical transmission rate of 21.3% observed was much 
lower compared to that obtained from previous studies 
prior to antiretroviral prophylaxis era of 30.7% and 27% 
[6,8]. This coincides with the general decrease in HIV-1 
prevalence in the general population and could be 
attributed to better access to antiretroviral prophylaxis. 
However, in this cohort receiving single dose nevirapine 
was not protective against HIV-1 vertical transmission 
[35]. This could possibly be due to a relatively small 
sample size. Intra-partum/postpartum transmissions 
constituted the majority, 69% of the infections. Other 
African studies have also shown such high transmission 
rates through breastfeeding [36]. In resource poor set- 
tings, where a large proportion of infants are infected 
through breastfeeding, concerted efforts should be made 
towards interventions aimed at reducing such transmis- 
sions by advocating for more effective HAART during 
pregnancy and or breastfeeding, encouraging exclusive 
breastfeeding for six months, with ongoing breastfeeding 
thereafter, during the introductions of complementary 
feeds [37]. 
  Generally male infants were more at risk of HIV-1 
vertical transmission though this was not statistically 
significant, unlike previous studies where in utero trans- 
mission was significantly higher among girl than boy 
infants [38]. Consistent with other studies was the fact 
that, in utero infected infants were 2.5 times more likely 
to die relative to intra-partum infected infants probably 
because they would have been infected for longer peri- 
ods [39]. 
  As early as 1964, it was recognized that a decrease in 
the TLC was associated with immune suppression [40]. 
The equipment and skills to perform total white blood 
cell count and differentials are readily available in most 
hospitals and clinics in resource-poor settings, and per- 
forming a TLC costs much cheaper compared to CD4 
cell count measurements. We applied WHO guidelines 
that acknowledge that TLC may be used as surrogate 
marker for CD4 counts in situations where CD4 cell 
count measurements may not be affordable. Observed 
was a negative correlation between HIV-1 RNA load 
and TLC. Pregnant women with high TLC were less 
likely to transmit to their infants compared to those 
with low counts and such findings have been observed 
by others [16,18]. Anaemic mothers were more likely to 
transmit to their babies. A mean decline of 0.46 g/dL 
hemoglobin level per unit increase in log 10 viral load 
has been observed in a South African study [41]. This 
value is relatively higher compared to 0.2 g/dL decrease 
in hemoglobin levels observed in our study. This is 
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probably due to the fact that the former study sampled 
only patients with acute HIV-1 infection which was not 
the case with our study. 
   In this cohort being single, having multiple partners 
and having a history of blood transfusion constituted 
significant risk factors for HIV-1 sero-conversion follow- 
ing delivery. Transmitting sero converters were more 
likely to be young and have a travelling partner. Preven- 
tion strategies should address these risk factors asso- 
ciated with sero-conversion to reduce HIV-1 incidence 
rates in the general population. In such poor resource 
settings a nested case control design reduced costs and 
efforts of data collection considerably with relatively 
minor loss in statistical efficiency [42]. However, all 
transmitting and non transmitting mothers selected in 
the study may not be a full representation of all the 
cases and controls in the original cohort due to failure 
to follow up all the mothers and infants, though gener- 
ally the follow-up rate was good. 
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Abstract 
We sought to predict virus coreceptor utilization using a simple bioinformatics method based on genotypic 
analysis of human immunodeficiency virus types 1 (HIV-1) env V3 loop sequences of 28 infected but drug-naive 
women during pregnancy and their infected infants and to better understand coreceptor usage in vertical 
transmission dynamics. The HIV-1 env V3 loop was sequenced from plasma samples and analyzed for viral 
coreceptor usage and subtype in a cohort of HIV-1-infected pregnant women. Predicted maternal frequencies of 
the X4, R5X4, and R5 genotypes were 7%, 11%, and 82%, respectively. Antenatal plasma viral load was higher, 
with a mean log10 (SD) of 4.8 (1.6) and 3.6 (1.2) for women with the X4 and R5 genotypes, respectively, p ¼ 0.078. 
Amino acid substitution from the conserved V3 loop crown motif GPGQ to GPGR and lymphadenopathy were 
associated with the X4 genotype, p ¼ 0.031 and 0.043, respectively. The maternal viral coreceptor genotype was 
generally preserved in vertical transmission and was predictive of the newborn’s viral genotype. Infants born to 
mothers with X4 genotypes were more likely to have lower birth weights relative to those born to mothers with 
the R5 genotype, with a mean weight (SD) of 2870 (Æ332) and 3069 (Æ300) g, respectively. These data show 
that at least in HIV-1 subtype C, R5 coreceptor usage is the most predominant genotype, which is generally 
preserved following vertical transmission and is associated with the V3 GPGQ crown motif. Therefore, 
antiretroviral-naive pregnant women and their infants can benefit from ARV combination therapies that include 
R5 entry inhibitors following prediction of their coreceptor genotype using simple bioinformatics methods. 
Introduction 
H       uman immunodeficiency virus type 1 (HIV-1) enters       target cells through interaction of the viral envelope (env) 
glycoprotein (gp) 120 with a host cellular receptor CD4 mol- 
ecule and a chemokine coreceptor. Based on chemokine cor- 
eceptor usage, HIV-1 can be classified as CCR5 (R5), CXCR4 
(X4), or dual tropic (R5X4).1 The genetic determinants of HIV- 
1 coreceptor usage are localized in the V3 loop of gp120, 
which has a highly conserved crown motif and glycosylation 
sites.2 More so, this V3 region is also crucial in viral replica- 
1 
2 
tion, transmission, infectivity, and neutralization.3 Genetic 
variation within this region has been linked to changes in 
coreceptor usage.2 
   Frequencies of R5 HIV-1 variants vary among different 
populations, being 80% and 50% in drug-naive individuals 
and patients receiving antiretroviral therapy, respectively.4,5 
During the course of HIV-1 infection, the virus changes its 
coreceptor usage from R5 to X4 with or without concurrent use 
of R5 in 50% of HIV-1 subtype B-infected individuals.6 This 
switch of coreceptor usage is associated with an accelerated 
decrease in CD4 cells and hence it could be an important 
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determinant of HIV pathogenesis and disease progression.7 
However, some subtype C and D studies have observed X4 
variants in newly infected individuals.8,9 
   Irrespective of the transmission route or HIV-1 subtype, R5 
viruses are preferentially transmitted in both adults and 
children except for subtype D.6,10 At least in subtype B, ma- 
ternal viral phenotype can be predictive of the newborn’s viral 
phenotype while the R5X4 phenotype is predominantly lost 
during vertical transmission.11 Contrary to this finding, ver- 
tical transmission of dual-tropic HIV-1 has been demon- 
strated.9 V3 loop genotypic characteristics with special 
emphasis on the predominant HIV-1 subtype C leading to 
preferential vertical transmission of a particular coreceptor 
genotype from mother to infant remains unclear, yet this in- 
formation is critical for the development of effective trans- 
mission-preventive strategies. 
   With the recent introduction of HIV-1 chemokine receptor 
antagonists on the market as components of antiretroviral 
therapy, it is increasingly important to screen HIV patients’ 
coreceptor usage prior to therapy.12,13 Hence simple and ef- 
ficient methods for routinely characterizing and monitoring 
HIV-1 coreceptor usage are needed to replace slow and re- 
source-intensive phenotypic assays. Excellent correlations 
between the HIV-1 V3 genotype and phenotype have been 
observed.14,15 Bioinformatics methods have been developed 
to improve the genotypic prediction of HIV-1 coreceptor 
usage from V3 sequences.16 There is little information re- 
garding the bioinformatics’ prediction of HIV-1 coreceptor 
usage in Zimbabwe, yet this information is important for 
drug or vaccine design and development. This study aimed to 
predict virus coreceptor usage using a simple bioinformatics 
method based on HIV-1 V3 sequences from infected but drug- 
naive mother–infant pairs to better understand coreceptor 
genotypes in the dynamics of vertical transmission. 
Materials and Methods 
Study design and setting 
  This was an antiretroviral therapy-naive Prevention of 
Mother-to-Child Transmission (PMTCT) cohort study of 
pregnant women attending three antenatal clinics all around 
the city of Harare.17 
Study population and procedures 
   Two groups of pregnant HIV-1-positive women who later 
transmitted their virus to their infants were studied. The main 
group consisted of pregnant women who were HIV-1 positive 
at baseline, regarded as having chronic HIV-1 infections, and 
a minor group of women who were HIV-1 negative during 
pregnancy but later on seroconverted after delivery during 
the follow-up period, regarded as having acute HIV-1 infec- 
tions (Fig. 1). 
   Consent was obtained from the women followed by en- 
rollment at 36 gestational weeks in a national PMTCT pro- 
gram between April and September 2002. Pre- and post-HIV 
test counseling was offered. The mode of HIV-1 acquisition 
was most likely heterosexual and generally all the women 
were asymptomatic at enrollment. HIV-1-positive mother and 
infant pairs were offered 200 mg of single dose nevirapine 
during labor and 2 mg/kg body weight within 72 h postde- 
livery, respectively.18 Mothers were encouraged to exclu- 
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FIG. 1. Summary of the sampling of the subset of 28 trans- 
mitters from the original cohort of 691 pregnant women. 
sively breastfeed during the first 6 months. Infants’ venous 
EDTA whole blood and plasma samples were collected at 
delivery, at 6 weeks, and at 4 and 9 months postpartum, and 
thereafter every 3 months until 2 years, thus generally coin- 
ciding with infant immunization visits. Samples were stored 
at À868C until testing. At each subsequent follow-up visit, 
HIV-1-negative mothers and previously DNA PCR test result- 
negative but exposed infants were retested for HIV-1 anti- 
bodies and antigen, respectively. In addition to HIV testing, 
plasma samples of seronegative mothers and their respective 
infants were aliquoted and stored for further analysis in the 
event that they seroconverted. 
Mothers’ and infants’ demographic characteristics 
and examination 
  All mothers answered a structured questionnaire at enroll- 
ment addressing information regarding their sociodemo- 
graphics, sexual behavior, and obstetric and reproductive 
health issues. A gynecologist performed physical and gyne- 
cological examinations. 
  A pediatrician examined the infants and recorded their 
date of birth, birth weight, gender, and single-dose nevirapine 
therapy administration. 
Mothers’ tests 
  Serial HIV-1/2 algorithm antibody tests were done using 
Determine (Abbott Diagnostics, Illinois) and Ora-Quick (Ab- 
bott Diagnostics, Illinois) rapid kits on mothers’ plasma 
samples. EDTA-anticoagulated venous blood samples were 
processed within 6 h for full blood counts using the Abbott 
Diagnostic Cell Dyne 3500R SL Hematology Analyser. Mo- 
thers were screened for sexually transmitted infections as 
previously described by Gumbo et al.18 Serum samples were 
shipped on dry ice to the Department of Microbiology, 
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Rikshospitalet in Oslo for further laboratory analysis. Ma- 
ternal baseline plasma samples were quantified for HIV-1 
RNA load using the automated TaqMan Roche Amplicor 1.5 
Monitor Test (Cobas AmpliPrep/Cobas TaqMan, Roche Di- 
agnostics, Branchburg, NJ) according to the manufacturer’s 
instructions. As for seroconverters, the first positive sample 
available was quantified. Baseline total RNA was extracted 
for V3 loop sequencing. 
Infants’ tests 
   Detection of infants HIV-1 infection was performed using 
qualitative the 1.5 Roche Amplicor HIV-1 DNA PCR kit 
(Roche Diagnostics). Infants that tested HIV-1 DNA PCR 
positive on whole blood collected within 10 days of birth were 
considered to be infected in utero. Infants who had negative 
HIV-1 DNA PCR results within the first 10 days of life but had 
positive results at 6 weeks were considered to be infected 
intrapartum and those positive thereafter were considered 
infected after birth. 
   The first DNA PCR-positive sample available was HIV-1 
env V3 loop sequenced. Seven infants had longitudinal sam- 
ples within the 2-month follow-up period. 
Nucleic acid extraction PCR amplification and cloning 
    Total RNA was extracted from plasma using the Boom 
et al.19 method. The primary PCR amplified an approximately 
800-base pair (bp) fragment spanning the V3 and V4 region of 
the envelope (positions 6948–7537) in the HIV-HXB2 genome 
using outer sense and antisense primers, 50 -GTCAGCACA 
GTACAATGTACACAT-30 and 50 -GCGCCCATAGTGCTTC 
CTGCTGC-30 , respectively. Secondary PCR amplified an ap- 
proximately 535-bp env gene fragment using inner sense 
and antisense primers 50 -ACAATGYACACATGGAATTARG 
CCA-30 and 50 -GGAGGGGCATACATTGCT-30 , respectively. 
Both positive and negative controls were included in all the 
PCR reactions to rule out any possible contamination and for 
assay sensitivity assessment. Detection and quantification of 
secondary PCR amplicons were done using a 1% agarose gel 
electrophoresed together with a standard mass ladder and 
then stained with SYBR safe stain. Gel reading was done using 
Gel Doc 2000 analyzer (Bio-Rad). The standard mass ladder 
was used to estimate molecular weights of the amplicons and 
the respective band intensity was used to estimate the quan- 
tities. Removal of salts and excess primers in amplicons was 
done using Microspin columns (Amersham Bioscience). 
Amplicons were diluted to a final concentration of 5–20 ng of 
template DNA for direct sequencing. 
    If direct sequencing was not possible cloning was done 
using an Invitrogen TOPO TA cloning kit version J, 2006. 
Secondary PCR products were cloned in an Invitrogen plas- 
mid vector, PCRR2.1-TOPOR, using the chemical transfor- 
mation method followed by expression in competent 
Escherichia coli cells (C4040-03). In the presence of galactosi- 
dase substrate, X–gal (5-bromo-4-chloro-3-indolyl-b-d- 
galactopyranoside) and an inducer, isopropyl thiogalactoside 
(IPTG) on an agar medium on a culture plate, transformed E. 
coli with PCR inserts in their LacZ open reading frame were 
unable to make b-galactosidase enzyme and presented as 
white colonies. Four randomly selected white colonies were 
streaked on a quarterly subdivided Luria-Bertani plate me- 
Variable 
Age in years 
  Mean (SD) 
Parity 
  No child, n (%) 
  ! One child, n (%) 
HSV infection 
  Not infected, n (%) 
  Infected, n (%) 
Syphilis 
  Not infected, n (%) 
  Infected, n (%) 
Trichomonas 
  Not infected, n (%) 
  Infected, n (%) 
Genital ulcer disease 
  Not infected, n (%) 
  Infected, n (%) 
Lympadenopathy 
  Absent, n (%) 
  Present, n (%) 
Baseline Hb 
  Mean (SD) 
Log10 viral load 
  Mean (SD) (copies/ml) 
GPGQ crown motif 
  Absent, n (%) 
  Present, n (%) 
Maternal death 
  No, n (%) 
  Yes, n (%) 
Baby delivery weight 
  Mean (SD) (g) 
Baby sex 
  Female, n (%) 
  Male, n (%) 
3 
dium containing 50 mg/ml kanamycin and incubated over- 
night at 378C. Plasmid DNA isolation was done using the 
mini-preparation method. 
DNA sequencing and analysis 
   Sequencing of both sense and antisense strands of the di- 
luted secondary amplicons was done using BigDye termina- 
tor sequencing standard kit version 3.1 (Applied Biosystems, 
Foster City, CA) using the inner amplification primers. Se- 
quencing reaction products were analyzed on an ABI 3730 
DNA analyzer (Applied Biosystem/HITACHI, Tokyo, Ja- 
pan). Forward and reverse sequences were assembled using 
the Vector NTI Advance 10 program. Alignment was done 
using Gene Doc, BioEdit, and Clustal X2 sequence alignment 
programs with manual editing to ensure that deletions or 
insertions did not alter the reading frame. Samples V3 loop 
sequences were aligned against a Los Alamos subtype C 
Table 1. Maternal Baseline Social Demographic, 
 Reproductive Health, and Markers of Disease 
 Progression Including Infant Characteristics 
among 25 Mothers with Chronic HIV-1 Infection 
X4/R5X4 
genotypes 
30.8 (3.8) 
0 (0) 
3 (14) 
1 (50) 
2 (11) 
5 (25) 
0 (0) 
3 (18) 
0 (0) 
5 (25) 
0 (0) 
3 (15) 
2 (67) 
11.0 (1.8) 
4.8 (1.6) 
2 (67) 
3 (14) 
4 (17) 
1 (50) 
2870 (332) 
2 (22) 
1 (9) 
   R5 
genotype 
27.0 (5.0) 
 1 (100) 
18 (86) 
 1 (50) 
16 (89) 
15 (75) 
 2 (100) 
14 (82) 
 3 (100) 
15 (75) 
 1 (100) 
17 (85) 
 1 (33) 
10.9 (1.0) 
3.6 (1.2) 
 1 (33) 
19 (86) 
19 (83) 
 1 (50) 
3069 (300) 
 7 (78) 
10 (91) 
p Value 
0.176 
0.684 
0.144 
0.421 
0.430 
0.567 
0.043 
0.925 
0.078 
0.031 
0.269 
0.205 
0.413 
n is for number tested; SD, standard deviation. 
X4 and R5X4 genotypes were grouped together. 
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FIG. 2. Baseline mother–infant pair coreceptor genotypes and infants’ longitudinal genotypes. 
either position 11 or 25.16 A mixture of both R5 and R4 ge- 
notype prediction in one sample was regarded as having a 
dual R5X4 genotype. 
Subtype determination 
   HIV-1 subtype was determined using secondary PCR am- 
plicons of the env gene fragment (535 bp). Sequences in their 
respective Fasta format were entered into the REGA HIV-1 
BioAfrica-Bioinformatics tool (version 2.0), website http:// 
www.bioafrica.net/, and the sequences were automatically 
subtyped. 
Data analysis 
   The data were collected and analyzed using SPSS (version 
17.0, Chicago, IL). The frequency and transmission pattern(s) 
of HIV-1 coreceptor usage genotype, the crown GPGQ motif, 
consensus. A year 2000 local Zimbabwean HIV-1 subtype C 
V3 loop consensus was also included in the alignment.8 
Coreceptor usage genotype prediction 
   Samples V3 loop sequences were aligned to the program 
training sequence. Gaps were introduced for optimization of 
homologous amino acid residues. Following alignment of the 
approximately V3 loop 35 amino acid residues, prediction of 
coreceptor usage genotype was automatically generated on 
a subC Position-Specific Scoring Matrices (PSSM) algo- 
rithm freely available online at the following website: http:// 
                                                             
16mullinslab.microbiol.washington.edu/computing/pssm/. 
Sequence scores of lower than the 5th percentile and higher 
than the 95th percentile were assigned to the R5 and R4 ge- 
notypes, respectively. The intermediate score were assigned 
a genotype prediction based on amino acid residues charge at 
                                                                                                                            ‰ 
FIG. 3. Mother–infant pairs of HIV-1 subtype C V3 loop sequences aligned with a Los Alamos consensus reference and their 
respective predicted coreceptor usage genotype. *Mother–infant pairs are identified by identification number (ID) with infant 
ID with a B (baby) prefix before the ID number. Infants’ ID and sequences are in italics. ID numbers with an asterisk indicate 
seroconverters (mothers with relatively acute HIV-1 infection). The number after the underscore indicates the time of blood 
collection for sequencing. 0 denotes at enrollment and delivery for the mothers and infants, respectively. WKS denotes weeks 
postpartum. M denotes months postpartum and seroconversion from delivery for infants and postdelivery for mothers. In 
parentheses at the end of each sequence are the number of V3 loop sequences analyzed for each sample. Generally all samples 
were directly sequenced except for IDs 39, 118, 205, and 366, which were also cloned. Within the alignment dots indicate 
identity with the consensus sequence and dashes indicate deletion for optimization of alignment. Paragraphs were used to 
separate different mother–infant pairs. 
ID No.                        10        20        30               
                ....|....|....|....|....|....|....|....|   CCR5/CXCR4 Usage 
Los Alamos      CTRPNNNT-RKSIRI-GPGQAFYA-TGEI-IGDIRQAHC       
Zim Cons        ........-......-........-.DD.-.........   R5     
39_0            ........-...V..-....T...-....-..-......(1)   R4  
39_0_A          .A..SK..-......-...RV...-ND-.-.....E.Y.(1)   R4  
39_0_B          ........-...V..-...RT...-....-..-......(3)   R5  
B39_4M          ........-...V..-........-.N.V-.......Y.(3)   R5 
  
46_6M*          ........-......-....V...-..N.-.........(2)   R5  
B46_12M         ........-......-....V...-..N.-.........(2)   R5 
  
67_0            ........-......-....T...-.NG.-.......Y.(2)   R5  
B67_9M          ........-...V..-........-.ND.-.........(2)   R5 
  
118_0           ....S...-......-....V...-ND-.-.....E...(2)   R5  
B118_0          .A..S...-......-....V..S-.ND.-..N..E...(2)   R5  
B118_9M         .A..SK..-......-....V...-.ND.-..N..E...(2)   R5 
  
139_0           .V..S...-......-....T...-....-.........(2)   R5  
B139_6wks       .V..S...-......-....T...-....-.........(2)   R5  
B139_9M         .V..S...-......-....T...-....-.........(2)   R5 
  
143_0           ........-......-....T...-..D.-.........(2)   R5  
B143_9M         ........-......-....T...-..D.-.........(2)   R5 
  
157_0           ........-...V..-....V..T-ND-.-.....E...(2)   R5  
B157_0          ........-...V..-....V..T-ND-.-.....E...(2)   R5 
  
165_0           ........-...V..-....T...-....-..N......(2)   R5  
B165_9M         ........-...M..-....T...-..D.-.........(2)   R5 
  
205Mo_0         ........-...V..-....V...-.N..-.....K...(2)   R5  
205Mo_0_A       .V......-STG...-....T...-P.R.-.........(4)   R4  
B205_12M_B      .I......-......-....T...-..G.-T.N......(3)   R5  
B205_18M_C      .I......-.Q....-....T...-P...-.........(2)   R5 
  
210_0           ....G...-.Q.V..-....T...-....-..N......(2)   R5  
210_24M         ........-...V..-....T...-....-..N......(2)   R5  
B210_0          ....G...-.Q.V..-....T...-....-.......Y.(2)   R5  
B210_6wks       ....G...-.Q.V..-....T...-....-.......Y.(2)   R5 
  
228_0           ........-......-....T..T-....-.......Y.(2)   R5  
B228_4M         ........-......-....T..T-....-.......Y.(2)   R5 
  
279_0           .I......-......-......F.-.TD.-..N....Y.(2)   R5  
B279_0          .I......-......-......F.-.TD.-..N....Y.(2)   R5 
  
344_0_A         ........-.R....-........-..D.-.....K...(2)   R5  
B344_18M        .A......-......-....T..T-N-D.-..N......(2)   R5 
  
345_0           ........-.R....-........-..D.-..N..E...(2)   R5  
B345_9M         .A......-......-....T...-..D.-.........(2)   R5 
  
366_MO_C        ........-...VW.-...RV...-..D.-.........(4)   R4  
B366_12M        ........-..GV..-....V...-..D.-..K..E...(4)   R5 
  
375_MO_A        ........-......-....T.F.-..A.-..N..K...(4)   R5  
B375_12M        ........-......-....TIF.-..A.-..N..K...(4)   R5 
  
453_6WKS        ........-......-....TYF.-..D.-..N......(2)   R5  
B453_6WKS       ........-.Q.V..-......F.-..D.-.....K.Y.(2)   R5 
  
504_0_A         ........-...V..-....T...-....-V.N......(2)   R5  
B504_0          ........-...V..-....T...-..D.-..N......(2)   R5  
B504_6WKS_B     ........-...V..-....T...-..D.-..N......(2)   R5 
  
506_0_B         ...H....-...V..-........-.N..-.....K...(2)   R5  
506_0_C         .M......-...V..-....T...-.ND.-.........(1)   R5  
B506_0          .M......-...V..-....T...-.ND.-.........(2)   R5 
  
541_0_A         ........-......-....T...-..D.-..N......(2)   R5  
B541_9M_A       ........-......-....T...-..D.-..N......(2)   R5 
  
567MO_0_A       ........-...V..-....S...-.-D.-.........(4)   R5  
567Mo_0_D       .V......-ST....-....T...-P.R.-.........(1)   R4  
B567_12M_C      ........-......-....S...-.D-.-.........(3)   R5 
  
683_0           ...C....-QQ....-....T...-.D-.-..N......(2)   R5  
B683_6wks       ........-...V..-....T...-..-.-..N......(2)   R5  
B683_15M        ........-......-...R....-.N-.-.........(2)   R4 
  
714_9M_A*       ....S...-......-........-.D-.-.........(4)   R5  
B714_9M-A       ....S...-......-........-.D-.-.........(2)   R5 
  
743_6WKS        .V......-.Q....-...R..F.-.KG.-..N....Y.(2)   R4  
B743_6WKS       .V......-.Q....-......F.-.KG.-..N....Y.(2)   R4  
B743_4M         .V......-.Q....-......F.-.KG.-..N....Y.(2)   R4 
  
3221_9M*        .I..G...-......-....T...-...V-..N......(2)   R5  
B3221_18M       .I.....-.Q..R.-....T...-...V-..N.......(2)   R5 
  
3351_0_A        ........-......-....T...-....-..N....Y.(4)   R5  
B3351_21M-A     ........-......-....T...-....-.......Y.(2)   R5  
B3351_21M-B     ........-.....V-....T...-....-..N......(1)   R5 
  
3551_6WKS       ........-.R....-....S...-..D.-.........(2)   R5  
B3551_17M       ........-......-....T...-....-.......Y.(2)   R5 
  
4031_0          .I......-.Q....-....T...-....-.........(2)   R5  
B4031_0_A       .I......-.Q....-....T...-....-.........(2)   R5 
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and the potential glycosylation site, six amino acids upstream 
of the first cysteine, were determined in both the mothers and 
infants. Viral load values were log10 transformed. The Stu- 
dent’s t-test was used to compare mean maternal age, log10 
viral load, hemoglobin (Hb) levels, and baby delivery weights 
of mothers with antenatal X4 and R5 genotypes. For analysis 
purposes women with X4 and R5X4 genotypes were grouped 
together as X4 and R5/X4. Regression analysis was used to 
investigate the association between mothers, infant geno- 
types, and vertical transmission. Tests of statistical signifi- 
cance included the 95% confidence interval of unadjusted 
relative risks, two-sided p values based on Chi-square, and 
Fisher’s exact tests. 
Results 
   From a cohort of 177 pregnant women with chronic HIV-1 
infections, 29 mothers transmitted the virus to their infants 
and of these 25 had their samples successfully sequenced. Out 
of the 514 HIV-1-negative pregnant mothers at baseline, 24 
seroconverted during the follow-up period and of these three 
infected their infants (acute HIV infections). Hence for both 
groups, a total of 28 transmitting mothers had their V3 loop 
successfully sequenced (Fig. 1). 
   When coreceptor usage was compared with other param- 
eters, some trends were observed that were, however, non- 
significant statistically. Mothers with X4 variants were more 
likely to be older, mean age (SD) 30.8 (3.8) versus 27.0 (5.0) 
years, and also to have more children, p ¼ 0.176 and 0.684, 
respectively. Interestingly, relatively younger women with 
the R5 genotype were generally more likely to have repro- 
ductive tract infections relative to their older counterparts 
with the X4 genotype, although this was also not statistically 
significant. Lymphadenopathy was significantly more com- 
mon among mothers with the X4 genotype (67%) versus those 
with R5 variants (33%), p ¼ 0.043. Higher viral load was as- 
sociated with the X4 genotype, mean log10 (SD) viral load 4.8 
(1.6) and 3.6 (1.2), respectively, p ¼ 0.078 (Table 1). 
HIV-1 subtypes 
  All the 28 mothers and their respective infants had purely 
HIV-1 subtype C virus. 
Predicted coreceptor genotypes 
for the 28 pregnant women 
   Overall, for the two groups of women, predicted maternal 
HIV-1 coreceptor usage frequencies for the X4, R5X4, and R5 
genotypes were 7%, 11%, and 82%, respectively, although the 
frequencies were somewhat different after stratification by 
maternal time of HIV-1 infection, whether chronic or acute. 
Predicted maternal coreceptor usage for 25 mothers 
and infants with chronic HIV-1 infection 
   Antenatal frequencies of X4, dual R5X4, and R5 genotypes 
among the 25 mothers with chronic infections were 8%, 12%, 
and 80%, respectively (Fig. 2). Maternal viral genotype was 
generally preserved in vertical transmission and was predic- 
tive of the newborn’s viral genotype. Infants born to mothers 
with X4 variants were more likely to have lower birth weights 
relative to those born to mothers with the R5 genotype, mean 
(SD) 2870 (332) g and 3069 (300) g, respectively, p ¼ 0.205. 
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   The infants’ baseline (first HIV-1-positive sample) cor- 
eceptor use genotypes were 8% and 92% for the X4 and R5, 
respectively. No infant had a dual-tropic genotype. There was 
no association between antenatal HIV-1 coreceptor usage and 
the time of infection of the infants, be it in utero, intrapartum, 
or postpartum, p ¼ 0.365. Seven infants had two longitudinal 
samples for coreceptor use determination within the 24- 
month follow-up period. Interestingly, six of these infants 
had the R5 genotype at baseline and of these, one switched 
coreceptor usage to the X4 genotype 15 months later. This 
infant’s mother had an R5 genotype at baseline. One of the 
seven infants acquired an X4 genotype from the mother at 6 
weeks after delivery and had maintained it by 4 months of age 
(Fig. 3). 
Coreceptor usage of three mothers and infants 
with acute HIV-1 infection 
   Three mothers seroconverted during the follow-up period, 
one at 6 months and two at 9 months postdelivery, also in- 
fecting their respective infants. All the mothers had baseline 
R5 genotypes. Like their counterparts in the main group with 
chronic HIV-1 infection, maternal baseline coreceptor geno- 
type was predictive of the newborn’s genotype. Dual tropism 
was also absent in these infants. 
V3 loop crown motif 
   Substitution from GPGQ to GPGR was associated with the 
X4 genotype ( p ¼ 0.031). The conserved GPGQ crown motif at 
the tip of the V3 loop was present in 88% of the mothers with 
chronic HIV-1 infection whereas all the seroconverters had 
this motif, indicating a possible functional significance for this 
site. 
   Ninety-six percent of the infants had the conserved GPGQ 
site with only one infant having the GPGR motif. This infant 
was infected at 6 weeks postpartum and had a baseline GPGQ 
motif. However, at 15 months of age the motif had switched to 
GPGR, associated with the X4 genotype. The mother had a 
baseline sample only, with the GPGQ motif. 
   All infants born to seroconverting mothers had GPGQ 
motifs. 
Glycosylation site 
   Potential glycosylation sites located six amino acids up- 
stream from the first cysteine were conserved in 96% of the 
mothers with chronic HIV-1 infection with only one infant 
losing this site. All the recent seroconverters and their infants 
had this site conserved. Generally for both the chronic and 
acute infections, there was no systemic loss or acquisition of 
glycosylation sites during vertical transmission. 
Discussion 
    This study is the first study in Zimbabwe where frequencies 
of coreceptor usage genotypes have been determined in a 
population of pregnant women and related to vertical trans- 
mission, more so applying a relatively new bioinformatics 
tool to predict HIV coreceptor usage based on genotypic data 
from HIV-1 V3 loop sequences of the env gp120. This tool has 
been confirmed to have a high accuracy and has been spe- 
cifically optimized for HIV-1 subtype C.16,20 The recent in- 
troduction of entry inhibitors in the clinics as components of 
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antiretroviral therapy has diversified research in coreceptor 
usage in HIV-1 infection. Interestingly, the anti-R5 inhibitor, 
maraviroc, can be taken with or without food and does not 
require refrigeration and hence can be very suitable for 
resource-poor settings where coincidentally subtype C pre- 
dominates with the R5 genotype being present throughout, 
regardless of disease stage.12 
   Prediction of R5 coreceptor usage of at least 82% among the 
mother and their infants was observed, which is in agreement 
with previous studies21 not from Zimbabwe.4 A previous re- 
port from Zimbabwe was different, studying mostly patients 
on antiretroviral therapy who had an R5 phenotype frequency 
of 50%. A generally high R5 genotype is quite common with 
HIV-1 subtype C, which is the predominant subtype in 
resource-poor sub-Saharan Africa. Such high levels of R5 
variants could possibly be attributed to the relatively high 
levels of immune activation caused by parasitic infections.22 
   Studies have shown that X4 viruses are more common 
among pretreated patients with high viral loads.23 Similarly in 
our study, surrogate markers of disease progression such as 
viral load and lymphadenopathy, showed a consistent trend 
with the X4 genotype being associated with disease progres- 
sion; however, this was not statistically significant, possibly 
due to the relatively smaller sample size. This was also con- 
firmed by the fact that mothers with X4 variants were sig- 
nificantly more likely to have infants with lower birth 
weights, possibly due to more advanced disease. 
   In our study the R5 genotype was preferentially transmit- 
ted from mother to infant, similar to HIV-1 subtype B where 
maternal viral phenotype was generally preserved in vertical 
transmission and was predictive of the newborn’s viral phe- 
notype. Likewise, X4 viruses have also been shown to be 
rarely transmitted to newborns.11 Similar to the findings of 
Casper and others in 2002, the X4 viral genotype in HIV-1- 
infected children was related to the presence of X4 in their 
mothers. The complete agreement between maternal and in- 
fant genotypes was also observed by Casper et al. from 11 
mother–infant pairs in the first year of life with discordant 
mother–infant coreceptor genotypes occurring much later at 
more than 12 months.6 An early infant genotype switch has 
been shown to be related to the transmission from the mother, 
whereas a late switch may be related to development of mu- 
tations in HIV-1. However, Clevestig et al. have shown that 
the X4 phenotype in children actually evolves from their own 
previous R5 population implying that at least in subtype D, 
the X4 genotype in infants is not caused by transmission.24 We 
could not determine whether the presence of X4 in the infant 
who was infected after delivery was due to transmission or 
was from evolution from R5, since these infants were not 
genotyped soon after infection. 
   The dual-tropic R5/X4 genotype was present in 11% of the 
mothers at baseline, whereas no dual tropism was detected in 
infants. This finding is in agreement with Cavarelli et al., who 
postulate that the R5X4 phenotype is predominantly lost 
during transmission.11 However, contrary to this finding, a 
Ugandan study has demonstrated that the X4 and R5X4 can 
be transmitted from mother to infant before, during, or 
shortly after delivery.25 
   An 8% frequency of X4 variants among infants in our study 
is quite comparable to the 9% observed in a Ugandan study 
with subtypes A and D-infected infants. Similarly, survival of 
the infants with the R5 variant was not significantly different 
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from survival of the infants with X4 variants as also observed 
by Church et al. 26 Generally studies have shown that children 
can progress to AIDS without evidence of X4 virus, and some 
with X4 variants can remain asymptomatic for more than 1 
year.27 
    Of the three more recently infected mothers with acute 
HIV-1 infection, one had R5 genotypes as expected since the 
X4 genotype is normally associated with advanced disease or 
is more common in patients receiving antiretroviral therapy.4 
Nevertheless, X4 variants are not very rare in early infection. 
In Zimbabwe among male seroconverters, X4 phenotype 
frequency has been shown to be 12%.8 Huang et al. observed a 
4% frequency of X4 viruses in a cohort of 150 recently HIV-1 
subtype D-infected individuals.9 The presence of X4 variants 
in recent infection may have implications for antiretroviral 
therapy and vaccine development. 
    X4 variants were also associated with a substitution of the 
conserved GPGQ crown motif to GPGR. Similar observations 
were also observed by Coetzer et al. in a South African cohort, 
also with a predominant HIV-1 subtype C.28 
    The potential N-linked glycosylation site within the V3 loop 
region is present in almost all the mothers’ and infants’ viral 
isolates, suggesting its importance in CCR5 interaction.29 Si- 
milar findings have been observed in a South African study 
where X4 viruses were associated with loss of the glycosylation 
site.28 The loss of this glycan has been shown to assist in more 
efficient use of CXCR4 and thus might be an important factor in 
the switching of the R5 to R4 viruses.30 Studies on subtype B 
virus have shown that the number of potential N-linked gly- 
cosylation sites increased significantly over time in individuals 
who do not switch from R5 to X4, whereas no change was 
observed for those who switched.31 Since glycans are an im- 
portant part of the viral defense against antibodies, it is possible 
that the difference in evolution of potential N-linked glyco- 
sylation sites may reflect differences in antibody responses 
directed toward switching and nonswitching populations.32 
    These data show that HIV-1 R5 coreceptor usage is the most 
predominant genotype among pregnant women and is asso- 
ciated with a highly conserved GPGQ crown motif and gly- 
cosylation site. Antenatal HIV-1 subtype C coreceptor usage is 
generally preserved in vertical transmission and can be pre- 
dictive of the newborn’s viral genotype. Hence, the majority 
of antiretroviral-naive pregnant women and later their infants 
can benefit from antiretroviral combination therapy that in- 
cludes R5 entry inhibitors following screening of virus geno- 
type using bioinformatics methods. 
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Abstract 
Background: Expensive CD4 count and viral load tests have failed the intended objective of enabling access to 
HIV therapy in poor resource settings. It is imperative to develop simple, affordable and non-subjective disease 
monitoring tools to complement clinical staging efforts of inexperienced health personnel currently manning most 
healthcare centres because of brain drain. Besides accurately predicting HIV infection, sequential appearance of 
specific bands of WB test offers a window of opportunity to develop a less subjective tool for monitoring disease 
progression. 
Methods: HIV type characterization was done in a cohort of infected pregnant women at 36 gestational weeks 
using WB test. Student-t test was used to determine maternal differences in mean full blood counts and viral load 
of mothers with and those without HIV gag antigen bands. Pearson Chi-square test was used to assess differences 
in lack of bands appearance with vertical transmission and lymphadenopathy. 
Results: Among the 64 HIV infected pregnant women, 98.4% had pure HIV-1 infection and one woman (1.7%) had 
dual HIV-1/HIV-2 infections. Absence of HIV pol antigen bands was associated with acute infection, p = 0.002. All 
women with chronic HIV-1 infection had antibody reactivity to both the HIV-1 envelope and polymerase antigens. 
However, antibody reactivity to gag antigens varied among the women, being 100%, 90%, 70% and 63% for p24, 
p17, p39 and p55, respectively. Lack of antibody reactivity to gag p39 antigen was associated with disease 
progression as confirmed by the presence of lymphadenopathy, anemia, higher viral load, p = 0.010, 0.025 and 
0.016, respectively. Although not statistically significant, women with p39 band missing were 1.4 times more likely 
to transmit HIV-1 to their infants. 
Conclusion: Absence of antibody reactivity to pol and gag p39 antigens was associated with acute infection and 
disease progression, respectively. Apart from its use in HIV disease diagnosis, WB test could also be used in 
conjunction with simpler tests like full blood counts and patient clinical assessment as a relatively cheaper disease 
monitoring tool required prior to accessing antiretroviral therapy for poor resource settings. However, there is also 
need to factor in the role of host-parasite genetics and interactions in disease progression. 
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Background 
Acquired Immunodeficiency Syndrome (AIDS) is cur- 
rently one of the most devastating diseases caused by 
HIV. Globally, in 2007 alone, 33 million people were liv- 
ing with HIV/AIDS and 20 million had died [1]. Studies 
have shown a cross-species transmission of HIV from a 
primate lentivirus to humans and the virus can be phy- 
logenetically classified into two types; 1 and 2 [2]. This 
distinction is essential for accurate surveillance and 
diagnosis as well as administration of appropriate antire- 
troviral therapies within a population. 
  HIV type 1 (HIV-1) is the first in the class of human 
retroviruses and accounts for more than 95% of the 
world’s HIV infections. Its origin can be traced back to a 
Simian Immunodeficiency Virus (SIV) isolated from a 
Chimpanzee (cpz) sub-species, Pan troglodytes troglo- 
dytes (SIVcpz)[3]. Both HIV-1 and SIVcpz have a unique 
Vpu gene in their respective genomic structures [2]. 
HIV-2 is the second in the same class and is largely con- 
fined to West Africa. Its closest relative is a monkey, 
sooty mangabey (sm), Cercocebus atys, SIVsm. A unique 
Vpx gene characterises both viruses’ gene structures 
[4,5]. However, HIV-2 and HIV-1/HIV2 co-infections 
have also been documented outside West Africa [6]. 
HIV-1 and HIV-2 are closely related viruses with nucleo- 
tide sequence homology of 58%, 59% and 39% in the 
group specific antigen (Gag), Pol and Env genes encoding 
the viral nucleocapsid, polymerase enzymes and envelope 
glycoproteins, respectively [7]. Relative to HIV-1, HIV-2 
has a reduced rate of transmissibility, disease develop- 
ment and has shown natural resistance to readily avail- 
able non-nucleoside reverse-transcriptase inhibitors [8,9]. 
  Classical algorithm of laboratory diagnosis of HIV 
infection has been the detection of anti-HIV antibodies 
using rapid tests with WB immunoassay as the gold stan- 
dard method for validating screening test results [10,11]. 
However, in Zimbabwe, a large proportion of HIV diag- 
noses are currently being done without WB confirmation 
yet its banding profiles can yield valuable patient infor- 
mation. In this setting, WB test is only used as a tie- 
breaker in cases of discrepancy in the results. Unlike 
screening tests that detect antibodies to one or all HIV 
antigen(s) without specifying which antigen reacts to 
which antibody, the WB test with separated viral proteins 
immobilized on a membrane, generates specific informa- 
tion on the reactivity of patient antibodies to specific 
HIV antigens. Positive reactions appear as bands of 
numerous patterns [12]. Variations in WB band intensi- 
ties, numbers, or their sequential order of appearance 
during different stages of HIV infection have been 
observed [13]. Following sero-conversion, anti-gag anti- 
bodies to p17, p24 and its precursor p55 appear first and 
tend to decrease with the onset of clinical symptoms 
[14]. A reduced prevalence of core antibodies has also 
been shown to be associated with the development of 
immunodeficiency [15]. In contrast, antibodies to env 
antigens have been detected in virtually all HIV infected 
persons regardless of clinical stage [16]. This sequential 
appearance of specific WB bands offers a window of 
opportunity to develop a simple and non-subjective dis- 
ease assessment tool and also to predict the likelihood of 
vertical transmission. 
  High cost of CD4 count and viral load tests has ham- 
pered the intended objective of accessing HIV therapy 
in poor resource settings. Hence, there is a need for 
alternative initiative towards development of simple, 
accurate, affordable and non subjective disease monitor- 
ing tools. In view of the current brain drain challenge, 
this development would complement clinical staging 
efforts of inexperienced health personnel currently man- 
ning most healthcare centres. 
  WB test has been in use in Zimbabwe for some time 
now, mainly for HIV diagnosis. However, critical analy- 
sis of the band profiles regarding their additional poten- 
tial applications has been overlooked. This study aimed 
to characterize HIV types among pregnant women using 
the WB test and to determine whether the presence or 
absence of particular band(s) correlated with HIV-1 dis- 
ease progression or predicted vertical transmission. 
Methods 
Study Design and Setting 
This was a nested case-control study in which the cases 
and controls were sampled from a cohort of pregnant 
women attending 3 antenatal clinics around the city of 
Harare, Zimbabwe. All participants were part of a 
national Prevention of Mother-To-Child Transmission 
(PMTCT) program and were naïve to antiretroviral 
therapy. The primary end point was an HIV-1 positive 
mother who transmitted the virus to her infant, trans- 
mitting mother (case). Each case was matched to one 
HIV-1 positive but non-transmitting mother (control). 
Matching of cases and controls was done with respect 
to important risk factors of HIV disease progression and 
vertical transmission notably maternal age, baseline 
sexually transmitted infections (STIs), clinical signs, the 
date of last menstruation and single dose nevirapine 
therapy, see figure 1. 
Study Population and Procedures 
Pregnant women were enrolled at 36 gestational weeks 
between April and September 2002. Pre-and post-HIV 
test counseling services were readily available. HIV-1 
positive mother and infant pairs were offered 200 mg 
single dose nevirapine during labour and 2 mg/kg body 
weight within 72 hours post delivery, respectively. 
Mothers were encouraged to exclusively breastfeed dur- 
ing the first six months post-delivery. 
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Figure 1 Summary of how the 32 Transmitters and 32 non-Transmitters were sampled from a cohort of pregnant mothers attending 
antenatal clinics around Harare. 
  The study population consisted of two groups of preg- 
nant HIV-1 positive women. The main group consisted 
of pregnant women who were HIV-1 positive at enrol- 
ment, considered to be having chronic HIV-1 infection, 
and a subgroup of pregnant women who were HIV-1 
negative during pregnancy but sero-converted after deliv- 
ery, thus regarded as having acute HIV-1 infection. Fol- 
low-up of HIV-1 negative mothers together with HIV-1 
exposed infants was from delivery, 6 weeks, 4 and 9 
months and thereafter 3 monthly until 2 years, thus gen- 
erally coinciding with infant immunization visits. At each 
subsequent follow-up visit, HIV-1 negative mothers and 
exposed infants were re-tested for HIV-1 antibodies and 
antigens, respectively. Besides HIV testing, serum sam- 
ples of sero-negative mothers and their respective infants 
were aliquoted and stored for further analysis. 
Mothers’ and Infants’ Demographic characteristics, 
Examination and sample collection 
sexual behavioural, obstetric and reproductive health 
issues was obtained. A gynecologist performed physical 
and gynecological examinations. 
  A pediatrician examined infants. Date of birth, birth 
weight, gender and single dose nevirapine therapy were 
recorded. Five milliliters of maternal venous blood sam- 
ples were collected in EDTA tubes at baseline and each 
follow-up visit in the cases of HIV-1 negative mothers. 
Two milliliters of venous EDTA whole blood samples 
were collected at each follow-up visit for HIV-1 negative 
but HIV-1 exposed infants. Samples were stored at 
-86°C until tested. 
Mothers’ Tests 
At enrolment all mothers answered a structured question- 
naire and information regarding their socio-demographics, 
Serial HIV-1/-2 algorithm antibody tests were per- 
formed on plasma samples using Determine (Abbott 
Diagnostics, Illinois USA) and Ora-Quick (Abbott Diag- 
nostics, Illinois, USA) rapid kits. Confirmation of 
screening HIV-1/2 rapid test results was done at the 
Norwegian Institute of Public Health using the WB test 
(HIV blot 2.2, MP Diagnostics, Singapore) according to 
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the manufacturer’s instructions. Interpretation of the 
WB test results was done in line with the World Health 
Organization guidelines [17]. A WB test was considered 
positive if at least two of the three envelope antigen 
bands for HIV-1 or glycoprotein (gp) 36 for HIV-2 and 
any of the four gag antigens or at least any one of the 
three pol antigens were present. A WB test result was 
considered to show dual reactivity when sera reacted 
with at least two env glyco-proteins and one core pro- 
tein of each virus. Specimens with reactive gp36 antigen 
were re-run on a WB test specific to HIV-2. 
  Full blood counts were done using Abbott Diagnostic 
Cell Dyne 3500R SL Hematology Analyser. Plasma samples 
were shipped on dry ice to the Institute of Microbiology in 
Oslo to be quantified for HIV-1 RNA load using an auto- 
mated TaqMan Roche Amplicor 1.5 Monitor Test (Cobas 
AmpliPrep/Cobas TaqMan, Roche Diagnostics, Branch- 
burg NJ) according to the manufacturer’s instructions as 
previously described [18]. The first available HIV-1 positive 
sample was quantified in the cases of sero-converters. 
Infants’ Test 
Ethical Consideration 
The study was approved by the Medical Research Coun- 
cil of Zimbabwe and the Ethical Review Committee of 
Norway. Written consent to participate in the research 
study was obtained from the mothers and they were free 
to discontinue at any given time without any prejudice. 
Results 
Demography and Reproductive Health Characteristics of 
the 58 mothers: 29 transmitting and their 29 matched 
non-transmitting mothers with chronic HIV infection 
Detection of infants’ HIV-1 infections was performed 
using qualitative 1.5 Roche Amplicor HIV-1 DNA PCR 
kit (Roche Diagnostics). Since this was a breastfeeding 
population, the criteria used to determine time of infec- 
tion was similar to that used by Bertolli et al. [19]. 
Infants that tested HIV-1 DNA PCR positive on whole 
blood collected within 10 days of birth were considered 
to be infected in utero. Infants who had negative HIV-1 
DNA PCR results within the first 10 days of life but had 
positive results at six weeks were regarded as infected 
during intra-partum and those testing positive thereafter 
were considered infected after birth. 
Statistical Analysis 
Mean age (standard deviation) of the women was 26.6 
(5.2) years, being 26.3 (5.6) and 25.6 (5.6) years for trans- 
mitters and non-transmitters respectively, p = 0.610. 
  All the women had at least 7 years in school and were 
not formally employed. Ninety-three percent were mar- 
ried and 90% had at least one child. All the mothers had 
spontaneous vaginal deliveries and were generally 
asymptomatic for HIV infection at enrolment. 
  There were two stillbirths, one among the HIV-1 
positive and the other within the HIV negative group. 
These two were excluded from analysis. From the 176 
HIV-1 positive mothers that delivered live births 126 
(72%) mother-baby pairs were successfully followed up 
and tested. There were no differences with respect to 
socio-demographic characteristics, sexual behavior, 
reproductive genital tract infections and medical history 
between the 58 mothers with chronic HIV-1 infection 
constituting the main group in this study population 
and the rest of the mothers were HIV-1 positive at 
enrolment but were excluded or lost to follow-up. How- 
ever, these 58 mothers were more likely to have more 
children, p = 0.016. 
HIV Prevalence, Types and Vertical Transmission of the 29 
Transmitting and their Matched 29 Non-Transmitting 
Mothers with Chronic Infection Data were entered and analyzed using STATA version 10. The frequency of WB bands were determined among 
the pregnant women in general and also after stratifying 
by the time of HIV infection (acute or chronic) and verti- 
cal transmission, as transmitting or non-transmitting 
mothers. A graph was plotted to show the frequency of 
different WB gag antigen bands between the two groups 
of mothers. Student-t test was used to determine differ- 
ences in mean viral load and maternal hemoglobin 
between mothers with and those without gag antigen 
bands. Pearson Chi-square test was used to assess differ- 
ences in the absence HIV gag antigen bands with vertical 
transmission and lymphadenopathy. Comparisons of the 
appearance of the HIV env, pol and gag antigens band 
profiles of mothers with chronic and those with acute 
HIV-1 infections were also done. Tests of statistical sig- 
nificance included the 95% confidence intervals of unad- 
justed relative risks and p values of less than 0.05 were 
considered statistically significant. 
At baseline 691 pregnant women were enrolled of whom 
177 (25.6%) and 514 (74.4%) were HIV-1 sero-positive 
and sero-negative, respectively. Performance concor- 
dance of the two serial HIV-1 rapid test results was 
100%. Confirmatory WB tests of the 58 women with 
chronic HIV infection showed a 98.3% pure HIV-1 infec- 
tion. None was found with solely HIV-2 infection. Only 
one woman (1.7%) had dual HIV-1/HIV-2 infections. 
  Twenty nine (23%) mothers transmitted the virus to 
their infants 10 (34%) and 19 (66%) during in utero and 
intra-partum/postpartum transmissions respectively. 
HIV Incidence, Type(s) and vertical transmission among 6 
sero-converters: 3 transmitting and 3 non-transmitting 
mothers 
Out of the 512 HIV-1 negative mothers that delivered 
live births, 24 sero-converted during the two year 
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follow-up period, giving an HIV-1 incidence rate of 2.3 
per hundred women years. Eighty-five percent of the 
mothers sero-converted after weaning their infants from 
breast-milk. Mothers with acute HIV-1 infections were 
generally younger relative to HIV-1 negative mothers in 
the cohort, with mean ages of 21.8 (4.6) and 23.7(5) 
years respectively, p = 0.06. More so, sero-converters 
were generally younger compared with mothers having 
chronic HIV-1 infection, mean (SD) ages, 21.8(4.6) and 
26(5.5) years respectively, p = 0.04. There were no dif- 
ferences with respect to level of education, age of sexual 
debut, reproductive tract infections and STIs between 
the mothers with acute and those with chronic HIV-1 
infections. 
  Among the 24 sero-converters with acute HIV-1 
infection, three (13%) transmitted the virus to their 
infants through breastfeeding around 9 months postpar- 
tum. All the three infants were exposed, through breast 
milk for about three months before acquiring HIV-1 
infection. All the sero-converting mothers had solely 
HIV-1 infection. Neither HIV-2 nor HIV-1/HIV-2 co- 
infections were detected in this subgroup. 
Frequency of HIV-1 WB Bands among 58 mothers with 
chronic HIV infection 
antibody reactivity to HIV-1 gag demonstrated no 
relationship with maternal age, marital status, age of 
sexual debut, the number of sexual partners the women 
had had, current nor history of STIs. 
  Gag p39 and p55 antigens were the most commonly 
missing bands among transmitting mothers. Generally 
band appearance was not significantly different when 
compared with band profiles of the non-transmitting 
mothers, see figure 2. Mothers who had gag p39 antigen 
bands missing were 1.4 times more likely to transmit 
the virus to their infants compared to those who had 
this band present though their number was too small to 
reach statistical significance, p = 0.104. 
  Lack of antibody reactivity to gag p39 antigen was signif- 
icantly associated with disease progression as demon- 
strated by the presence of maternal lymphadenopathy, 
anaemia and higher viral load, p = 0.010, 0.025 and 0.016 
respectively, see table 1. Women with p39 gag antigen 
band missing were about 6 times more likely to have a 
viral load of more than 10 000 copies/mL relative to their 
counterparts who had that band present, 5.58 [1.74-17.86]. 
  Presence of gag p17 antigen band was associated with 
established or advanced HIV-1 infection in mothers 
with chronic HIV-1 infection p = 0.002, see table 2. 
Frequency of HIV WB Bands among mothers with acute 
HIV-1 infection 
Reactivity to all the 10 WB HIV-1 proteins was observed 
in 78% of the HIV-1 positive women. All specimens 
showed a strong positive reaction to both the HIV-1 
envelope glycoproteins (gp160, gp120 and gp41) and the 
polymerase antigens (p31, p51 and p66). However, anti- 
body reactivity to the gag core antigens varied among 
the women, being 100%, 90%, 70% and 63% with the 
p24, p17, p39 and p55 respectively. Absence of maternal 
All the mothers with acute HIV-1 infection had anti- 
body reactivity to all the 3 env antigens, gp41, 120 and 
160. However, reactivity to HIV-1 gag antigens varied, 
but because of the small number of women in this sub- 
group, it was difficult to make any conclusive remarks. 
Lack of antibody reactivity to pol antigens, p31, p51 or 
Figure 2 Frequencies of different gag protein among transmitters and non-transmitters 
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Table 1 Associations of antenatal surrogate markers of disease progression of 58 pregnant women (chronic HIV-1 
infections) with presence or absence of gag proteins reactivities 
Antenatal variable 
Band 
Lymphadenopathy Number/Total (%) Present 
Absent 
p-value 
Hemoglobin Mean (SD) Present 
Absent 
p-Value 
Viral load log10 Mean (SD) Present 
Absent 
P-value 
Vertical Transmission 
Number/Total (%) 
Present 
Absent 
P-value 
P17 
4/51 (8%) 
0/2 (0%) 
0.680 
10.8 (1.3) N = 54 
11.7 (1.0) N = 2 
0.312 
3.3(1.0); N = 56 
2.3 (0); N = 2 
0.167 
29/56 (52%) 
0/2 (0%) 
0.150 
HIV-1 WB gag antigen band reactivity 
P39 
0/32 (0%) 
4/21 (19%) 
0.010 
11.0 (1.2); N = 33 
10.4 (1.5); N = 23 
0.025 
3.0 (0.8); N = 35 
3.7 (1.2); N = 23 
0.016 
15/36 (42%) 
14/22 (64%) 
0.104 
P55 
2/38 (5%) 
3/15 (13%) 
0.316 
10.9 (1.4); N = 39 
10.6 (1.0); N = 17 
0.395 
3.1 (0.9); N = 41 
3.6 (1.2); N = 17 
0.072 
20/41 (49%) 
9/17 (53%) 
0.773 
p66 was significantly associated with early infection, 
hence absence of these bands on a WB test result could 
predict acute HIV-1 infection, see table 2. 
WB band Profiles of the mother with HIV-1/-2 co-infection 
In addition to the weak HIV-2 specific p36 band, reac- 
tivity to all the env, pol and gag antigens was observed. 
The mother was generally well with a relatively low 
baseline viral load of 690 viral copies per mL and did 
not transmit the viruses to her baby. 
Discussion 
This study is a first attempt to correlate simple WB 
band profiles with disease progression and to some 
extent vertical transmission in Zimbabwe. The WB test 
is simple and easily interpreted by skilled users. 
Table 2 Reactivity of different env, pol and gag proteins 
of mothers with chronic HIV-1 infection and sero- 
converters 
Positive HIV-1 antigen 
Band 
gag 
p17 
p24 
p39 
p55 
pol 
p31 
p51 
p66 
Env 
Gp41 
Gp120 
Gp160 
58 (100) 
58(100) 
58(100) 
6(100) 
6(100) 
6(100) 
- 
- 
- 
58 (100) 
58 (100) 
58 (100) 
3 (50) 
4 (67) 
4 (67) 
0.001 
0.002 
0.002 
57 (98) 
57 (98) 
35 (60) 
41 (71) 
3 (50) 
5 (83) 
2 (33) 
2 (33) 
0.002 
0.183 
0.186 
0.251 
Chronic 
infections 
N = 58 (%) 
Sero- 
converters 
N = 6 (%) 
p- 
value 
Key: P: protein, gp: glycoprotein 
Nevertheless, rapid tests are even simpler and can be 
conducted in rural settings without electricity. Although 
WB test remains relatively more expensive compared to 
rapid tests, it could be worthwhile using provided it 
yields a wealth of information on patients’ serology. 
Besides accurately predicting HIV infection, sequential 
appearance of specific bands on WB test result offers a 
window of opportunity to develop a less subjective tool 
to monitor disease progression. 
  In our study of pregnant women recruited around 
Harare, HIV 1 was the predominant type with only one 
HIV-1/HIV-2 co-infected mother. This observation is in 
agreement with a previous bigger study, coincidentally 
also done in Harare in the same population that showed 
an HIV-2 and HIV-1/HIV-2 prevalence of 1.3% and 
0.5%, respectively [20]. 
  A recent study has shown that serological cross-reac- 
tivity for HIV-2 in HIV-1 infected individuals is rare 
when using synthetic peptide based assays which was 
the case with the MP Diagnostic HIV BLOT 2.2 kit we 
used in our study [21]. Similar to the findings of the 
same study, a weak reactivity to gp36 band was observed 
in the co-infected mother. However, a more specific 
HIV-2 PCR should have been done to confirm the HIV- 
2 immuno-blot test result. With the world fast becom- 
ing a global village, the possibility of importing and/or 
exporting new HIV types is inevitable, more so for most 
unemployed Zimbabweans who have resorted to cross- 
border trading with regional countries such as Mozam- 
bique and Angola with HIV-2. 
  Antibodies to the env and pol antigens were well 
detected in all the HIV infected pregnant women. Simi- 
lar findings of band reactivities were reported earlier 
[13,16,22,23]. These results emphasise the importance of 
considering both the env and pol antigens in the inter- 
pretation criteria of WB HIV positive test results at least 
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in this population. Antibodies to gag antigens, p17, p39 
and p55 were not expressed efficiently in these women 
as was the case with other previous related studies 
[22,23]. Unlike the Indian study, where p55 antigen 
band was not detected at all in the patients with WHO 
clinical stage 1, our study observed a 63% expression of 
this antigen [22]. Interestingly in our study population, 
this antigen was the least expressed of all the WB test 
HIV antigens. This difference could be due to the fact 
that most of our women had surpassed the WHO clini- 
cal stage 1. 
   Fiebig et al., have classified primary infection of HIV 
into seven stages incorporating WB test results. A char- 
acteristic band appearance indicative of an indeterminate 
test result has been shown to occur at stage IV with a 
true positive WB test result at stage V but without the 
p31 antigen band which only appears in the final acute 
infection stage VI [24]. Also observed in our study 
amongst sero-converters, was the absence of reactivity to 
pol antigens hence these could be predictors of sero-con- 
version. Analogous results have also been demonstrated 
by Sudha et al., who have shown p31 antigen to be a pre- 
dictor for early HIV infection [13]. Presence of p17 anti- 
gen band was associated with chronic infections and 
hence could be a predictor of established HIV infection 
contrary to the results observed by some studies [14,15]. 
Lack of antibody reactivity to p39 and p55 antigens was 
associated with disease progression as confirmed by the 
presence of lymphadenopathy, anemia, high viral load of 
above 10 000 viral RNA copies per mL and a higher like- 
lihood of vertical transmission. Similar findings were also 
obtained elsewhere [25]. 
   Without any intervention, majority HIV-1 positive 
pregnant women do not transmit the virus to their 
infants. Highly active antiretroviral therapy (HAART) is 
not yet readily available in PMTCT programs in 
resource limited settings. The long term side effect of 
single dose nevirapine therapy offered to most HIV 
positive pregnant mothers poses a threat to the health 
of the naturally non-transmitting mothers should they 
require nevirapine later as part of their antiretroviral 
combination therapy. Hence, it is critical to precisely 
predict mothers who are likely to vertically transmit and 
offer them nevirapine monotherapy. Accurately predict- 
ing pregnant mothers likely to transmit the virus to 
their infants has long term benefits of saving on drugs 
and minimizing drug resistance problems. Lack of anti- 
body reactivity to gag p39 antigen during the last trime- 
ster of pregnancy could be a predictor of vertical 
transmission although bigger studies are necessary to 
verify this observation. The current small sample size 
could not permit conditional logistic regression analysis 
to control for variables that could have had an effect on 
disease progression other than WB band profiles. Hence 
results should be interpreted cautiously because disease 
progression and transmission also depend on other fac- 
tors including host-parasite genetics and interaction. 
  Control of viral replication following infection has been 
attributed partly to cytotoxic T lymphocyte (CTL) CD8+ 
activity. Studies have shown that CTLs directed against 
gag antigens correlate with improved clinical markers of 
disease progression [26]. Hence absence of antibody 
responses to p39 antigen could interfere with normal 
host neutralization of virus and may contribute to disease 
progression. Missing bands among the HIV chronically 
infected women were likely to have been due to dimin- 
ished antibody responses with progressive disease whilst 
in recent sero-convertors the missing bands may have 
been due to immature antibody responses or possibly 
due to mutations in the pol gene [27]. 
Conclusion 
These data support the rationale of using WB band pro- 
files plus simple laboratory tests like differential counts 
together with clinical symptoms such as lymphadenopa- 
thy in establishing and evaluating disease progression 
before accessing antiretroviral therapy. This could have 
important practical applications especially in resource 
poor settings, where over 95% of the 40 million HIV 
infected people live, who unfortunately cannot afford 
costly viral load and CD4 cell tests. However, bigger stu- 
dies are necessary to shed more light on the use of sim- 
ple WB band profiles to determine the likelihood of 
vertical transmission as an initiative to reduce HIV-1 
vertical transmission in developing countries. 
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Abstract 
To characterize phylogenetic relatedness of plasma HIV-1 RNA subtype C env gp120 viral variants capable of 
establishing an infection following heterosexual and subsequent vertical transmission events a 650-base pair 
fragment within the C2-V5 subregion was sequenced from four HIV-1-infected families each consisting of 
biological parent(s), index children (first), and subsequent (second) siblings. None of the family members had 
received antiretroviral therapy at the time of sample collection. Sequence alignment and analysis were done  
using Gene Doc, Clustal X, and MEGA software programs. Second siblings’ sequences were homogeneous and 
clustered in a single branch while first siblings’ sequences were more heterogeneous, clustering in separate 
branches, suggestive of more than one donor variants responsible for the infection or evolution from founder 
variant(s) could have occurred. While the directionality for heterosexual transmission could not be determined, 
homogeneous viral variants were a unique characteristic of maternal variants as opposed to the more hetero- 
geneous paternal variants. Analysis of families’ sequences demonstrated a localized expansion of the subtype C 
infection. We demonstrated that families’ sequences clustered quite closely with other regional HIV-1 subtype C 
sequences supported by a bootstrap value of 86%, confirming the difficulty of classifying subtype C sequences 
on a geographic basis. Data are indicative of several mechanisms that may be involved in both vertical and 
heterosexual transmission. Larger studies are warranted to address the caveats of this study and build on the 
strengths. Our study could be the beginning of family-based HIV-1 intervention research in Zimbabwe. 
Introduction 
     ub-Saharan Africa (SSA) is the region hardest hit by 
     the HIV/AIDS pandemic, harboring 63% of the world’s 
40 million HIV-infected individuals.1 Heterosexual and ver- 
tical transmissions are the primary modes of HIV acquisition 
in adults and children, respectively.2,3 Each transmission 
route represents a distinct microenvironment and conse- 
quently a unique set of factors influencing transmission of 
selected viral variants.4 The nature of the genital mucosal 
surfaces, gender, age of the transmitter or recipient, host im- 
1 
2 
S 
munology, and viral characteristics play important roles 
during HIV transmission.5 The observation that 70% of HIV- 
1-exposed infants remain uninfected even in the absence of 
any antiretroviral therapy underlines the importance of viral 
determinants in vertical transmission.6–8 Almost 30 years into 
the HIV scourge, mechanisms of transmission are still poorly 
understood, especially for the predominant subtype C. Iden- 
tifying viral characteristics capable of establishing an infection 
also remains elusive, a gray research area worth exploring in 
the current desperate attempt to develop effective HIV 
transmission preventive strategies. 
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   Single or multivirus transmission event(s) can initiate 
HIV-1 infections.9–11 Despite the fact that the transmitter 
harbors heterogeneous variants, newly transmitted HIV-1 
gp120 env sequences in the recipient show relative uni- 
formity until the immune responses drive the founder 
virus to diversify into a quasispecies, closely related viral 
swarms.3,12–15 HIV-1 subtype B studies have shown a lin- 
ear increase in env diversity during the first few years of 
infection, which tends to stabilize or even decrease at some 
point but often becomes homogeneous once more as the 
immune system wanes.16–18 The founder variants have 
been shown to reappear as the dominant quasispecies in 
plasma later during infection.19 Diversity of recent het- 
erosexually transmitted variants has been shown to be 
greater in women than men.20 Studies have shown that 
the use of hormonal contraceptives and sexually trans- 
mitted infections increase the likelihood of acquiring het- 
erogeneous variants from a single donor.21–23 Acquisition 
of homogeneous viral quasispecies is a unique and con- 
sistent feature of perinatal HIV-1 transmission, suggesting 
the presence of selective host pressures.24–26 However, some 
studies have reported infants with exclusive heterogeneous 
viral populations,27,28 while other studies suggest multiple 
mechanisms with different proportions of both homoge- 
neous and heterogeneous viral populations.29–32 At least for 
HIV-1 subtype A, homogeneous viral populations have been 
observed in 50% of vertically infected infants.33 
   The current knowledge on HIV-1 transmission is biased 
toward homosexually or parenterally acquired subtype B and 
is confined to Europe and America at the expense of the most 
widespread subtype C. Phylogenetic assessments of the 
HIV-1 subtype C env gp120 region during both acute and 
chronic infections are limited in Zimbabwe, particularly, fol- 
lowing concurrent heterosexual and vertical transmission 
events. Four HIV-1-infected families provided an opportunity 
to characterize phylogenetic relatedness of the virus variants 
capable of establishing an infection following heterosexual 
and subsequent vertical transmission events by genotyping a 
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650-base pair fragment of the HIV-1 subtype C env gp120 C2- 
V5 subregion. 
Materials and Methods 
Study population and procedures 
   Four HIV-1-infected families labeled 205, 366, 375, and 567 
consisting of biological parent(s)-infected siblings, an index 
child (older), and an index child’s sibling (younger) consti- 
tuted the study population. The unit of analysis was a family 
and these four were willing to participate in the phylogenetic 
study. The index child in this study was defined as the first 
child to be recruited into our study. Two families comprised 
both parents and a respective biological index child. The other 
two families had parent(s) and two subsequent biological 
children, the first and second siblings. In family 567 the father 
figure was missing as he was working in another regional 
country. Each member of the four families was HIV-1 infected 
and none had received antiretroviral therapy at the time of 
sample collection. We hereby describe a unique HIV-1 trans- 
mission clusters of four families for which the time and di- 
rectionality of vertical transmission were known but were 
unknown for heterosexual transmission. 
   Consent was obtained from the four pregnant mothers of 
each family participating in the national PMTCT program in 
the periurban Harare mother and child clinic who were 
known to be HIV-1 positive at 36 weeks gestations. Spouses 
also consented to participate in the family phylogenetic study. 
Similar recruitment and procedures were followed as previ- 
ously described for the mothers and infants.34 Despite being 
encouraged to exclusively breastfeed during the first 6 
months of life, all the infants were exposed to breast milk for 
at least 9 months. First siblings’ plasma samples were col- 
lected at 60 – 10 months of age as there were insufficient 
sample volumes from their respective first HIV-positive 
samples. The first available HIV-1-positive sample was 
genotyped for the second sibling at about 15 – 3 months; 
for details see Table 1. Sexually transmitted infection (STI) 
Table 1. Family Members’ Demography and HIV-1 Clone Characteristics Based on Nucleotide Sequences 
Age 
(years) 
39 
30 
5.3 
1.2 
39 
38 
5.8 
36 
36 
4.9 
35 
5 
1.3 
Unique 
clones 
3/5 
3/6 
3/4 
2/4 
3/6 
4/6 
2/5 
3/5 
4/6 
1/4 
2/5 
2/4 
3/4 
 Intrapatient 
  min-max 
diversity (%) 
7.7 
1.5 
0.0 
5.7 
(0.0–11.6) 
(0.8–2.0) 
(0.0–0.0) 
(0.02–8.1) 
Intrapatient 
   genetic 
distance (%) 
4.70 
1.53 
0.00 
3.80 
4.86 
1.50 
0.25 
6.95 
0.00 
0.00 
8.90 
0.50 
1.07 
  Family 
 members 
mean diversity 
Interfamilies 
    mean 
  diversity 
  Entire 
population 
 diversity Parent/sibling 
205 
  F 
  M 
  1st_ 
  2nd\ 
366 
  F 
  M 
  1st\ 
375 
  F 
  M 
  1st\ 
567 
  M 
  1st_ 
  2nd_ 
3.41 
2.04 
6.55 
6.56 
5.12 
7.36 
4.77 
9.43 
7.94 
10.6 (0.3–14.9) 
 3.1 (0.0–6.2) 
 0.6 (0.0–1.3) 
14.5 (0.03–21.7) 
 0.0 (0.0–0.0) 
 0.0 (0.0–0.0) 
14.4 (0.01–21.6) 
 0.3 (0.0–0.7) 
2.23 (0.0–4.5) 
6.41 
5.75 
3.89 16.42 
F, father; M, mother; 1st, first siblings; 2nd, second siblings; gender symbols denoting male _ and female \. 
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screening, nucleic acid extraction, polymerase chain reaction 
(PCR) amplification, cloning, and DNA sequencing methods 
for the HIV-1 env gp120 C2-V5 region were done as previ- 
ously described and so was HIV-1 subtype determination.35 
Briefly, the primary PCR amplified an approximately 800- 
base pair (bp) fragment spanning the C2 and V5 region of the 
envelope, positions 6948–7537 in the HIV-HXB2 genome 
while the secondary PCR amplified an approximately 650-bp 
env gene fragment. 
DNA sequence analysis 
   Phylogenetic and molecular evolutionary analyses are 
pivotal in the clarification of transmission patterns of HIV. To 
visualize the extent of the genetic relatedness of the HIV-1 env 
gp120 C2-V5 region among members of the four families 
following heterosexual and vertical transmission env amino 
acid sequences were analyzed including the construction of a 
phylogenetic tree using MEGA 5.0 software.36 Using the 
Clustal X program positions with gaps were excluded before 
tree building, consequently DNA sequences had an equal 
length before alignment. The most popular test for tree reli- 
ability, bootstrap, was used. The bootstrap value is a per- 
centage of how often each branch is present in exactly the 
same topology in all the resampled trees. A bootstrap cut-off 
value of > 70% signified at least a 95% probability that the 
topology of a branch is real.37 An HIV-1 group O sequence 
obtained from the Los Alamos national database of HIV Se- 
quence Compendium 2009 was used as the outgroup for 
rooting each of the families’ trees.38 Families’ sequences were 
compared with other HIV-1 group M subtype reference se- 
quences retrieved from the same database including other 
subtype C sequences from different countries within the SSA 
and other geographic regions such as Argentina, China, and 
India. 
   Genetic distance between two HIV-1 sequences is the 
count of the number of differences arising due to muta- 
tions and genetic drift resulting in genetic diversity. Dif- 
ferences were computed using Tamura and Tamura-Nei 
distribution-based distances also in MEGA.36 Diversity, 
which is a measure of genetic variation at a given time, 
was calculated by measuring nucleotide diversity (p) im- 
plemented in MEGA 5. Homogeneity or heterogeneity of 
the C2-V5 regions in the viral clones of fathers, mothers, 
and first and second siblings was evaluated by comparing 
the number of unique DNA sequences among multiple 
clones per family member. Comparison of the genetic di- 
versity and maximum genetic distance between families 
and different groups of family members, fathers, mothers, 
index children, or index children siblings was done. An 
arbitrary cut-off value of less than 1% was used to define 
viral homogeneity.20 
Results 
Characteristics of the four families 
  Three of the four mothers were in a monogamous marriage 
except for mother 375 who was in a polygamous relationship. 
All parents had at least 7 years in school and were of low 
economic status. Mothers were generally 5 years younger 
than their spouses. Table 1 summarizes the demography of 
family members. 
HIV infections 
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   Parents of the four families were HIV-1 positive but did not 
know when and how they got infected. Parents’ mode of HIV-1 
acquisition was most likely heterosexually as none mentioned 
any history of blood transfusion, drug abuse, or homosexu- 
ality except for one mother, 366, who had a history of blood 
transfusion. The index children of families 366, 375, and 567 
and second siblings of families 205 and 567 were HIV-1 DNA 
PCR negative at delivery and 6 weeks postpartum but later 
became infected through breastfeeding. Index child 205 
was HIV-1 DNA PCR negative at delivery but was not at the 
6 week visit, hence the exact time of infection could not be 
established. 
Mothers’ reproductive health and single-dose 
nevirapine (SdNVP) prophylaxis 
   All mothers had spontaneous vaginal deliveries. One life- 
time sexual partner was generally reported except for mother 
375 who reported two. Due to religious beliefs mother 205 
never used any method of contraception and moreover she 
refused to take SdNVP for herself and for both her infants. 
Otherwise the other mothers were on oral contraceptives and 
received SdNVP for themselves and their respective infants. 
All mothers had negative results for the RPR syphilis test but 
two of the four mothers were HSV-2 positive at enrollment.39 
Mothers 375 and 567 reported itchy genitals but no discharges 
were observed upon examination. 
Subtypes and phylogenetic analysis 
   A total of 64 sequences from four family members were 
cloned of which a total of 35 unique clones were analyzed. On 
average four (three–five) clonal nucleotide sequences were 
determined for the env C2-V5 gp120 env region (650 bp) from 
each infected family member. Phylogenetic analysis of env 
amino acid sequences showed that HIV-1 subtype C had 
infected each one of the four families’ members. The neighbor- 
joining phylogenetic tree showed that sequences were ge- 
netically linked and formed interfamilial clusters of HIV as 
shown in Fig. 1. Clusters were clearly distinguished with high 
bootstrap values suggestive of infections of monophyletic 
origin or a localized expansion of the subtype C epidemic at 
least among these four families. Our families env C2-V5 se- 
quences clustered with other HIV-1 subtype C from South 
Africa, Malawi, Botswana, Tanzania, India, China, Argentina, 
and also from other previous Zimbabwean subtype C studies 
as evidenced by a bootstrap value of 86% (see Fig. 1). Se- 
quences from families 205, 375, and 567 clustered more closely 
with sequences from South Africa, Malawi, and Botswana. 
Genetic distances 
   Although all the families sequences turned out to be sub- 
type C with respect to the env gene, the interfamilies mean 
genetic distances varied being furthest apart between families 
205 and 366 (20%) while families 205 and 567 showed the least 
genetic distances of 16.5% (see Table 2). The mean pairwise 
genetic distance was higher among the fathers, mean 18.13% 
(0.00–28.38), being highest between fathers of families 205 and 
366. Mothers’ percentage mean genetic distances were sig- 
nificantly lower, 17.21% (0.00–24.28), and the longest distance 
was between mothers of families 366 and 375. The mean 
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FIG. 1. Phylogenetic relationships between families’ nucleotide sequences and other subtype C from different geographic 
regions. The first letter represents the subtype followed by the name of the country: AR, Argentina; BW, Botswana; ZA, South 
Africa; TZ, Tanzania; IN, India; ZM, Zimbabwe; CN, China. Shaded triangles and circles represent fathers’ and mothers’ 
sequences, respectively, while open triangles and circles represent first and second siblings sequences, respectively. Bootstrap 
values are expressed as percentages per 1000 replicates and only proportions of ‡ 70% are shown. 
genetic distance was statistically higher among the adult 
population, 16.5% relative to that of children, 11.5%. The in- 
tergroup mean genetic distance between fathers and first 
siblings was 17.7% (see Table 3). 
Heterosexual transmission 
  Transmission events were epidemiologically linked, sup- 
ported by high bootstrap values, suggestive of predominantly 
monogamous relationships. Paternal sequences showed the 
highest average number of unique isolates by nucleotide se- 
quence. Father 205 had the most heterogeneity followed by 
366 and then 375. Comparison of all viral populations re- 
vealed that fathers’ sequences exhibited the most heteroge- 
Table 2. Percent Nucleotide Genetic 
    Distances Between Families 
Family 
205 
366 
375 
567 
205 
20.4 
17.5 
16.5 
366 375 
F 
M 
1st 
2nd 
neous viral quasispecies, which were observed to cluster in 
several separate branches suggestive of multiple variants. 
However, mothers showed a consistent pattern of limited 
viral diversity. Consequently both single and multiple trans- 
mission events may have occurred in these close contacts. 
Since the direction of transmission was not known we could 
not show how diversity changed with heterosexual trans- 
mission. 
Vertical transmission 
  Mothers and second siblings had limited heterogeneity, 
indicative of a relatively recent infection or suggestive of 
Table 3. Nucleotide Genetic Distances 
      Between Families’ Groups 
F 
16.9 
17.7 
17.2 
M 1st 
19.0 
19.9 
16.8 
15.3 15.9 
18.4 
F, fathers; M, mothers; 1st, first siblings; 2nd, second siblings. 
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vertical transmission of a single or very few closely related 
maternal variants. However, a more heterogeneous virus 
population was generally observed for first siblings of fami- 
lies 205, 375, and 366, demonstrated by the intermingling of 
their sequences with the parental ones. Viral sequences were 
distributed into several branches suggesting multiple distinct 
lineages probably as a result of evolution away from maternal 
viral sequences through immune selection pressures. 
Phylogenetic analysis of family 205 sequences 
   Figure 2a represents the neighbor-joining phylogenetic tree 
for family 205 family member’s sequences intermingled with 
each other. Despite the limited number of clones per family 
member’s sample, genetic heterogeneity was detected in the 
father’s sequences, which intermingled with sequences from 
the mother and both the two children. The less prevalent 
paternal strain clustered in a single branch of the tree sup- 
ported with a 98% bootstrap value with both the maternal and 
second sibling variants. The most prevalent strain of the first 
sibling appeared on its own branch supported with the lowest 
bootstrap value of 79%. The topology of the tree reflects the 
vertical transmission of at least two maternal variants that 
diverge over time as seen in the first sibling’s sequences. It is 
worthwhile to note that in this family there was no SdNVP 
prophylaxis selection pressure. 
Phylogenetic analysis of family 366 sequences 
   Figure 2b represents the neighbor-joining phylogenetic tree 
for family 366. The high bootstrap values of > 95% indicated 
the sequences are closely related and monophyletic. In con- 
trast to family 205 sequences, homogeneous infections were 
presumed based on the level of genetic diversity. The child 
sequences were in between the parent sequences. All se- 
quences of mothers and child clustered tightly on one branch 
with paternal sequences on the other, but all sequences were 
supported with a bootstrap value of 81%. In this case the child 
could have been infected with a single maternal variant, but 
because of the time factor in between, the variant could also 
have evolved under host immunological selective pressure. 
Phylogenetic analysis of family 375 sequences 
   Like family 366, paternal sequences clustered tightly on one 
branch while the mother–child sequence also clustered tightly 
on another branch with a bootstrap value of 99%, indicative of 
a relatively more recent infection, as shown in Fig. 2c. The 
overall family tree is supported by a high bootstrap value. As 
with family 205, the child sequences were also intermingled 
with those of the mother and consequently this case supports 
the transmission of multiple maternal variants. Since it is the 
father with the most divergent variants it can be assumed that 
he was infected much earlier and probably infected his spouse 
with a minor variant, which has also undergone selective 
pressure over the years. In family 375, the appearance of child 
HIV-1 variants closely related to antenatal maternal sequences 
at 55 months of age possibly supports the hypothesis of the 
reappearance of the founder virus later on during infection. 
Phylogenetic analysis of family 567 sequences 
   The mother’s sequences were closer to those of the second 
sibling’ while the first sibling’s sequences were further apart. 
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FIG. 2. Rooted neighbor-joining trees of HIV-1 env (C2-V5) 
amino acid sequences for four family members (a–d). Boot- 
strap values are expressed as percentages per 1000 replicates. 
Only bootstrap values greater than 70% are shown. Shaded 
triangles and circles represent fathers’ and mothers’ se- 
quences, respectively, while open triangles and circles rep- 
resent first and second siblings’ sequences, respectively. 
Filled in squares stand for the divergent HIV group O se- 
quences for rooting the trees. 
890 
Family sequences were supported by a bootstrap value of 
86% (see Fig. 2d). 
Discussion 
   In the absence of antiretroviral therapy, studies have 
shown that HIV-1 replicative fitness, which in turn impacts 
virus transmission, is largely determined by the functions of 
the envelope gene that was genotyped in our study.40–42 This 
is the first report attempting to assess HIV-1 subtype C en- 
velope gp120 C2-V5 phylogenetic relatedness among close 
contacts in Zimbabwe following concurrent heterosexual and 
subsequent vertical transmission. In SSA where HIV preva- 
lence is high, it is culturally acceptable for men to have more 
than one wife and/or extramarital sexual relationships. Ir- 
onically, the underrepresentation of these male sexual part- 
ners’ involvement in PMTCT programs in this setting where 
HIV-1 transmission is predominantly heterosexual has com- 
promised holistic HIV control strategies. 
   In 80% of heterosexual transmission cases, single viruses 
have been shown to establish infection9,43–45 with women 
harboring homogeneous env sequences being less likely to 
transmit per sexual act.46 Limited heterogeneity observed in 
our mothers suggests that a single variant could have been 
acquired from the local site of infection. This could be a gender 
difference during pregnancy of HIV-1 subtype C possibly 
influenced by hormonal balances. In our study the direction- 
ality of heterosexual transmission, whether it was female to 
male (FTM) or male to female (MTF), could not be ascertained. 
Some subtype C studies have demonstrated similar FTM and 
MTF transmission rates.47 Semen-derived viral populations 
have been shown to exhibit lower genetic diversity relative to 
the blood variants and this could probably be the reason for the 
limited heterogeneity observed in the mothers.48 It could be 
worthwhile to explore similar but larger studies with many 
clones from the plasma and other compartments. 
   Contrary to our findings, some studies have demonstrated 
that women are often infected with multiple variants.20 Di- 
verse virus population in such studies could be attributed to 
reinfection by multiple partners since this other study’s pop- 
ulation was a cohort of female sex workers in Nairobi, Kenya 
with predominant A and D and to a lesser extent C HIV-1 
subtypes. In the Kenyan study none of the five men and only 
two of 32 women had HIV-1 subtype C and interestingly both 
women had homogeneous virus populations. Homogeneous 
subtype C viruses have also been described elsewhere.49,50 
This is suggestive of the fact that subtype could influence the 
pattern of viral transmission. 
   Differences between the two studies could be due to vari- 
ations in the study populations, the exact env region being 
analyzed, possibly variations in the sampling times at differ- 
ent stages of HIV-1 infection, and also different subtypes. 
Studies have shown that heterosexual and vertical transmis- 
sion of HIV-1 subtype C viruses spread more rapidly due to 
increased mucosal and vaginal shedding.51–53 Compared to 
other subtypes, subtype C has also been shown to replicate 
and be transmitted more efficiently.54–56 Hence, there is a need 
to address subtype C-specific research questions rather than 
extrapolating and applying subtype B findings if curbing of 
the pandemic is to be realized. 
   Similar to previous observations a low degree of maternal 
HIV-1 genetic heterogeneity has been shown to correlate 
DURI ET AL. 
with vertical transmission contrary to observations by 
others.31,57,58 If diversity remained low, then it could be likely 
that fewer variants could be harbored and hence there could 
be a narrow breadth of maternal neutralizing antibodies as- 
sociated with increased risk of vertical transmission. Other 
important factors could be associated with infant exposure 
such as diverse viral inoculum, including other maternal 
factors such as nutritional status, human leukocyte antigen 
(HLA) genotype, coreceptor expression, or the presence of 
STIs among others. Successful transmission of maternal es- 
cape mutants has been reported in children sharing HLA al- 
leles with their mothers.59 Coinfection with human simplex 
virus type 2 (HSV-2) at delivery has been associated with 
increased intrapartum transmission of HIV-1.60 
   Smaller genetic distances indicate a close genetic relation- 
ship whereas large genetic distances indicate a more distant 
genetic relationship. Our observation of distant first siblings’ 
sequences is consistent with previous studies where viral di- 
vergence has been found to increase over time in children.11 
The first siblings were much older, about 60 months old, 
hence their HIV-1 could have evolved further from the ma- 
ternal HIV, which was more or less closer to that of the second 
siblings who were about 15 months old. 
   The route of transmission may influence the genetic di- 
versity, with some authors postulating that HIV homogeneity 
and heterogeneity patterns are likely to be different between 
infants and adults due to different exposures, different viral 
dynamics and set points following infection, and different 
immunity maturities in the recipients.61 Studies have shown 
that most HIV-infected infants have a deficiency in cytotoxic T 
lymphocyte (CTL) responses to HIV62,63 and inadequate CD4 
T cell help.64,65 Infection of infants with maternal CTL escape 
variants may further compromise the infant’s ability to con- 
tain the virus.66 On a positive note diversity may also disrupt 
the function of the env gene resulting in attenuation of HIV-1 
virulence probably resulting in long-term nonprogressors in 
the absence of antiretroviral therapy observed in these pedi- 
atric patients.67,68 Differences in mother–infant pair viral 
heterogeneity may also be due to virus compartmentalization 
between the plasma and breast milk variants. The immuno- 
logical milieu of breast milk has been found to be distinct from 
that in blood as it contains a high concentration of HIV-1- 
specific T cells, antibodies, chemokines, and innate factors 
that modulate HIV-1 transmission risk.69–71 However, a sub- 
type C study of breastfeeding mothers found no differences 
between breast milk and blood variants.72 
   Families’ subtype C intermingled with subtype C se- 
quences from other regions, confirming the difficulty of clas- 
sifying subtype C sequences on a geographic basis.73 Due to 
the limited number of clones sequenced per family member it 
was not possible to determine the minor or major variants. 
More so, the directionality of heterosexual transmission could 
not be ascertained. It could be worthwhile to explore the de- 
termination of directionality of transmission using glycosyl- 
ation patterns and amino acid lengths of HIV-1 env variable 
regions. 
   Few subtype C studies have looked at variation of the V1- 
V2 on transmission.74,75 It would have been more interesting 
if the whole env region was sequenced including the V1-V2 
region for comparison. However, sequencing of longer frag- 
ments has its own challenges. Phylogenetic analysis per- 
formed for each family sequence set suggested that several 
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mechanisms may be involved in both vertical and hetero- 
sexual transmission. The star-shaped families tree suggested a 
localized expansion of the subtype C epidemic at least among 
these our families. Generally families’ sequences clustered 
quite closely with sequences from South Africa, Malawi, and 
Botswana. Paternal sequences exhibited the most heteroge- 
neous viral quasispecies while maternal sequences were rel- 
atively homogeneous. First siblings viral sequences were 
distributed into several branches suggesting multiple distinct 
lineages probably as a result of the evolution away from 
maternal viral sequences through immune selection pressures 
during their 5–6 years of life while second siblings’ HIV-1 
sampled between 12 and 15 months of age had relatively 
homogeneous viral populations closely related to maternal 
variants. Larger studies are warranted to address the caveats 
of this study and build upon its strengths. Our study could be 
the beginning of a family-based intervention in HIV research 
in Zimbabwe. 
Sequence Data 
  Sequences were submitted to GenBank and the accession 
numbers assigned were JQ070719–JQ070752. 
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Consent Form in English

 CONSENT FORM 
STUDY TITLE 
HIV Diversity among Pregnant Women and their infants in Harare Peri-urban; 
Implications in Disease Diagnosis, Monitoring and Transmission 
Name of Clinic: 
Study Number: 
…………………………… 
………………………… 
Study Explanation 
There are different types of HIV variants called subtypes. Currently we do not know 
which HIV subtype you harbour and hence we are going to determine maternal and infant 
subtype that is if your baby if also HIV positive. This is important for more effective 
chemotherapy and also forms the basis for vaccine development, which so far has been a 
challenge. There is also need to find out whether subtype plays a role in vertical 
transmission. For HIV and subtype determination, 3ml and 1ml of EDTA blood will be 
drawn from the mothers and babies respectively. 
There is no risk in participating in this study except for the pain you may experience 
during bleeding. You are free to participate in this sub-study if you wish and should you 
decide to join the study, you are free to withdraw from this study at any time. If for some 
reasons you are not willing to participate in the sub-study you are still entitled to all your 
full benefits from the main study. You will be reimbursed your bus-fare for coming to the 
clinic and will also have the privilege to be examined by a gynaecologist and your baby 
by a paediatrician. Do you have any questions pertaining to this study? Should you have 
any questions in future feel free to contact Mrs. K Duri on telephone number 791631. If 
you have understood and are willing to participate in the study you can show by signing 
this form on the space provided below. 
Date ________ Participant’s Signature ____________________________ 
Date ________ Interviewer’s Signature _____________________________ 

Consent Form in Vernacular Language (Shona)

 GWARO RETSANANGUDZ YECHIRONGWA NECHIBVUMIRANO 
HIV Diversity among Pregnant Women and their infants in Harare Peri-urban; 
Implications in Disease Diagnosis, Monitoring and Transmission 
(Mhando dzeutachiwana hweHIV-1 (subtypes): Kukosha kwemhando idzi pakutapurirwa 
kwehutachiona kubva kuna amai kumwana wake) 
Name of Clinic: 
Study Number: 
…………………………… 
        …………………………… 
Tsanangudzo yechirongwa 
Sezvo paine mhando dzakasiyana-siyana dzehutachiwana hweHIV-1 pari zvino hatisati 
tavakuziva kuti mune mhando ipi. Chirongwa chino chiri kuenderera mberi 
chichiongorora kuti mune mhando ipi yeutachiwana. uye kuti utachiwana hwenyu 
hwashanduka zvakadii mumakore apfuura. Izvi zvakakosha mumatanho ari kuitwa pasi 
rese ekutsvaga mushonga wokudzivirira nekurapa chirwere cheHIV usati wavanikwa pari 
zvino. Tinoda kuongorora zvakare kuti kusiyana kwemhando dzeutachiwana kune 
chekuita here pakutapurirwa kungaita utachiwana kubva kuna amai kumwana wake. 
Zvichirewa kuti tinoda kuona kuti utachiwana huri muna amai hwakasiyana sei nehuri 
mune mwana wake. 
Kuti izvi zviitike ropa rinoita mamiririta matatu (3ml) richange richizotorwa kwamuri imi 
pamwe chete nemwana (1) ml kana achinge ainewo utachiwana. Hapana zita renyu 
richashandiswa paongororo iyi asi tinoshandisa namba chete. Zita renyu, kero yenyu 
pamwe chete nezvimwe zvakabvunzwa pamusoro penyu zvichange zvakachengetedzwa. 
Vashandi wemuchirongwa vanoongorora ropa renyu havafi vakaziva zvinhu izvi. Kana 
musinganzwe zvavakanaka, pana chiremba wemadzimai nevevana anokwanisa kukuona 
imi kana mwana wenyu. Vana chiremba ivavo vanogona kukutumidzirai kuzvipatara 
zvikuru kana zvichikodzera. Chirongwa chichahadhara mari dzinenge dzichizodiwa kana 
mapiwa mubhedha, mishonga pamwe neongororo dzamungangoitwa. Muchadzorerwa 
zvakare mari yenyu yebhazi yamunenge mashandisa kuuya kuchirongwa. Hapana njodzi 
inowanikwa mukupinda muchirongwa kunze kwemarwadzo angangowanikwa pakutorwa 
kweropa. Munhu haamanikidzwe kupinda muchirongwa chino. Kana muchinge mapinda 
muchirongwa chekutanga mune kodzero yekuramba kuenderera mberi nechirongwa 
chero zvayo nguva. Kuramba kwenyu hakushandure mabatirwo amunoitwa muchirongwa 
chekutanga. Mune mibvunzo here pamusoro petsanangudzo yechirongwa ichi? 
Mukazoita zveimwe mibvunzo ridzirai Mai Duri runhare panhamba dzinoti 791631. 
Kana manzwisisa chirongwa ichi sainai pazasi zvichireva kuti mabvuma kupinda 
muchirongwa. 
Date 
Date 
________ 
________ 
Participant’s Signature _____________________________ 
Interviewer’s Signature __________________ 

